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Thesis abstract 
Introduction 
Asymptomatic gastro-oesophageal reflux and aspiration may be associated with 
allograft dysfunction post lung transplant. Early anti-reflux surgery has been 
advocated in selected patients and may improve long-term survival. Little has been 
published on this topic and the current evidence supporting this is flawed. The 
understanding of the pathophysiology of aspiration in lung transplant recipients is 
currently limited. This study reports a prospective analysis of reflux/aspiration 
immediately post-transplantation to date and its subsequent management. 
Methods 
Lung transplant recipients were recruited over 12 months. At one and six months 
post-transplantation, patients completed a reflux symptom index (RSI) questionnaire 
for symptoms of extra-oesophageal reflux and underwent objective assessment for 
reflux (manometry & pH/impedance). Testing was performed with subjects on 
maintenance proton pump inhibitor. Bronchoalveolar lavage fluid was assessed for 
pepsin, bile salts, interleukin-8 and neutrophils. Laparoscopic fundoplication was 
performed on selected patients. Subsequent laboratory based work was performed to 
determine the composition of gastric juice and to assess the effects of aspiration on 
primary bronchial epithelial cells and HT29-MTX goblet cells. 
Results 
18 patients with a median age of 46 years (range 22-59) were studied. Manometry 
was abnormal in 8/18 (44%) patients. Seventeen patients completed 24 hour pH-
impedance measurements. 12 of 17 (71 %) had evidence of GORD on pH-impedance 
monitoring. 3 of 12 (25%) of patients had exclusively weakly-acid reflux. A 
statistically significant correlation existed between proximal reflux events and 
neutrophilia at one month (n=13)(Spearman correlation r=0.52, p=0.03). Pepsin was 
detected in BALF signifying aspiration. Bile salts were rarely detected using 3 
separate assays [sensitivity 0.1 /lmolll]. The prevalence of reflux increased over the 
first six months post-transplant despite a reduction in immunosuppression and normal 
lung function. Nine patients have subsequently undergone fundoplication for severe 
Xlil 
or symptomatic reflux. No major complications occurred. This was associated with 
improved quality of life and decreased symptoms. Laboratory work gave useful 
background information on pepsin and bile salts. Mean levels in gastric juice were 
380llg/ml (range 0-3892) for pepsin and 50llmolll (range 0-8000) for bile salts. 
Microaspiration may lead to primary bronchial epithelial cell damage and death. 
Conclusion 
Reflux/aspiration is prevalent early post-operatively. Pepsin but rarely bile salts were 
detected in the lavage fluid suggesting pepsin to be a more common biomarker of 
aspiration. This study suggests that the causes for reflux are not all related to adverse 
thoracic changes and immunosuppression as surprisingly. despite a lack of a 
significant increase in immunosuppression levels, reflux indices increased over the 
first six months. Laboratory based work provides background information on the use 
of biomarkers and suggests aspiration could lead to cell death. Fundoplication is safe 
in selected patients and improved quality of life and GORD symptoms. Further 
studies are required to assess the effects on lung function and survival. 
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1. Introduction 
1.1. Gastro-oesophageal reflux disease 
Gastro-oesophageal reflux disease (GORD) is defined as any symptomatic condition 
or histopathological alteration secondary to retrograde movement of gastric contents 
into the oesophagus. It is common in the general population. Eleven percent of 
Americans experience symptoms of daily reflux, and 33 % experience these over a 72 
hour period (Wise and Murray 2007). In lung transplant recipients. gastro-
oesophageal reflux disease and chronic aspiration have been linked to the 
development of BOS and this process may be prevented by fundoplication (Davis, 
Lau et al. 2003). More severe GORD has been suggested to be associated with 
decreased FEV 1 and increased frequency and severity of BOS. This is a fairly recent 
concept and was first suggested in 1990 (Reid, McKenzie et al. 1990). 
There is a suggested high prevalence of reflux disease in patients with asthma, cystic 
fibrosis, pulmonary fibrosis, COPD, BOS-associated pneumonia and diffuse 
bronchiolitis in the non-lung transplant population, (Davis, Lau et al. 2003; Young, 
Hadjiliadis et al. 2003; Cantu, Appel et al. 2004; Casanova, Baudet et al. 2004; 
D'Ovidio, Mura et al. 2005; Ward, Forrest et al. 2005; D'Ovidio and Keshavjee 2006; 
Sweet, Patti et al. 2007; Blondeau, Dupont et al. 2008; Gasper, Sweet et al. 2008). 
Gastro-oesophageal reflux may contribute to pulmonary pathophysiology, e.g. in 
asthma; cystic fibrosis and pulmonary fibrosis (Cantu, Appel et al. 2004; Havemann, 
Henderson et al. 2007). The Japanese have proposed an entity- diffuse aspiration 
bronchiolitis. This has been described in elderly patients with dementia who suffer 
from chronic aspiration (Teramoto, Matsuse et al. 1999). There is an even higher 
prevalence of gastro-oesophageal reflux disease post-transplantation (D'Ovidio and 
Keshavjee 2006). 
Clinical studies have also suggested a link between GORD and BOS (Davis, Lau et al. 
2003). Anti-reflux surgery, especially early fundoplication, may have a role in 
preventing BOS and prolonging survival (Appel and Davis 2004). 
1.1.1. Pre-operative reflux in patients with chronic advanced lung disease 
Extra-oesophageal reflux is increased in chronic advanced lung disease. There is a 
high prevalence of foregut motility problems and GORD in patients with end-stage 
lung disease (ESLD) including interstitial lung disease. pulmonary fibrosis and cystic 
fibrosis (D'Ovidio, Singer et al. 2005). 
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Seventy two percent of pre-transplant patients have decreased lower oesophageal 
sphincter pressure (D'Ovidio, Singer et al. 2005). Thirty three to forty seven percent 
of patients have oesophageal body dysmotility and impaired peristalsis (D'Ovidio, 
Singer et al. 2005; Sweet, Herbella et al. 2006). In total, almost 80% of these patients 
have oesophageal dysmotility and or a hypotensive lower oesophageal sphincter 
(D'Ovidio, Singer et al. 2005). Sweet et aI, in a study of end stage lung disease 
patients, suggests that 55% of patients with reflux had a hypotensive lower 
oesophageal sphincter compared with 26% of patients without reflux (Sweet, Herbella 
et al. 2006). Impaired oesophageal peristalsis was associated with reflux and 
respiratory symptoms (Sweet, Herbella et al. 2006).The amplitude of peristalsis in the 
distal oesophagus is lower in GORD positive patients (Sweet, Herbella et al. 2006). 
Forty four percent of these patients had prolonged gastric emptying for solids and 
24% for liquids (D'Ovidio, Singer et ai. 2005). The combination of a defective lower 
oesophageal sphincter and delayed gastric empting leads to an increase of abnormal 
reflux findings (D'Ovidio, Singer et al. 2005; Sweet, Herbella et ai. 2006). In a study 
by Sweet et aI., 17 patients underwent gastric emptying studies due to symptoms of 
delayed gastric emptying: post-prandial bloating, fullness, nausea and vomiting. Most 
of these patients (16 of 17) had abnormal distal oesophageal acid exposure. Four of 
these 16 had delayed liquid emptying and ten had delayed solid emptying (Sweet, 
Herbella et al. 2006). However, as only symptomatic patients were tested, the 
conclusions that can be drawn from this data are limited. 
There is a high prevalence (63-68%) of GORD in patients with end stage pulmonary 
disease awaiting lung transplant (Cantu, Appel et al. 2004; Sweet, Herbella et ai. 
2006). D'Ovidio et al (2005) report a lower prevalence- 38%. In that study, PPIs were 
only stopped for 5 days prior to the assessment. PPIs can affect acid secretion for upto 
10 days. Therefore, the prevalence of GORD may be underestimated (Sweet, Herbella 
et al. 2006). Twenty to thirty seven percent of patients have documented proximal 
reflux on ambulatory pH monitoring. Proximal oesophageal reflux is more dangerous, 
as it predisposes to microaspiration. There is conflicting data whether proximal reflux 
events in ESLD patients occur mainly in the upright (Sweet, Herbella et al. 2006) or 
in the supine position (D'Ovidio, Singer et al. 2005). Interestingly, although rare. 
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patients with normal distal reflux but abnormal proximal reflux were encountered 
(Sweet, Herbella et al. 2006). 
It is unclear whether GORD causes pulmonary pathology or whether disordered 
pulmonary function leads to GORD. There is evidence to suggest that in patients with 
COPD, episodes of reflux may be associated with a drop in arterial oxygen saturation 
(Casanova, Baudet et al. 2004). 
The presence of reflux in ESLD may be related to an increased negative intrathoracic 
pressure and increase positive abdominal pressure. Lung hyper-expansion may 
interfere with the oesophageal hiatus in the crura and also the lower oesophageal 
sphincter pressure (Linden, Gilbert et al. 2006). 
1.2. Lung transplantation 
Lung transplantation has been performed since 1963 (Cantu, Appel et al. 2004). It is 
now a life saving treatment for end-stage lung disease (Hosenpud, Bennett et al. 1998; 
Davis, Lau et al. 2003; Cantu, Appel et al. 2004; D'Ovidio and Keshavjee 2006). 
Transplants performed in Newcastle have a one year survival of 82-84% and a 5 year 
survival of 60%. Forty percent of lung transplant recipients at the Freeman Hospital 
Cardiothoracic Transplant Unit now survive for 10 years. The survival rate continues 
to improve (Rutherford, Fisher et al. 2005) and is comparable with the International 
Society for Heart and Lung Transplantation registry (ISHL T 2010). The main 
indications for lung transplantation are chronic obstructive pulmonary disease 
(COPD) (45%), pulmonary fibrosis (16%) and cystic fibrosis (14%). Primary 
pulmonary hypertension has decreased as an indication for transplant due to 
improvements in its medical management (Appel and Davis 2004). In the early post-
operative period, mortality is commonly due to infection and primary graft failure. 
Over a longer time period- several years, bronchiolitis obliterans syndrome is a major 
cause of morbidity and mortality (Appel and Davis 2004). 
Lung transplant survival is reduced when compared to heart, liver and kidney 
transplants (Appel and Davis 2004). This may occur as the lungs are exposed to the 
external environment. The process of transplantation involves denervating the donor 
lung, reducing the cough reflex and muco-ciliary clearance (Veale, Glasper et al. 
1993). This attenuates the protective mechanisms of the lung against infection and 
aspiration. 
1.3. Long-term complications 
1.3.1. Bronchiolitis obliterans syndrome 
Death post-lung transplant is commonly due to chronic allograft dysfunction 
otherwise known as obliterative bronchiolitis (Davis, Lau et al. 2003: Cantu, Appel et 
al. 2004). Obliterative bronchiolitis is likely to be the pathological process of chronic 
rejection and is diagnosed on open lung biopsy. Although open biopsy is the gold 
standard, it is very invasive. Usually trans bronchial biopsies are performed but due to 
sampling problems these are not reliable in diagnosing obliterative bronchiolitis. 
In 1993 Bronchiolitis obliterans syndrome (BOS) was defined as the clinical 
equivalent of obliterative bronchiolitis (Hadjiliadis, Duane Davis et al. 2003). The 
BOS score, based on lung function, is of great value. BOS is a significant process 
which leads to decreased quality of life and increased mortality. BOS normally 
develops between 6 months & 2 years post transplantation (Palmer, Miralles et al. 
2000). It affects 50-60% of patients at 5 years post-transplantation. BOS accounts for 
30% of deaths after the 3rd post-operative year and its associated survival is only 30-
40%, 5 years after its onset. The 5 year post-transplantation survival is 20-40% lower 
than average in patients with BOS (D'Ovidio, Mura et al. 2005). It is a leading cause 
of late graft failure (Zheng, Walters et al. 2000). The pathology behind this process 
involves progressive fibrosis of the small airways leading to complete obstruction 
with sclerosis of the airways, intimal thickening and destruction of the pulmonary 
vasculature. 
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Figure 1-1: Model of non-alloimmune lung allograft injury and inflammation in BOS 
pathogenesis from Robertson et al Am J Trans 2009 
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NORMAL 
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EMT 
Infection Infection 
(Robertson, Griffin et al. 2009) (Artwork by IA Brownlee) 
FIBROSIS 
Airway 
Remodel ling 
Pathologicall y there are two different types- an acellular type with a concentric 
fibrosing picture limited to the terminal bronchioles and a foca l cellular process which 
is associated with aspirated food content and foreign body-type giant cell s in the 
alveolar spaces (Abernathy, Hruban et al. 1991 ; D'Ovidio, Mura et al. 2005 ; D'Ovidio 
and Keshavjee 2006). Clinically this is accompanied by a decreased FEV I and 
progressive dyspnoea. The accepted ISHL T definition of BOS is a decrease FEV I 
from the best post-operative function , in the absence of anastomotic stricture, 
infection, bronchitis or other complications (Estenne, Maurer et al. 2002). BOS scores 
are shown in Table 1-1 (Estenne and Hertz 2002). The revised score from 2002 
inc ludes a new grade of BOS: BOS Op. This is beneficial as it allows the identificati on 
and early treatment of deteriorating lung function. 
BOS is thought to be mediated by both alloimmune and non-alloimmune factors . Ri sk 
factors for BOS include number, time to and severity of acute rejection (a process 
characterised by T-I ymphocyte infiltration of the allograft) , HLA mismatch, 
cytomegalovirus, and other viral infections, age of patient, ischaemic time, and single 
lung transp lant. More putati ve assoc iations include GORD with aspiration (Appe l and 
Dav is 2004; Cantu, Appel et al. 2004; Ward, Forrest et al. 2005: D'Ovidio and 
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Keshavjee 2006). It has recently been suggested that BOS is a heterogeneous 
condition with neutrophilic reversible allograft dysfunction representing a patient 
subset, which may have important therapeutic implications. An implication of this 
model, is that the definition of BOS, which currently is described as irreversible may 
need to be revised (Yanaudenaerde, Meyts et al. 2008). 
T bill B a e - ronc 10 I IS 0 d I erans syn rome (BOS) scores 
1993 classification 2002 classification 
BOSO FEY}: 80% or more of baseline FEY}: >90% of baseline and BOSO 
FEF25-75 >75% of baseline 
FEY}: 81-90% of baseline and BOS Op 
FEF25-75 S;75% of baseline 
BOSI FEY l: 66-80% of baseline FEY 1: 66-80% of baseline BOSI 
BOS2 FEY l: 51-65% of baseline FEY l : 51-65% of baseline BOS2 
BOS3 FEY l : S;50% or more of FEY}: S;50% or more of BOS3 
baseline baseline 
(Estenne and Hertz 2002; Estenne, Maurer et al. 2002) 
1.3.2. Reflux post-lung transplant 
GORD with potential aspiration, as determined by an abnormal pH study, is prevalent 
after lung transplantation (70-75%) (Davis, Lau et al. 2003; Hadjiliadis, Duane Davis 
et al. 2003). Post-transplantation remodelling of the chest and oesophagus may help to 
recreate the lower oesophageal sphincter and reduce reflux (D'Ovidio, Singer et al. 
2005). This benefit may be off set, by suspected predisposing factors such as 
immunosuppressive medication, vagal nerve damage (leading to delayed gastric 
emptying) and the high pre-operative prevalence of reflux disease (Hadjiliadis, Duane 
Davis et al. 2003; D'Ovidio and Keshavjee 2006). pH monitoring is becoming routine 
practice in several transplant units due to the high incidence of post transplant reflux 
and the potential improvement in lung function post fundoplication (Davis, Lau et al. 
2003). Few studies exist which assess longitudinal data on GORD in lung transplant 
recipients. 
One study demonstrated an increase in the prevalence of reflux from 35% pre-
transplantation to 65% post-transplantation (Young, Hadjiliadis et al. 2003). An 
abnormal test was defined as an acid contact time of greater than 3%. Acid contact 
time increased by a mean of 3.7% post-lung transplant. The greatest increase in acid 
contact time was in the supine position where the increase was 6.3%. Most of these 
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patients were asymptomatic. The changes in acid contact time were not always 
explained by changes in oesophageal manometry or gastric emptying studies. This 
suggested a multifactorial aetiology to this condition (Young, Hadjiliadis et al. 2003). 
A strong correlation exists between distal and proximal pH monitoring (Davis. Lau et 
al. 2003). Many patients with evidence of reflux on distal pH monitoring will have 
proximal reflux. 
Another study of 43 patients showed that mean oesophageal acid exposure time was 
10%. Thirty of 43 patients had abnormal tests in total. Twenty four of 43 had 
abnormal tests in the upright position and 29 of 43 were abnormal when supine. This 
cohort of patients with GORD consisted of asymptomatic and symptomatic patients 
(Hadjiliadis, Duane Davis et al. 2003). A further study suggests that of lung transplant 
recipients with GORD, a third will have ineffective oesophageal motility (Davis, 
Shankaran et al. 2010). 
GORD is associated with worse pulmonary function tests in the post-transplant 
population (Hadjiliadis, Duane Davis et al. 2003). Over half of patients in this study 
had allograft dysfunction based on FEV 1 measurements- 9 had BOS 1. 7 had BOS2 
and 10 had BOS 3. Seventy six percent of patients with allograft dysfunction had an 
abnormal oesophageal pH study compared to 59% of patients without allograft 
dysfunction. A negative correlation existed between the severity of total/upright acid 
reflux and FEV1 (Hadjiliadis, Duane Davis et al. 2003). 
Another study by D'Ovidio evaluated reflux post-lung transplantation, using a 2 probe 
pH monitor. Abnormal distal or proximal pH was present in 32% of patients at 3 
months and 53% at 12 months (D'Ovidio, Mura et al. 2006). This suggests a 
worsening of reflux over the first year post-transplant. The frequency and severity of 
reflux, especially the upright acid exposure time, is associated with chronic allograft 
dysfunction. Proximal oesophageal reflux is also associated with decreased lung 
function (Hadjiliadis, Duane Davis et al. 2003). 
A further study has suggested that 48% of lung transplant patients have reflux after 
the first year post-transplant. Almost a third of these patients had exclusively weakly 
acid reflux (pH>4) (Blondeau, V. Mertens et al. 2008). A further study using pH 
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impedance supports this prevalence of weakly acid reflux (27%) (King, Iyer et al. 
2009). There is evidence suggesting a link between non-acid reflux on pH/impedance 
testing and aspiration (Blondeau, Mertens et al. 2009). The study from Harefield 
Hospital suggested that total reflux detected by impedance is a risk factor for BOS 
whereas oesophageal acid exposure was not (King, Iyer et al. 2009). The presence of 
reflux, rather than the pH of reflux, may be the important issue. Thus PPI therapy is 
excluded as an anti-reflux therapeutic option in lung transplant recipients. An 
important implication of this study is that impedance may be important in GORD 
assessment post-lung transplantation. 
A small study from Australia suggests that many transplant patients experience reflux 
and obstructive sleep apnoea overnight. This may be important as studies in a lung 
transplant population showed the upper oesophageal sphincter has no intrinsic tone 
during sleep and there is a predisposition to reflux (Shepherd, Chambers et al. 2008). 
Post transplant pH studies have had to be performed after discontinuing anti-acid 
therapy (Hadjiliadis, Duane Davis et al. 2003). Adopting a pH based approach to 
reflux, potentially ignores weakly acidic or non-acid reflux. This may be 
physiologically important especially if this leads to aspiration in this vulnerable 
population (Stovold, Forrest et al. 2007). It would be of interest to assess patients 
whilst on PPI therapy and to evaluate non-acid or weakly acidic reflux. Combined 
Impedance/pH studies provide the opportunity to do this (Hirano 2006). 
1.4. Causes of post-operative reflux 
1. -1.1. Pre-operative reflux 
There is a high prevalence of GORD (63-68%) in patients with end stage lung disease 
(Cantu, Appel et al. 2004; Sweet, Herbella et al. 2006). 
1. -1.2. Vagal nerve damage 
The recipient pneumonectomy requires meticuluous haemostasis. The vagal nerves 
are at risk from direct trauma and electrocautery. Injuries often occur near the lung 
hila. Both nerves lie posterior-inferiorly in the mediastinum to the lung root. The right 
vagus nerve is in apposition to the trachea. The left lies in the interval between the 
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common carotid and the subclavian artery. At the lung roots nerve branches are given 
off to the pulmonary plexus (Au, Hawkins et al. 1993). 
It is important to preserve the vagus, phrenic and recurrent laryngeal nerves. However 
this may prove difficult and maintaining haemostasis has a higher priority. 
Biomechanical vagal damage leads to delayed gastric emptying and dysmotility of the 
distal third of the oesophagus, promoting reflux post-transplantation (Au, Hawkins et 
al. 1993). 
The physiological consequences of vagotomy on the oesophagus have been studied in 
animals. The vagus innervates the striated muscle of the oesophagus. The effects are 
dependent on the proportion of striated muscle present. Dysphagia may result from a 
complete vagotomy. (Au, Hawkins et al. 1993). 
Complete vagotomy results in complete atonia. Partial vagotomy enhances liquid 
gastric emptying and delays solid gastric emptying as it disrupts receptive relaxation 
of the stomach and leads to increased intragastric pressure. The increased liquid 
emptying is mainly dependent on an antro-duodenal pressure gradient. By disturbing 
antral motility solid emptying is slowed (Au, Hawkins et al. 1993). 
The lower oesophageal sphincter is under neural (vagal) and hormonal control. 
Vagotomy in dogs and cats affects the lower oesophageal sphincter resting tone and 
may induce spasm. In humans delayed gastric emptying predisposes to GORD. 
Evidence of oesophageal dysmotility and delayed gastric emptying is a manifestation 
of a complete vagotomy. 
Modification of surgical technique can decrease the risk of vagal injury and thus 
reduce morbidity. This involves circumspect or bipolar diathermy and stapling. Risk 
to the vagal nerve is minimized by performing an alternative operation- bilateral 
sequential lung transplantation. Thus dissection of the distal trachea, subcarinal and 
posterior mediastinum can be avoided and the vagus can be preserved (Au, Hawkins 
et al. 1993). 
1. -1.3. Post-operative gastroparesis 
Up to 90% of patients have delayed gastric emptying post-lung transplant (D'Ovidio 
and Keshavjee 2006; D'Ovidio, Mura et al. 2006). 
A study by Au et al. involved patients post heart-lung transplantation. A radioisotope 
of technetium was used to perform gastric emptying studies for liquids and solids to 
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evaluate foregut dysmotility. Symptoms of dysmotility- flatulence, nausea and reflux 
were common. Evidence of foregut dysmotility and vagal damage (delayed gastric 
emptying) were also common post transplantation. Thirty percent (3/1 0) of patients 
had grossly delayed liquid/solid emptying compatible with complete vagotomy. Six 
patients had delayed liquid emptying but normal solid emptying. This finding is 
unusual and the opposite of what is expected post vagotomy. The physiological 
mechanisms behind this are unknown (Au, Hawkins et al. 1993). When compared to a 
heart-lung transplant, a single lung transplant or a single sequential lung transplant 
requires less extensive dissection and thus less risk of vagal nerve damage. 
Several other studies have shown delayed gastric emptying to be prevalent post lung 
transplant (23-91 %) (Hadjiliadis, Duane Davis et al. 2003; Young, Hadjiliadis et al. 
2003; D'Ovidio, Mura et al. 2006). Gastroparesis did not necessarily predispose 
patients to reflux as determined by pH monitoring (Young, Hadjiliadis et al. 2003). 
The above evidence suggests gastric dysmotility is common post-lung transplantation. 
1. -I. -1. Transplant medication 
Gastrointestinal complications are common post-transplantation, often due to 
immunosuppressant therapy (Lubetkin, Lipson et al. 1996; Nunes, Lucey et al. 1999; 
Gautam 2006). After renal transplant, 20% of patients develop gastrointestinal 
complications (Ponticelli, Passerini et al. 2005) and 8% of renal patients have been 
reported to have upper gastrointestinal complications (Logan, Morris-Stiff et al. 
2002). These may be related to side effects of medication or infection. Nausea, 
vomiting and dyspepsia (83%) are common (Ponticelli. Passerini et al. 2005; Ekberg, 
Kyllonen et al. 2007). Forty seven percent of renal transplant patients report reflux 
symptoms (Ekberg, Kyllonen et al. 2007). These may be related to gastroparesis from 
the gastrotoxicity of calcineurin inhibitors, steroids and mycophenolate mofitil 
(Austin, Gougoutas et al. 2000; Ponticelli, Passerini et al. 2005). Viral gastric 
infection may also affect gastric motility (Austin, Gougoutas et al. 2000). 
Gastroparesis has been documented post-transplantation in lung, renal and bone 
marrow transplant patients (Au, Hawkins et al. 1993; Eagle, Gian et al. 200 I; Logan. 
Morris-Stiff et al. 2002). 
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1 . .:1.5. Post-pneumonectomy reflux 
Pneumonectomy with and without transplantation, has been associated \\ ith 
oesophageal dysfunction (Suen, Hendrix et al. 1999; Mitchell, Hazelrigg et al. 2006). 
Reflux has been associated with pneumonectomy in the non-transplant situation 
(Kopec, Irwin et al. 1998). This may be due to anatomical changes. local trauma, 
traction on the oesophagus, vagal injury or diaphragmatic complications (Kopec, 
Irwin et al. 1998; Suen, Hendrix et al. 1999; Berry, Friedberg et al. 2006; Mitchell, 
Hazelrigg et al. 2006). 
1.5. Detection of reflux 
Many methods have been developed to detect and quantify GORD. Most have been 
aimed at all patients but only some have been specific to lung transplant recipients. 
1.5.1. Endoscopy 
Flexible endoscopy is often performed early in the management of reflux symptoms. 
It is performed to exclude malignancy, achalasia and strictures and can diagnose 
oesophagitis. Endoscopy allows histological samples to be taken. A third of patients 
with a normal oesophagus on endoscopy will have pathological reflux (Lundell, Dent 
et al. 1999). 
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Figure 1-2 Endoscopic views of oesophagus and Los Angeles grades of oesophagitis (Lundell , 
Dent et at. 1 
Grade 2 Mucosal break > 5mm 
Grade 4 Mucosal break ;::75% of oesophageal 
circumference 
G rade 3 M ucosa l break cont inu ous between > 2 
mucosal folds 
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1.5.2. Ambulatory pH testing 
Ambulatory pH monitoring has been used for many years to evaluate GORD. It has 
previously been called the "gold-standard" (Hirano 2006). pH monitoring- the 
measurement of H+ ions- is very useful for assessing acid reflux. (Wise and Murray 
2007). Measurements are based on the time that the pH of the oesophagus is less than 
4. This is detected by applying a probe 5cm above the lower oesophageal sphincter 
(Hirano 2006). However, there are several disadvantages. Its main shortcoming is its 
inability to detect or acknowledge weakly acid and non-acid reflux. It is also unable to 
measure the proximal extent of reflux. Dual channel pH monitors have been designed 
to measure proximal and distal reflux. 
1.5.3. Bravo capsule 
To remove the technical difficulties of nasal catheterisation, the Bravo Capsule 
(Medtronic, Minneapolis, MN, USA) has been developed. This is a wireless pH probe 
which is attached to the lower oesophageal mucosa during endoscopy or by using a 
dedicated catheter. Its advantages are its tolerability and the fact it allows recording 
for over 24 hours (Hirano 2006). 
1.5.-1. Bilitec 
The Bilitec 2000 (Medtronic. Minneapolis, MN. USA) device only measures bile 
reflux (Hirano 2006). A specific diet has to be used. Refluxate can get stuck in the 
sensor opening overestimating bile exposure. There can be difficulties with dietary 
compliance. The detection of bile refluxate is important. It may be better achieved by 
the biomarker approach assessing levels in the bronchoalveolar lavage fluid. 
1.5.5. Multichannel intraluminal impedance 
Standard pH monitoring may underestimate the degree of reflux. Therefore 
oesophageal impedance was developed and has a growing role in the detection of 
reflux (Wise and Murray 2007). Convergences of improvements in catheter 
technology and computer software in the last decade have increased the availability of 
multichannel intraluminal impedance (MIl). an exciting technology that is very 
sensitive in the detection of reflux. The direction and the proximal extent of liquid and 
gas reflux events can be accurately measured by MIl (Wise and Murray 2007). It is 
becoming the gold standard for assessment of reflux (Bredenoord 2008). 
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Theory, validation, intra-observer variability & reproducibility 
Impedance is inversely proportional to electrical conductivity and cross sectional area 
of the lumen. It is studied using a catheter with multiple spaced, pairs of cylindrical 
metal rings connected in circuits to the lumen of the tubular organ. Each paired ring 
circuit has a voltmeter outside the body. As boluses pass, there are changes in 
impedance recordings. Gases cause a sharp rise in impedance, with rapidly decreasing 
conductivity. Fluids (food, water and gastric contents) decrease impedance by 
connecting circuits between electrodes (Wise and Murray 2007). 
Before a fluid or food bolus passes, the oesophagus is empty and the impedance is 
intermediate reflecting the intermediate conductivity of the oesophageal mucosa. 
Whilst a fluid bolus passes, impedance is low. After it has passed, impedance is again 
intermediate (Figure 1-3). These changes in impedance occur when the bolus is 
between a pair of electrodes. Liquid reflux will drop impedance by 50% in 2 
consecutive sensors. Gas reflux is defined as a retrograde, simultaneous rise in 
impedance to >3,000 ohms (Wise and Murray 2007). Initially impedance was 
measured in the lumen of the gastrointestinal tract and has been validated by barium 
radiographs in anaesthetised cats (Sifrim, Silny et al. 1999). 
Multichannel intraluminal impedance collects data samples at high frequency rates, 50 
Hz. This enables it to determine the direction of the bolus. Swallowed liquids can be 
distinguished from reflux events and swallowed air can be distinguished from 
"belched" air (Wise and Murray 2007). 
There is some intra- and inter-individual variability with impedance measurements. 
Bredenoord et al evaluated 20 healthy volunteers, 2 weeks apart. They found that 
there was more variability between different subjects by >50%, than within the same 
subjects measured at different times (Bredenoord, Weusten et al. 2005: Wise and 
Murray 2007). 
Refluxate can be acid, weakly acid or weakly alkaline and can be composed of liquid, 
gas or a mixture of the two. Patients with pathological GORD. have more acid events 
and fewer non-acid and weakly acid reflux events when compared to normal subjects. 
Pure gas reflux is a non-acidic event (Wise and Murray 2007). Gas reflux often occurs 
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whil st in the left lateral decubitus position , and liquid reflu x tends to occur in the right 
latera l decubitus position (W ise and Murray 2007). 
Figure 1-3: A weakly-acid liquid reflux event 
6th Ring r,4 
(17cm) 
5th R' lng 
(lScm) 
4th Ring 
(9cm) 
3rd R' lng 
(7cm) 
2nd R' lng 
(Scm) 
1 st Ring (3cm) 
pH7 
pH pH4 
- -
~--­( f'~ 
Legend: This picture shows a combined pH/impedance trace. The bottom reading is of 
pH , measured by the pH sensor located 5cm above the lower oesophageal sphincter. 
As the reading does not drop below pH 4, it shows that this is a weak ly-acidic event. 
The traces above the bottom reading represent the impedance values from 3.5.7.9.15 
and 17cm (1 st ring to 6th ring) above the lower oesophageal sphincter. The traces 
measure electrical impedance within the oesophagus. The sequential drop in 
impedance from the 1 st to the 6th ring, demonstrates a reflux event reaching the 
proximal oesophagus. 
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"Some" reflux is physiological, with an oesophageal acid exposure of <4.5% beim! 
considered normal (DeMeester, Wang CI et al. 1980). In a "normal" population (72 
healthy volunteers with a mean age of 35 years, with no known gastrointestinal 
disease or history of thoracic or abdominal surgery), a study showed that on average 
there will be 40 reflux events per 24 hours (Zerbib, des Varannes et al. 2005). After a 
standardised liquid meaL most events were mixed gas and liquid reflux events (Wise 
and Murray 2007). Two thirds of reflux events are non-acidic or weakly-acidic events 
(Wise and Murray 2007). 
Impedance allows detailed evaluation of refluxate and evaluation in patients on PPI 
therapy (Wise and Murray 2007). Proton pump inhibitors have been shown not to 
decrease reflux events but render the events non-acid or weakly acid. Thus, PPls do 
not prevent reflux (Wise and Murray 2007). There is evidence to suggest that PPls 
may not reduce the volume of gastric secretions (Verdu, Viani et al. 1994). A study of 
pH monitoring of 250 patients on PPI therapy showed 3.8% to have an abnormal 
study. Impedance showed that weakly acid events were just as common after proton 
pump inhibitor therapy as acid events prior to acid suppression. The acid levels 
detected were greatly reduced but impedance showed that reflux events were just as 
common (Wise and Murray 2007). At least a third of reflux events are weakly alkaline 
or weakly acidic. These episodes may elicit symptoms (Sifrim 2005; Sifrim, Dupont 
et al. 2005). The association between atypical extra-oesophageal symptoms with 
reflux is controversial. A study, using pH-impedance, was performed on 10 subjects 
with symptomatic reflux. Half of the patients have a temporary association with reflux 
and cough. A causative link has yet to be proven (Wise and Murray 2007). 
Standard definitions have been created for acid reflux, superimposed acid reflux, 
weakly acid reflux (Figure 1-3) and weakly alkaline reflux on the basis of combined 
pH/impedance measurements (Table 1-2). Oesophageal and extra-oesophageal 
symptoms can be related to less acid reflux (Shay. Tutuian et al. 2004; Sifrim 2004; 
Sifrim, Castell et al. 2004; Zerbib, des Varannes et al. 2005). The distinction between 
"acidic", "weakly-acidic" and "non-acid" is artificially created on the basis of pH and 
is of limited importance. All refluxate if aspirated will be damaging to the lungs 
regardless of pH. 
Table 1-2: Standard definitions for reflux events 
Acid reflux Refluxate of gastric juice which reduces the pH<4 
Superimposed Further refluxate of gastric juice before the pH has recovered to 
acid reflux >4. 
Weakly acid Refluxate of gastric juice when the pH remains between -.t- 7. 
reflux 
Weakly alkaline Refluxate of gastric juice when the nadir pH is greater than 7 
reflux 
(Shay, TutUlan et al. 2004; Slfnm 2004; Sifrim, Castell et al. 2004: Zerbib, des 
Varannes et al. 2005) 
Weakly acid reflux events often occur near meal times. If there is prolonged gastric 
emptying, patients experience an increase in weakly acid reflux and a decreased acid 
reflux (Sifrim, Castell et al. 2004). Weakly acid refluxate causes less heartburn when 
compared to acid reflux, but patients may suffer regurgitation or chronic cough. 
(Sifrim, Castell et al. 2004). 
1.5.6. Comparison ofpH monitoring to impedance 
Acid reflux events, detected by impedance appear to be shorter. as neutralisation of 
acid takes longer than the clearance of oesophageal volume. There is a higher 
detection rate of reflux events with impedance compared to pH monitoring. In one 
study, Impedance detected 96% of reflux events compared to 28% detected by pH 
study using acid reflux event definition. Non-acid and weakly acid reflux events are 
common in normal subjects and those with GORD (Sifrim 2004; Wise and Murray 
2007). 
The Porto consensus on the detection of reflux stated that reflux is best evaluated by a 
combination of impedance and pH monitoring (Hirano 2006). This is in agreement 
with the British Society of Gastroenterology guidelines (Bodger and Trudgill 2006). 
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1.5. 7. Reflux questionnaires 
Questionnaires have been designed to detect symptoms suggestive of both 
oesophageal and extra-oesophageal reflux. These have been used to assess severity of 
symptoms and responses to treatment. 
Symptoms do not always correlate with objective assessments of reflux (Young, 
Hadjiliadis et al. 2003; D'Ovidio, Singer et al. 2005; Hartwig, Appel et al. 2005; King, 
Iyer et al. 2009). In one study, there was no difference in the prevalence of abnormal 
pH studies in end-stage lung disease patients reporting or not reporting symptoms. 
There was no relationship between the severity of symptoms and the DeMeester score 
(Sweet, Herbella et al. 2006). This is a method for analysing acid reflux based on the 
number of reflux events and the duration of reflux events (pH <4) within a 24 hour 
period (Johnson, Demeester et al. 1974). 14-33% of patients had asymptomatic distal 
reflux (Young, Hadjiliadis et al. 2003; D'Ovidio, Singer et al. 2005; Sweet, Herbella 
et al. 2006). The symptoms of reflux may be absent in patients post-transplant 
(Hartwig, Appel et al. 2005; Sweet, Herbella et al. 2006). This hyposensitive 
condition may be partially due to damage to the vagal nerve. 
Little is known of the value of extra-oesophageal reflux questionnaires in assessing 
reflux in lung transplant recipients. The DeMeester Reflux Questionnaire is a 
validated straightforward tool to assess basic reflux symptoms (DeMeester, Wang CI 
et al. 1980). It is based on a score of 0-3 for symptoms of reflux, regurgitation and 
dysphagia. The DeMeester Reflux Questionnaire has been useful in assessing the 
responses to treatment of both medical and surgical patients however it has never been 
validated in lung transplant recipients. 
Laryngopharyngeal reflux does not always cause classical heartburn or oesophagitis. 
Signs and symptoms of laryngopharyngeal reflux include hoarseness, vocal fatigue, 
excessive throat clearing, globus pharyngeus, chronic cough, post-nasal drip and 
dysphagia. Several laryngopharyngeal reflux questionnaires have been designed. One 
validated questionnaire which focuses on extra-oesophageal reflux symptoms is the 
reflux symptom index (RSI) (Figure 2.1). This is a 9 item questionnaire (Belafsky. 
Postma et al. 2002). An alternative LPR questionnaire is the laryngopharyngeal 
reflux-health related quality of life questionnaire (Carrau, Khidr et al. 2005). This was 
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considered for our study. As it is a 43 point questionnaire, we favoured the more 
concise RSI questionnaire for ease of administration. The RSI is easily administered 
and highly reproducible. It was validated on 25 laryngopharyngeal reflux patients and 
25 controls. A limitation of this questionnaire is that 5 points can be attributed to 
heartburn. Thus, the RSI is not limited to extra-oesophageal reflux symptoms but can 
be elevated in patients with typical reflux symptoms. A RSI score of greater than 13, 
is abnormal (Belafsky, Postma et al. 2002). As this is predominantly based on extra-
oesophageal reflux questions, it may have a role in assessing lung transplant recipient. 
There is no literature to support this suggestion. 
Quality of life is a concept which is subjective and not directly measurable (Yano, 
Sherif et al. 2009). In 1948, the World Health Organisation released a consensus 
definition of quality of life as a complete state of physical, psychological and social 
health and not merely the absence of disease. Questionnaires need to cover physical 
function, symptoms experienced, social function, role performance, subjective feeling 
of well-being and emotional state (Kirk 1986; Eypasch, Williams et al. 1995; Yano, 
Sherif et al. 2009). A diversity of questionnaires exist and are both generic and 
system/disease specific. The gastrointestinal quality of life index (GiQLI) was 
developed by Eypasch in German. This has been subsequently translated into English 
and French (Eypasch, Williams et al. 1995). It is a well established, tested and 
validated tool which has been shown to be reproducible (Eypasch, Williams et al. 
1995; Yano, Sherif et al. 2009). It is system specific (Eypasch, Williams et al. 1995). 
Both the gastro-oesophageal reflux disease health-related quality of life questionnaire 
and short form- 36 are useful and patient centred. They do not address the 
gastrointestinal system alone. Combined, the questionnaires work well but require the 
patient to fill out two separate forms. The quality of life in reflux and dyspepsia 
questionnaire was also considered but was dismissed as it focuses towards the foregut 
rather than the whole gastrointestinal system (Wiklund, Junghard et al. 1998). The 
GIQLI is a single form that is a good alternative to using the gastro-oesophageal 
reflux disease health-related quality of life questionnaire and short form- 36 
(Eypasch, Williams et al. 1995; Yano, Sherif et al. 2009). The use of GIQLI is 
recommended for the assessment of anti-reflux surgery by the European Association 
for Endoscopic Surgery and has been validated for this purpose (Korolija, Sauerland 
et al. 2004). 
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1.6. Aspiration techniques 
Aspiration studies have been carried out In the stomach, oesophagus and lungs. 
Historically oesophago-gastric aspiration studies have proven reflux occurs. Now 
these studies have been applied for a different reason. Bronchoalveolar lavage 
technique can now be analysed for gastrointestinal contents. 
GORD may deleteriously influence lung allografts in several ways. It may trigger 
bronchoconstriction via a vagal reflex. Lung transplant recipients have denervated 
lungs and the oesophagus may also have undergone denervation due to vagal damage. 
Bronchoconstriction secondary to vagal reflex is unlikely to be a mechanism of injury 
in this population. Extra-oesophageal reflux may lead to microaspiration and lung 
injury (Linden, Gilbert et al. 2006). Microaspiration is difficult to define. We propose 
that it means the aspiration of small volumes of gastric contents into the lungs causing 
subclinical damage. This does not lead to aspiration pneumonia. Microaspiration may 
lead to epithelial damage, stimulation of cytokine production, inflammation, graft 
failure and may lead to BOS. Post-transplantation there are impaired pulmonary 
defence mechanisms: cough and muco-ciliary clearance (Veale, Glasper et al. 1993). 
Muco-ciliary clearance has been shown to be less than 15% of normal (Veale, Glasper 
et al. 1993). These factors may lead to a prolonged and increased contact between 
reflux material and the lung parenchyma (Young, Hadjiliadis et al. 2003; Cantu, 
Appel et al. 2004; D'Ovidio, Mura et al. 2005; Ward, Forrest et al. 2005; D'Ovidio and 
Keshavjee 2006). The cough reflex has been shown to improve over the first year 
post-transplant (Duarte, Terminella et al. 2008), but it is unknown whether muco-
ciliary clearance improves or not. 
Little is known about the role of aspiration during swallow. A recent study by Atkins 
(2007), shows that 64% of lung transplant recipients aspirate during swallowing, 78% 
of these patients were asymptomatic. This is associated with a prolonged hospital stay 
and increased episodes of severe rejection (Atkins, Trachtenberg et al. 2007). In 
studies on rats by Duke University exposure of the lung allograft to gastric juice lead 
to grade 4 acute rejection, characterised by monocyte infiltration, fibrosis and lung 
destruction. Aspiration has been shown to increase CD8+ T -cells. T-cell activation is 
involved in acute rejection (Hartwig, Appel et al. 2006; Stovold, Forrest et al. 2007). 
Furthermore chronic aspiration in rats is associated with obliterative bronchiolitis (Li. 
Hartwig et al. 2008). Further animal models of aspiration suggest lung damage is 
independent of pH. It could even be damaging at pH >7. suggesting acid 
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neutralization therapy to be inadequate in the treatment of reflux (Downing, Sporn et 
al. 2008). There are limitations to these animal models and no studies have been 
performed looking at microaspiration (Robertson, Shenfine et al. 2009). A further 
study looking at aspiration in miniature swine has suggested that aspiration may 
increase fibrosis, obliterans bronchiolitis and infection. There was an increased 
shedding of allograft alloantigens and increased activity of the indirect alloimmune 
response. This is where the host antigen presenting cells present donor processed 
MHC peptides to the immune system (Meltzer, Weiss et al. 2008). One hypothesis to 
explain this may be that aspiration leads to increased cell death and breakdown, MHC 
peptides are released and picked up by host antigen presenting cells and immunity is 
then triggered. Aspiration may introduce bacterial infection into the allograft. Little 
evidence supports this and no single organism has been implicated. Aspiration studies 
could be carried out in BALF and gastric fluid to search for gastric microflora. 
The danger signal hypothesis, first suggested by Matzinger (Matzinger 1994) may 
explain the link between aspiration and chronic rejection. It suggests that the immune 
system's main priority is not the recognition of foreign material but of material that is 
injurious and harmful (Matzinger 1994; Matzinger 2002). It suggests that tissues 
undergoing stress, damage or abnormal death processes will release endogenous 
danger signals which will activate dendritic cells. This then triggers both innate and 
specific immunity (Gallucci, Matzinger et al. 2001). Thus injury to the allograft may 
trigger both inflammation and rejection. 
The Toll-like 4 receptor is a membrane receptor highly expressed on alveolar 
macrophages and airway epithelia which detects antigens and stimulates innate 
immunity. Studies have suggested that activation of innate immunity via the Toll-like 
4 receptors may also activate specific immunity. There is growing evidence to suggest 
that stimulation of the Toll-like 4 receptor by external factors, including 
lipopolysaccharide, may stimulate the specific immunity and lead to inflammation and 
acute rejection (Palmer, Burch et al. 2003; Palmer, Burch et al. 2005: Garantziotis. 
Palmer et al. 2007). 
The end results of injuries leading to BOS are fibrosis and airway remodelling. The 
fibroblasts which effect fibrosis may originate from recruited circulating fibrocytes 
and through in situ airway proliferation. It has been suggested by our group that 
fibroblasts may originate from injured epithelium through Epithelial Mesenchymal 
Transition (EMT) (Ward, Forrest et al. 2005). EMT is recognised to occur in 
organogenesis, metastasis and chronic rejection of other transplant organs. It is 
denoted by loss of epithelial markers and up-regulation of mesenchymal properties. 
Reflux injury is associated with the loss of E-cadherin in the oesophageal epithelium 
of patients with Barrett's oesophagus. This loss is more marked in oesophageal 
adenocarcinoma (Bailey, Biddlestone et al. 1998). It occurs despite the presence of 
defences such as carbonic anhydrase, evolved in the oesophagus to protect against 
reflux. The airway epithelia without such defences may be expected to be more 
vulnerable to aspiration injury. It is reasonable to hypothesise that microaspiration 
may directly injure the allograft leading to EMT, fibrosis and BOS. A translational 
implication of this is that treatments of GORD may reduce microaspiration, epithelial 
injury and EMT thus impacting favourably on BOS (Robertson, Ward C et al. 2010). 
1.7. Biomarkers of aspiration 
1.7.1. Pepsin 
Pepsin, a proteolytic enzyme, is secreted by chief cells located in gastric pits in the 
stomach as a precursor pepsinogen (Wallace 1989). The reported "normal" 
concentration of pepsin in gastric juice in people without PPI therapy is 100-600Jlg/ml 
(Wallace 1989; Gotley, Morgan et al. 1991; Balan, Jones et al. 1996). Pepsin has been 
used as a marker of extra-oesophageal reflux in bronchiectasis and cystic fibrosis. It is 
a potential marker of gastric aspiration (Ward, Forrest et al. 2005). Several papers 
have been published using pepsin as a biomarker of extra-oesophageal reflux with 
glue ear and as a marker of aspiration with lung disease and pulmonary damage 
(Tasker, Dettmar et al. 2002; Tasker, Dettmar et al. 2002; Ufberg, Bushra et al. 2004: 
Ward, Forrest et al. 2005). 
Assay variability, in general, can be a serious problem (Haslam, Baughman et al. 
1999) and the analysis of results for pepsin between units is varied (Table 1-3). Pepsin 
can be measured using an ELISA and also as an activity assay (Badellino, Buckman et 
al. 1996). Gastric juice contains 100-600Jlg/ml of pepsin(Wallace 1989: Gotley, 
Morgan et al. 1991). Alveolar fluid is diluted one hundred to two hundred fold by 
bronchoalveolar lavage. If neat gastric juice was aspirated then the alveolar fluid 
would contain approximately 100-600Jlg/ml. With a hundred to two hundred fold 
dilution of gastric juice this would then become 0.5-6Jlg/ml. Some papers published 
have a lower limit of detection of 1 Jlg/ml (Metheny, Chang et al. 2002). This cut off 
would most likely miss aspiration events. Further variability arises over the exact 
volume of lung fluid (approximately 1-2ml) in each patient- the volume instilled in 
the BAL and the volume of BAL recovered from the lung. These variables can 
explain some of the differences in levels of biomarkers reported in the BAL fluid. 
Comparing results from units can be difficult (Haslam, Baughman et al. 1999). 
T bl 1 3 S f a e - : ummary 0 pepsm levels in aspiration studies 
Study Instilled volume Pepsin levels 
(Ward, Forrest et al. 2005) 180ml 35-1375ng/ml 
(Stovold, Forrest et al. 2007) 180ml 0-51.7ng/ml 
(Blondeau, V. Mertens et al. 2008) 100ml 0-2000ng/ml 
(Starosta, Kitz et al. 2007) Unknown 0-2500ng/ml 
Pepsin is a general marker of aspiration in lung transplant patients (Blondeau, V. 
Mertens et al. 2008). Bronchoalveolar lavage (BAL) pepsin levels in clinically stable 
lung transplants were shown to be up to one hundredfold higher when compared to 
controls (l09ng/ml vs <lng/ml) suggesting gastric aspiration (Ward, Forrest et al. 
2005). Levels detected were 10-1,000 times higher than serum reference range (Ward, 
Forrest et al. 2005). Pepsin was still detected even after treatment with a PPI. This 
further supports the hypothesis that prophylactic PPIs will suppress symptoms, but 
there may still be occult aspiration of gastric contents (Ward, Forrest et al. 2005). 
Further studies using a pepsin( ogen) ELISA were performed to evaluate the levels of 
pepsin in the BAL samples (Stovold, Forrest et al. 2007). 
36 lung transplant patients in three equal groups: clinically stable; acute vascular 
rejection and BOS were studied. BAL pepsin levels were increased in transplant 
patients compared to control volunteers (8.3 vs 1.1 ng/ml) (p=0.02). BAL pepsin was 
raised in lung transplant patients without BOS showing that pepsin can be present 
without airflow limitation (Stovold, Forrest et al. 2007). Detection of pepsin. as 
evidence of aspiration, is present even in those on proton pump inhibitor therapy. 
The highest levels were present in patients with acute A2+ histological rejection. 
These patients also had the highest grades of inflammation on pathology. This is 
important and further supports the hypothesis that there may be interaction between 
alloimmune and non-alloimmune factors suggesting a link between acute rejection 
and aspiration (Stovold, Forrest et al. 2007). There was no statistical significant 
difference in pepsin levels between stable and BOS patients although levels in BOS 
patients were higher. BAL pepsin levels were similar in those on or off PPI therapy. 
There was no relationship between time post-transplant and pepsin levels (Stovold. 
Forrest et al. 2007). 
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1. 7.2. Bile salts 
Bile salts (aka bile acids) are water soluble steroids synthesised in the liver by 
hepatocytes during the catabolism of cholesterol. They are a major component of the 
bile secreted by liver (Jenkins and Hardie LJ 2008). Bile salts are normally conjugated 
with glycine or taurine before secretion (Klokkenburg, Hoeve et al. 2009). Their role 
is to aid digestion and absorption of lipids in the small intestine. They are strongly 
cytotoxic and associated with gastrointestinal malignancy (Jenkins and Hardie LJ 
2008). The main bile acids present are the glycine and taurine conjugates (Table 1-4) 
(Janowitz, Swobodnik et al. 1990; Jenkins and Hardie LJ 2008). Bile salts are later 
resorbed in the ileum and colon (Klokkenburg, Hoeve et al. 2009). Bile acids exist as 
mixtures and due to their detergent status, they will influence each other's solubility. 
For example, taurine conjugates are strong sulphonic acids, which can protonate other 
bile acids. This allows other bile acids to enter the epithelium without any regard for 
established solubilities (Jenkins and Hardie LJ 2008). 
Table 1-4: ComposItion of bile and biochemical properties 
Bile acid Water solubility pKa 
Free bile acids 
Cholic acid Poorly soluble 
Deoxycholic acid Poorly soluble 
Chenodeoxycholic acid Poorly soluble 
Glycine conjugates 
Glycocholic acid Poorly soluble 
Glycodeoxycholic acid Poorly soluble 
G lycochenodeoxycho lie Poorly soluble 
acid 
Taurine conjugates 
Taurocholic acid Very soluble 
Taurodeoxycholic acid Very soluble 
Taurochenodeoxycholic Very soluble 
acid 
modified from (Jenkms and HardIe LJ 2008) 
5.2 
6.2 
6.2 
3.8 
4.8 
4.3 
<2 
<2 
<2 
% in bile 
Trace 
Trace 
Trace 
30 
15 
30 
10 
10 
5 
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Duodenogastric reflux is a physiological event especially in the post-prandial 
(Klokkenburg, Hoeve et al. 2009) and early morning periods (Byrne, Romagnoli et al. 
1999). Decreasing gradients of bile concentration have been reported from the pre-
pylorus to the oesophagus (Klokkenburg, Hoeve et al. 2009). suggesting dilution of 
bile salts over distance. 
Pancreatic and biliary secretions may be cytotoxic both to gastro-oesophageal mucosa 
and also to pulmonary epithelium (Henderson, Fung et al. 1975; Oelberg, Downey et 
al. 1990). Unconjugated bile acids may pass the cell membrane in a non-ionised 
lipophilic form at pH 3-6. After entering the cell they become ionised due to high 
intracellular pH and are trapped inside the cell. Bile acids may reach intracellular 
levels eight times higher than luminal levels. This injures cells and their tight 
junctions and may makes cells susceptible to other injuries (Jenkins and Hardie LJ 
2008; Klokkenburg, Hoeve et al. 2009). 
Various methods have been reported to detect bile salts. A common method is the 3a 
hydroxylase method described by Fausa & Skalhegg (Fausa and Skalhegg 1974). This 
assay is not affected by pH but the presence of food or colourants can interfere with 
results (Collins, Watt et al. 1984). There is some contention about the lower limit of 
detection of photo spectrometric assays; Collins et al suggested 62.5/lmoI/L (Collins, 
Crothers et al. 1985), Klokkenburg et al claims 5/lmolll (Klokkenburg, Hoeve et al. 
2009), Biostat, who produce the commercially available assay claim a lower limit of 
detection l/lmollL and the Leuven group have claimed an accuracy of 0.2/lmollL 
(Blondeau, Dupont et al. 2008; Blondeau, V. Mertens et al. 2008). These levels are 
lower than serum bile salt levels «8/lmollL) (D'Ovidio, Mura et al. 2005). One group 
have found this type of assay to be unreliable (Gotley, Morgan et al. 1990). The 
presence of 3a hydroxyl groups and sterol molecules interferes with and cause cross 
reactivity with the dehydrogenase enzyme and this assay. In normal serum. other 3a 
hydroxysteroids are present in less than a few nmollL (Klokkenburg, Hoeve et al. 
2009) and in one study lavage samples contaminated by blood had less bile salts 
present (Klokkenburg, Hoeve et al. 2009). 
There is a wide variation of intra-gastric bile salt concentrations reported between 
individuals and at varying times. Intra-gastric levels have been reported between 0-
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13,000flmol/l (Schindlbeck, Heinrich et al. 1987; Gotley, Morgan et al. 1990). 
Normal intra-gastric levels have been reported at <1 00-700flmolll (Collins, Watt et al. 
1984). 90% of people will have intra-gastric bile salts concentrations of less than 
250flmol/l (Gotthard, Bodemar et al. 1985). Intra-gastric levels up to 34,256flmolll 
have been reported post-gastrojejunostomy (Watt, Sloan et al. 1984). No data exists of 
intra-gastric bile salt levels in lung transplant recipients. 
There was no significant difference between fasting and post-prandial intra-gastric 
bile levels in one study (Collins, Crothers et al. 1985). Nine of these patients had 
levels >200flmol/l. Of these 9, seven had a pH < 3.5, showing high concentration of 
bile salts can be present in acidic refluxate (Collins, Crothers et al. 1985). 
A study compared levels of intra-gastric bile salts in controls, patients with duodenal 
ulcers, those undergoing highly selective vagotomy, polya partial gastrectomy. truncal 
vagotomy and pyloroplasty, truncal vagotomy and gastrojejunostomy. This showed 
patients with duodenal ulcers had increased intra-gastric bile salt concentrations pre-
operatively. Post-operatively patients who had undergone polya partial gastrectomy, 
truncal vagotomy and pyloroplasty, truncal vagotomy and gastrojejunostomy had 
increased intra-gastric bile salts. Those who underwent a highly selective vagotomy 
had decreased intra-gastric bile salts. Highly selective vagotomy preserves the pylorus 
and the antropyloroduodenal complex, whereas a complete vagotomy and 
pyloroplasty will not (Dewar, King et al. 1982). 
In summary intragastric bile acid concentrations are very variable between patients 
and throughout the day. Increased levels are seen in patients who have undergone 
surgery to disrupt the pylorus and antropyloroduodenal complex. 
Reported levels of bile salts in the oesophagus range from 0 to greater than 
10,000flmo1lL although most studies report a low median level (3.5-5.1 flmollL) 
(Kauer, Peters et al. 1997; Klokkenburg, Hoeve et al. 2009). A quarter of patients had 
no bile salts detectable in the oesophagus and levels greater than 1 ,000flmoliL are rare 
(Gotley, Morgan et al. 1991). Bile reflux often occurred on a background of acidic 
reflux pH 4-7(Kauer. Peters et al. 1995). 
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The artificial distinction between "acid" and "bile" reflux is a common 
misunderstanding. Whilst pure "bile" (or duodenal) reflux may occur post-
gastrectomy, virtually all duodenal reflux events will combine with gastric refluxate 
by mixing with gastric contents. When bile salts are detected in the oesophagus on a 
background of a higher pH, likely explanations are PPI use or elevation of gastric pH 
by food or bicarbonate from the duodenum. It must be remembered that the detection 
of elevated bile salts signifies gastric as well as duodenal reflux. 
In a further study, Kauer et al. assessed distal oesophageal aspirates for the presence 
of bile salts. Distal oesophageal bile salts were increased in the supine position and in 
the post-prandial period. Bile salts were present in 58% of normal controls and 86% 
of patients with GORD. The bile detected in the oesophagus consisted of 60% 
glycocholic acid 16% glycodeoxycholic acid, 15% glycochenodeoxycholic acid and 
remainder 10% taurocholic acid, taurodeoxycholic acid. taurchenodeoxycholic acid 
and glycolithocholic acid. 
In summary, oesophageal levels of bile salts are variable. Although the majority of 
oesophageal bile salt concentrations appear low, levels have been reported up to 
15,000f.1molil. 
Bile salt levels have been analysed in the saliva of patients. Levels detected in cystic 
fibrosis patients, pre-transplant have been reported at a median of 3.3f.1molll (Range 
2.4-6.1) and in patients with GORD a median of 1.23 f.1molll (Range 1.2-2.3). 
Chronic cough patients have a lower reported level 0.72f.1mol/l (0.2-1.2) (Blondeau, 
Dupont et al. 2008). 
In a study by De Corso et aI, patients undergoing Billroth II gastrectomy or total 
gastrectomy revealed 17/52 (32.6%) of patients having bile in saliva. Controls were 
negative for bile salts. A correlation existed between salivary bile. bilirubin. 
pepsinogen and laryngeal damage, suggesting extra-oesophageal reflux may be 
associated with laryngeal damage. Concentrations of bile salts have been documented 
with a mean of 1 f.1mol/l (range 0.5-5). 
The median level reported from a single study of middle ear effusion \\ere 
17.7f.1mollL (5.9-40.9f.1molll) (Klokkenburg, Hoeve et al. 2009). These were three to 
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twenty times higher than serum levels (Klokkenburg, Hoeve et al. 2009). The median 
level reported in middle ear is similar to oesophageal levels but the maximal levels 
reported are lower. 
Bile salts in the bronchoalveolar lavage fluid are markers of duodenal gastro-
oesophageal reflux and aspiration(D'Ovidio, Mura et al. 2005). BOS is associated 
with abnormal pH, the presence of bile salts in the BALF and duodeno-gastro-
oesophageal aspiration. 50% of patients with abnormal pH studies and 20% of 
patients with normal pH studies post-transplant had bile acids in the BALF. This may 
be significant as the presence of bile acids in the bronchoalveolar district, may 
decrease the time to the development of BOS significantly. 70% of patients with high 
levels of bile acids (>8 ~mo1/ml) in their BALF samples have been proposed to 
develop BOS within 12 months (D'Ovidio, Mura et al. 2006). 
Bile acid aspiration is associated with severe pulmonary injury (Henderson, Fung et 
al. 1975; D'Ovidio, Mura et al. 2005). Bile aspiration is cytotoxic, disrupts the cellular 
membrane and alters cationic permeability, as demonstrated in vitro on Type II 
pneumocytes (Oelberg, Downey et al. 1990; D'Ovidio, Mura et al. 2005; D'Ovidio and 
Keshavjee 2006). In the stomach, bile acids break the mucosa barrier. In the lungs 
they may disrupt the mucus layer and their detergent effect may disrupt the lipids in 
the surfactant. They may also cause direct injury to Type II pneumocytes that are 
responsible for surfactant protein and phospholipids production and homeostasis. Bile 
salts may also lead to down-regulation of innate immunity receptors on monocytes 
and macrophages (D'Ovidio, Mura et al. 2006). It has been shown in rabbits that bile 
salts cause decreased macrophage function by decreasing phagocytosis and LPS 
mediated cytokine production. Interferon-mediated signal transducers may be down-
regulated by bile salts (D'Ovidio, Mura et al. 2006). 
Bile aspiration is thought to disrupt the regional innate immunity. This encourages 
local infection and affects the balance of innate and adaptive immunity. Paradoxically 
this may lead to an up-regulation of and a more aggressive adaptive immunity as well 
as encouraging infection. (D'Ovidio, Mura et al. 2006). This immune response maybe 
augmented via damage to the surface epithelial cells (Davis, Lau et al. 2003). 
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The presence of bile salts has been associated with elevated neutrophils, IL-8 and the 
presence of bacteria, fungi, lower levels of pulmonary surfactant and higher 
inflammatory scores on transbronchial biopsy (D'Ovidio, Mura et al. 2006; Vos. 
Blondeau et al. 2008). There are lower levels of surfactant surface proteins A & D, 
(collectins) which are opsonins and regulate cytokine production. These proteins are 
involved in the cross-talk between innate and adaptive immunity (D'Ovidio, Mura et 
al. 2006). There are decreased levels of dipalmitoylphosphatidyl-choline and 
phosphatidyl-I-glycerol phospholipids, which play a role in maintaining the 
pulmonary epithelium and local innate immunity. There is increased lipid 
sphingomyelin (a membrane related phospholipid), which further supports the 
evidence of the cytotoxic effects of bile acids. This damages phospholipids and leads 
to alterations in the prospective mucosal barriers (D'Ovidio, Mura et al. 2006). 
A prospective study of 120 lung transplant patients evaluated bronchoalveolar lavage 
bile salts, interleukins, differential cell counts, microbiology testing, trans bronchial 
biopsies and BOS scores. (D'Ovidio, Mura et ai. 2005). The median score for bile 
acids in BOS negative patients (0.3f-LmollL) was lower than in BOS positive patients 
(1.6f-LmollL) (p=0.002). Patients with early BOS (developed within one year) had 
higher levels of bile acids (2.6f-LmoI/L) than those with late BOS (developed after one 
year) (0.8f-LmoI/L) (p=0.02) (D'Ovidio, Mura et al. 2005). Bronchiolitis obliterans 
syndrome positive patients had significantly higher levels of IL-8 (121 pg/ml vs 64.5) 
(D'Ovidio, Mura et al. 2005). 
Bile acid levels were divided into 3 groups: high >8f-LmollL 9.3% (10/107). low 0.1-
8f-LmoliL 57% (61/107) or none Of-Lmoi/L 34% (36/1 07). Patients with BOS had higher 
levels than those without. Of the two types of onset of BOS, levels of bile acids in the 
bronchoalveolar district seem to predispose to early BOS. IL-8 was also increased in 
correlation with increased bile acids and neutrophils. There was a correlation between 
bile acids and neutrophils. There was also a correlation between bile acids, IL-8 and 
early development of BOS (D'Ovidio, Mura et al. 2005). The relationship between 
bile salts and BOS is further supported by Blondeau (Blondeau, V. Mertens et al. 
2008). 
In a study by D'Ovidio et aI., the median bile salts level in those with positi\e 
biopsies for inflammation (1.1 f-LmollL) was higher than those with a negati\e biopsJ 
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(0.2~moI/L). Patients with positive microbiology samples had higher levels of bile 
salts (0.7~mollL) than those with negative samples (0.3~mollL). Higher bile acid 
levels were associated with increased fungal growth (0.75 versus 0.36~mollL). 
Cytomegalovirus status was not affected by bile salt levels (D'Ovidio, Mura et al. 
2005). 
The median IL-8 was 118 pg/ml in the high bile acid group, 107 pg/ml in the low 
group and 61 pg/ml in the group with no bile salts. Neutrophils in the high group (5%) 
were elevated when compared with the low group (2%) and for those with no bile 
acids (2%) (D'Ovidio, Mura et al. 2005). 
A further recent study in patients with cystic fibrosis suggests an increase in duodenal 
gastro-oesophageal reflux and aspiration post-transplantation (40% versus 60%). 
However the numbers are small and this was not a longitudinal study (Blondeau, 
Dupont et al. 2008). A summary of bile salt levels detected in several studies is shown 
in Table 1-5. 
Table 1-5: Summary of reported bile salt levels reported III t e upper an . h d I ower airways 
Study Fluid Instilled volume Bile salt levels 
(D'Ovidio, Mura et al. BALF Unknown 0-32 ~molll 
2005) 
(D'Ovidio, Mura et al. BALF Unknown 0->3.5 ~molll 
2006) 
(Blondeau, V. Mertens BALF 100ml 0-0.8 ~molll 
et al. 2008) 
(Vos, Blondeau et al. BALF 100ml 0.1-3.7 ~molll 
2008) 
(Blondeau, Dupont et al. BALF 100ml 1.2-6.1 ~molll 
2008) sputum 
(Blondeau, Mertens et BALF 100ml 0.4-1.5 ~molll 
al. 2009) 
(Klokkenburg, Hoeve et Middle Ear 0-0.5ml 5.9-40.9 ~molll 
al. 2009) 
(Starosta, Kitz et al. BALF Unknown 0.6-5.4 ~molll 
2007) 
1.7.3. Trypsin 
Trypsin is a protease secreted by the pancreas into the duodenum and can be used as a 
marker of duodeno-gastro-oesophageal reflux. It has been suggested that most of the 
active trypsin refluxed into the stomach, may be degraded by pepsin and cannot pass 
through the acid environment to reach the oesophagus. In one study. trypsin \\as 
found in 17 of 365 gastric juice aspirates and only 4 specimens had levels >20llg/ml. 
All of these samples had a pH >4.6. This suggests that trypsin may be a less useful 
indicator of aspiration and injury (Gotley. Morgan et al. 1991). 
1.8. Biomarkers of inflammation 
1.B.1. Neutrophils 
Neutrophils are likely to be associated with chronic rejection and contain potent 
inflammatory mediators. These include proteases, acid hydro lases and low molecular 
weight cationic proteins. Reactive oxygen metabolites induce parenchyma cell injury 
and extracellular matrix degradation. This may lead to pulmonary fibrosis (Zheng. 
Walters et al. 2000). 
The pathological mechanisms of BOS are unclear but involve T -cells. macrophages 
and the adaptive immunity. Little consideration has previously been given to the 
innate immunity. Persistent neutrophilic inflammation is associated with fibrosing and 
inflammatory pulmonary conditions including pUlmonary fibrosis, asbestosis and also 
severe asthma. Increased neutrophils & IL-8 in the BALF have been implicated with 
BOS and increased mortality (Zheng, Walters et al. 2000). Alveolar neutrophilia has 
been proposed as a predictor of mortality (Henke, Golden et al. 1999; D'Ovidio and 
Keshavjee 2006). 
Chronic inflammation affects all 3 compartments: the airway wall, lung parenchyma, 
and BAL fluid. Zheng et al (2000) performed a study investigating airway 
neutrophilia post-lung transplantation. Neutrophils were found beneath the 
epithelium, in the epithelium and in the lamina propria. The BALF neutrophil count 
was 557 neutrophils/mm2 for BOS, 450 neutrophils/mm2 for stable lung transplant 
patients and 220 neutrophils/mm2 for normal controls (Zheng, Walters et al. 2000). 
There was neutrophil accumulation in the airway walls of lung transplant patients 
with and without BOS. These levels were significantly higher when compared to 
normal controls. BALF neutrophils and IL-8 were increased in both groups but higher 
levels were present in those with BOS. There was a positive correlation between wall 
and BAL neutrophils (Zheng, Walters et al. 2000). There is also an association 
between elevated BAL neutrophils, increased IL-8 concentrations and BOS (Zheng, 
Walters et al. 2000). 
Henke, (1999) evaluated the median levels of neutrophils in the BAL samples as a 
predictor of mortality. Neutrophil levels were lower in survivors (2% of SAL 
3.+ 
leukocytes), compared to non-survivors (7% of BAL leukocytes). Deaths \\ere due to 
BOS, infection or non-pulmonary causes. High neutrophil counts in lavage fluid are a 
suggested predictor of increased mortality. Neutrophils are also a marker for acute 
rejection (Henke, Golden et al. 1999). 
A neutrophilic response to epithelial Injury from pathogens or aspiration may 
constitute a final common pathway, linking impaired defence mechanisms, infection, 
aspiration, inflammation, airway remodelling and BOS (Walters, Reid et al. 2008). It 
is increasingly recognised that epithelia may be both a target for injury and playa role 
in the damage process, including airway scarring. Epithelial mesenchymal transition 
(EMT) is a response to injury in which epithelial cells transform into fibroblasts. This 
potentially indicates a direct link between activation and injury of epithelium with 
subsequent fibrosis, airflow limitation and BOS (Ward, Forrest et al. 2005; Robertson, 
Griffin et al. 2009). 
1.8.2. lnterleukin 8 
Interleukin 8 is a marker of injury and is produced by many cells including epithelial 
cells, fibroblasts, smooth muscle cells, endothelial cells and alveolar macrophages in 
response to injury. It is an important chemokine in pulmonary pathology. Not only 
does it have a role in leukocyte trafficking especially neutrophils, but it also 
stimulates angiogenesis and has a direct stimulatory effect on lung mesenchymal and 
parenchymal cells. lL-8 is also a mucin secretagoge (Zheng, Walters et al. 2000; 
Strieter 2002). 
The mechanisms of BOS appears to involve lL-8 and neutrophils (D'Ovidio, Mura et 
al. 2005). BOS positive patients had significantly higher mean levels of lL-8 (121 
versus 64.5 pg/ml). There was no difference for lL-8 levels between early and late 
BOS patients (D'Ovidio, Mura et al. 2005). BAL lL-8 levels are highest in BOS 
patients, then stable lung transplant patients, then normal controls (Zheng, Walters et 
al. 2000). Immunostaining has localised lL-8 to peribronchial lesions in OB. 
Therefore it may contribute to the development of BOS through its neutrophil 
attracting and angiogenic role. It has multiple inflammatory and immunological 
activities and may also lead to airway remodelling. This could be another mechanism 
involved in the pathophysiological process ofBOS (Zheng, Walters et al. 2000). 
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1.9. Airway mucus and goblet cells 
Airway pathologies involving chronic airflow limitation or neutrophilia and 
suppuration can lead to mucus hypersecretion. In lung transplant there is a possibility 
for disordered mucus homeostasis and this may be problematic (Veale, Glasper et al. 
1993). To date, little research has been performed on this topic. Mucus also plays a 
role in other pulmonary pathologies including CF, COPD and asthma. Respiratory 
mucus is produced from the secretions of submucosal tracheobronchial glands and 
epithelial goblet cells. Epithelial surfaces are lined by mucus which consists of water. 
ions, glycoproteins (mucins), proteins and lipids. The mucins may be secretory or 
membrane tethered. Mucus is involved in muco-ciliary defence and the innate 
immune defence system. In the respiratory tract, it protects the airway against 
pathogens and environmental toxins by trapping and clearing particles. It has an 
antibacterial effect and humidifies the inspired air (Rose and Voynow 2006). 
Hypersecretion of mucus contributes to the morbidity of airways diseases, predisposes 
to respiratory infections and contributes to airflow obstruction and patient discomfort. 
It is associated with increased mortality (Kim 1997). 
In health, there is little mucus in the lungs. The amount is governed by production 
and clearance by cough and ciliary activity (Kim 1997). 
Hypersecretion of mucus may lead to the accumulation of mucus. An increased 
volume may be beneficial to combat infection or detrimental and lead to airway 
obstruction with enhanced deposition of inhaled particles in the tracheobronchial tree 
(Kim 1997). 
Mucin levels are increased in airway disease and lead to increased airway obstruction. 
Inflammatory/immune response mediators activate mucin gene regulation and airway 
remodelling including goblet cell hyperplasia. These changes are sustained and an 
increase in mucin production may contribute to airway obstruction (Rose and Voynow 
2006). 
The effects of aspiration on the respiratory mucus layers are complex and not fully 
understood. Pepsin and bile salts will disrupt this layer and expose the epithelium. 
They may also lead to an up-regulation of mucus secretion leading to airway 
obstruction. The overall changes are unknown. 
Mucins are highly glycosylated macromolecules. They are characterised by numerous 
tandem repeats containing proline. They are high in serine and lor threonine residue, 
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the sites of O-glycosylation. Mucins are complex glycoproteins with a large molecular 
weight (2-20x 106 Daltons) and high carbohydrate content: 50-90% content/weight. 
Mucins are characterised by the MUC protein backbone produced from MUC genes. 
Transcripts have 1.1-15 kilobases and proteins have several hundred to eleven 
thousand amino acids in their backbone (l0-50% of weight) (Rose and Voynow 
2006). 
Of the 18 types ofmucins, MUC5AC and MUC5B are the two major mucins found in 
the airway. In health, goblet cells produce MUC5AC and glandular mucosal cells 
produce MUC5B and MUC8. MUC5B is expressed in goblet cells as a marker of 
disease but this has also been reported in healthy individuals. MUC7 mucin is 
produced from the mucosal and serosal cells in salivary glands. It is also found in 15-
20% of normal individuals where it is produced from localised subsets of serous cells 
in submucosal glands of airway tissue (Jackson 2001; Rose and Voynow 2006). In 
health, goblet cells and submucosal glands are present in the large airways and are 
sparse in the periphery with few or none in the small non-cartilaginous airways 
(Jackson 2001). Terminal and respiratory bronchioles are not cleared by cough and do 
not possess the same muco-ciliary clearance capacity of the large airways. 
1.9.1. Mucus secretion 
Exposure to cytokines and leukocytes may trigger mucus secretion. Injurious stimuli 
including bacteria, lipopolysaccharide, a Gram negative bacterial endotoxin, smoke, 
matrix metalloproteinases, neutrophil elastase, reactive oxygen species, triphosphates 
(markers of cell injury), bacterial by-products and growth factors have been shown to 
increase mucin production. These may work directly or via stimulation of leukocytes 
(Kim 1997; Jackson 2001). In vitro studies have shown lipopolysaccharide to increase 
MUC5AC, MUC5B and IL-8 (Smimova, Guo et al. 2003). This study suggests that 
goblet cells, via IL-8 and mucins secretion in response to lipopolysaccharide, are an 
important part of mucosal immunity. 
Mediators triggering mucin release result in hypersecretion within minutes via the 
secretory cascade. This protects the lungs from infection and damage but 
overproduction may be deleterious (Rose and Voynow 2006). 
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Previous sections of this introduction have proposed the case that GORD and 
aspiration are important injuries post-lung transplant. The paucity of longitudinal data 
and data from the early post-transplant period has created the opportunity for this 
thesis. As a result of these clinical suspicions, therapeutic strategies have been 
proposed to treat GORD in the hope of improving lung function and survival. 
1.10. Treatments of GORD in lung transplant recipients 
Historically, peptic ulcer disease has been associated with transplant recipients due to 
high dose steroid immunosuprresion use. PPls have an important role in these patients 
to reduce the incidence and sequelae of ulceration and in the symptomatic relief of 
heartburn (Logan, Morris-Stiff et al. 2002). PPls have no effect on the lower 
oesophageal sphincter and will not prevent reflux events. Although they reduce the 
acidity of gastric contents and perhaps the volume of contents, this may not be 
important. As BALF pepsin is detectable in patients both on and off proton pump 
inhibitor, it is thought that prophylactic PPls do not prevent aspiration of gastric 
contents in lung transplant recipients (Hartwig, Appel et al. 2005; Ward, Forrest et al. 
2005; Wise and Murray 2007). The pH of aspirated contents does not influence 
pulmonary damage in an animal model (Downing, Sporn et al. 2008). Treatment with 
PPI therapy may have a deleterious side effect by increasing intragastric pH leading to 
an increase of bacterial flora. This may potentiate the effects of aspiration and 
introduce bacteria into the lungs (Verdu, Viani et al. 1994). 
Alginates are popular in the symptomatic management of dyspepsia and GORD. They 
work by creating a raft in the stomach to prevent reflux into the oesophagus 
((Klinkenberg-Knol, Festen et al. 1995). No evidence supports their role in preventing 
reflux and aspiration in lung transplant recipients. 
Promotility agents may, however, be of benefit by preventing or reducing reflux. 
Azithromycin has been shown to improve airflow limitation even in those patients 
with longstanding BOS (Yates, Murphy et al. 2005). Azithromycin, a macrolide, has 
multiple beneficial activities: anti-inflammatory, antibacterial and promotility (Arts, 
Caenepeel et al. 2005; Murphy, Forrest et al. 2007; Gottlieb, Szangolies et al. 2008). 
The presence of GORD symptoms predicts a favourable outcome of treatment. This 
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improvement in lung function may be partially through an amelioration of GORD 
(Gottlieb, Szangolies et al. 2008) and a reduction of aspiration. 
1.11. Anti-reflux surgery 
Anti-reflux surgery has been used as a treatment for extra-oesophageal reflux 
(Westcott, Hopkins et al. 2004) and has been perfonned in the setting of end stage 
lung disease (Tsai, Peters et al. 1996; Linden, Gilbert et al. 2006; Gasper, Sweet et al. 
2008; Gasper, Sweet et al. 2008). The first documented case of GORD as a reversible 
cause of decreasing lung allograft function was reported in 2000 by Palmer et al. After 
anti-reflux surgery the patient had improved pUlmonary function tests and resolution 
of bronchial inflammation (Palmer, Miralles et al. 2000). 
A key paper was published in 2003 by Davis et al. This suggests that anti-reflux 
surgery may lead to increased survival and improved lung function post-
transplantation, by preventing lung damage through aspiration. There is less evidence 
for the effectiveness of surgery in advanced disease as there may already be 
irreversible pathological scarring (Davis. Lau et al. 2003; D'Ovidio and Keshavjee 
2006). This study involved 43 patients undergoing antireflux surgery post-lung 
transplantation. The predominant procedure was laparoscopic Nissen' s 
fundoplication. 10 patients had abnonnal gastric emptying and 9 of these had further 
surgery to improve gastric drainage. Fundoplication was perfonned on the basis of 
abnonnal pH studies, but occasionally due to other factors: reflux demonstrated on 
barium swallow. after a repeat transplant in which graft failure was secondary to 
chronic aspiration and for recurrent aspiration (Davis, Lau et al. 2003). 
FEV1 increased significantly by an average of 24% post-fundoplication and greater 
than 80% of patients had an increase in FEV 1 after fundoplication surgery. Those free 
from BOS before fundoplication were free from this after surgery. 77% (10113) of 
patients with BOS-l improved post surgery. 43% of patients with BOS-2 improved 
but only 17% of BOS-3 patients improved. This shows that the decrease in lung 
function is reversible but the further advanced BOS is, the less there is to be gained. 
(Davis, Lau et al. 2003). Survival was significantly better in patients with no reflux 
after transplant compared to those with reflux: 3 year survivals were 91 % versus 82% 
and 5 year survivals were 77% versus 48% (Davis, Lau et al. 2003). 
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1.11.1. Timing of surgery: a role for fundoplication before lung transplant? 
Introduction of fundoplication has not been systematic. but has been considered in 
patients with end stage lung disease (Linden, Gilbert et al. 2006; Gasper. S\\eet et al. 
2008). There is a risk of morbidity and mortality and some patients derive little 
benefit. There are potential benefits to performing fundoplication before transplant. 
This allows immediate protection from microaspiration, a decreased risk of peri-
operative aspiration and may allow an improvement, stabilisation or reduced decline 
in function (Linden, Gilbert et al. 2006). Small series of antireflux surgery in patients 
with end-stage lung disease have been described. In one series. there was no statistical 
significant decrease in pulmonary function over 15 months post-operatively, although 
4 patients died before lung transplant (2-19 months) due to progressive respiratory 
failure. One patient with pulmonary fibrosis had a significant improvement in FEY 1 
from 77% of predicted to 103%. He subsequently had decreased oxygen requirements, 
and was taken off the transplant list. Patients with pulmonary fibrosis who underwent 
fundoplication, had decreased oxygen requirements, when compared to those who had 
no surgery (Linden, Gilbert et al. 2006). The second series demonstrates that anti-
reflux surgery can be safe in the pre-lung transplant (n=15) and post-lung transplant 
(n=17) population (Gasper, Sweet et al. 2008). 
1.11.2. Early versus late fundoplication 
Davis et ai's earlier work from Duke University suggested that the decreased FEY 1 
post-transplant was reversible if fundoplication was performed early. If treated later 
this may not be successful as irreversible fibrosis may have developed. Cantu et al 
(2004) carried out a study to evaluate the effect of early versus late fundoplication. 
Fundoplication was performed if pH studies showed a total oesophageal acid exposure 
time of> 10% or there was an unexplained decrease in FEY 1 (Cantu, Appel et al. 
2004). Laparoscopic Nissen's fundoplication was the procedure of choice unless 
oesophageal dysmotility was present. If present, then a Toupet procedure was 
performed (Cantu, Appel et al. 2004). Seventy six patients underwent fundoplication. 
All post-transplant patients were divided into 5 groups: Normal pH study; reflux with 
no fundoplication; reflux and early fundoplication (within 90 days); reflux and late 
fundoplication (after 90 days) and unknown reflux status. Figure 1--+ shows those \\ho 
were free from BOS at 1 and 3 years. There is a significant difference between those 
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who underwent early fundoplication and the other groups (p=0.01) (Cantu. Appel et 
al. 2004). 
Figure 1-4: Freedom from bronchiolitis obliterans syndrome (Cantu, Appel et al. 2004) 
1.0 
0.8 
r./) C.B 
0 
to 0.7 
E 0.6 0 
.... 
LL 05-
E 
0 
"C 
;).4-
en 
C1> 0.3 ~ 
U. 
02 
0.1 
0.0 
0 
-- r - .---~-,-- 6 i J I i 
2 ,3 " 5 6 7 8 9 10 
Years 
PiJ~it'nt:; iJ: risk ut Y·IJ<JJ 0 2 J .! 5 6 7 8 9 10 
Normal pH Study 47 44 13 20 10 4 2 0 0 
Reflux r 0 Surgery 79 68 49 20 15 10 5 :3 3 
Reflux Early Sur~ry 14 12 8 [, 3 0 0 0 0 0 
Reflux L8:1} Surge .. y 6~ 50' 44 30 H 10 B 2 0 0 
Unknol'm 180 158 131 97 72 44 ~I 20 12 4 3 
Freedom from BOS 1 year 3 year 
• No reflux (n=47) 91% 62% 
0 Reflux & no surgery (n=79) 92% 60% 
~ Reflux & early 100% 100% 
fundoplication (n=14) 
~ Reflux & late surgery (n=62) 90% 47% 
.1 Unknown (n=1S0) 90% 66% 
There was no significant difference between groups for episodes of acute rejection. 
Survival however. was significantly better (p=0.02) after one year with patients who 
underwent early fundoplication (100%), when compared to the rest of the patients 
.+1 
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(90-98%). This difference was more pronounced at 3 years (p=0.03) (Table 1-6) 
(Cantu, Appel et al. 2004). 
Ta bl 6 e 1- : Patient survival at 3 years (Cantu, Appel et al. 2004) 
% Survival 
Reflux & early fundoplication (n=5) 100% 
No reflux (n-20) 71% 
Reflux & late surgery (n=30) 86% 
Reflux & no surgery (n=26) 69% 
Unknown (n= 197) 66% 
A survIval advantage was shown In patients undergoing early fundoplication, even 
when compared to those with a normal pH study. This may be partly due to a 
"normal" pH study containing patients with mild reflux (7.9%) (physiological values 
for acid exposure are <4.2% (Johnson, Demeester et al. 1974). This suggests that any 
degree of reflux may be deleterious to this patient group. Patients with advanced BOS 
have a lesser chance of improvement with surgery because the later stages of this 
disease are irreversible (Cantu, Appel et al. 2004). 
There were several serious flaws and significant limitations to this study of Cantu et 
al. Firstly it was a retrospective study with a non-random analysis open to significant 
bias. Those with reflux, who did not undergo fundoplication, may have been excluded 
from treatment due to significant co-morbidity, explaining their increased mortality. 
The early fundoplication cohort underwent their transplants towards the end of the 
study. Their survival advantage may be due to general improvements in post-
transplant management and increased clinical experience. Finally the numbers at risk 
at each time point were extremely small in the early fundoplication group (i.e. n=5 at 
3 years). Slight changes in the prevalence of BOS or mortality in the early group (e.g. 
n=l) would massively affect the overall results and conclusions of this study (Cantu, 
Appel et al. 2004). This groups most recent data presented at the ISHL T suggests that 
in patients undergoing early fundoplication (n=67) there is a lower incidence of BOS 
at 1 year (15.9% versus 47.7%) when compared to patients undergoing late 
fundoplication (p<O.OOOl) (Balsara, E. Cantu et al. 2008). A recent study of late 
fundoplication (mean time to surgery 768 days post-transplant) suggests late 
intervention may stabilise lung function and slow decline but does not improve FEY 1 
(Burton, Button et al. 2009). The overall evidence supporting this practice is limited 
and flawed. 
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1.11.3. Choice of procedure 
Open approaches to anti-reflux surgery have excellent long term success rate (25 year 
success rate of 70-80%) in controlling reflux (Luostarinen, Isolauri et al. 1993). The 
laparoscopic approach, first performed in 1991, is now the procedure of choice and 
has been shown to be as successful in the control of reflux as open procedures in the 
medium to long-term (Kelly, Watson et al. 2007). Laparoscopic surgery requires 
increased operative time, but has the advantage of shorter hospital stay, lower 
operative morbidity and faster time to recovery when compared to open procedures 
(Darling, Deschamps et al. 2005). These benefits are important in lung transplant 
recipients. Most of the evidence in the non-transplant population is based upon Nissen 
fundoplication and the evidence supporting tailoring the wrap (Watson, Jamieson et 
al. 1999; Stewart, Watson et al. 2004; Baigrie, Cullis et al. 2005; Rice, Watson et al. 
2006; Guerin, Betroune et al. 2007; Booth, Stratford et al. 2008; Cai, Watson et al. 
2008; Fein, Bueter et al. 2008; Strate, Emmermann et al. 2008) and routine division of 
the short gastric vessels (Luostarinen and Isolauri 1999; Blomqvist, Dalenback et al. 
2000; O'Boyle, Watson et al. 2002; Yang, Watson et al. 2008) is limited. None of 
these trials are relevant in the context of lung transplant recipients. Published studies 
in the lung transplant population favour laparoscopic Nissen fundoplication (Cantu, 
Appel et al. 2004; Hartwig, Appel et al. 2005). 
1.11.1. Morbidity & mortality 
O'Halloran et al (2004) compared the results of 28 lung transplant recipients 
undergoing uncomplicated laparoscopic Nissen fundoplication with 63 non-transplant 
patients. No peri-operative deaths occurred (O'Halloran, Reynolds et al. 2004). 
Compared to the non-transplant population there were no significant differences in the 
intra-operative data. (O'Halloran, Reynolds et al. 2004). The transplant population had 
an increased length of stay and a higher readmission rate, due to transplant co-
morbidity (O'Halloran, Reynolds et al. 2004). Only one lung transplant death post-
fundoplication has been reported (Burton, Button et al. 2009). The patient had a pre-
operative FEY I of 30% predicted and developed chronic vascular rejection and 
pneumonia, dying 17 days post-operatively (Burton, Button et al. 2009). Reported 
complications include pneumonia, urinary tract infections, nausea, ileus and 
dysphagia (Hartwig, Appel et al. 2005). Specific problems include temporary 
dysphagia, nausea (Hartwig, Appel et al. 2005), gas bloat and flatulence. 
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Results suggest that fundoplication may retard the development of BOS, and extend 
survival (Cantu, Appel et al. 2004). Several fundamental questions remain 
unanswered however including: how should one confirm aspiration? and what are the 
indications for anti-reflux surgery (D'Ovidio and Keshavjee 2006)? In particular. the 
criteria for selection to surgery are yet to be defined and vary greatly from unit to unit. 
It may be the case that some reflux is physiological, but safe levels, are unknown. 
Most of the available data supporting anti-reflux surgery in lung transplant recipients 
is derived from a single centre; however, other centres are actively studying the role 
of fundoplication. The current data from different units and even from the same unit is 
conflicting and although there are some early promising studies (Table 1-7) we 
suggest that there is a need for appropriate trials, and solid evidence based guidelines 
(Robertson, Shenfine et al. 2009). 
Table 1-7: Summary of pu Ishe stu les on un opllcatlOn ~re- an br d dO f d r d I t post- ung transplan 
Authorl Unit Number of Outcome PFTs Survival Operative 
date patients mortality 
undergoing 
fundoplication 
Lau 2002 D 18 FeasibilliY Improved nla 0% 
Davis 2003 D 43 Survival Improved Improved 0% 
O'Halloran D 28 Safety Improved nla 0% 
2004 
Cantu 2004 D 76 Survival Improved No 0% 
change 
Benden GOSH 5 Paediatric No change No 0% 
2005 change 
Linden H 19 Pre- Slowed No 0% 
2006 transplant decline in change 
lung some 
function patients 
Gasper UCSF 32 Safety pre nla nla 0% 
2007 & post 
transplant 
Balsara D 184 BOS Improved nla 0% 
2008 
Burton M 21 QoL Slowed nla 1121 
2009 decline in 
some 
patients 
° Key to table: D= Duke University, GOSH= Great Ormond Street HospItal, H-
Harvard University, UCSF= University of California, San Francisco, QoL= 
quality of life 
Aims 
-To identify gastro-oesophageal reflux and aspiration occurring within in the first 
month post-lung transplantation 
-To evaluate longitudinal changes in gastro-oesophageal reflux and aspiration in the 
first six months post-lung transplantation 
-To analyse gastric juice for biomarkers of aspiration and presence of bacteria 
-To investigate the effects of pepsm and mixed gastric JUIce on goblet and 
bronchoepithelial and cells in vitro 
-To evaluate the effects of anti-reflux surgery on reflux symptoms and quality of life 
in lung transplant recipients 
2. Methods 
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2.1. General study design 
Patients undergoing lung transplantation at the Freeman Hospital. Newcastle, \\ ere 
studied in a longitudinal manner to test for the presence of reflux. Their lung 
allografts were under standard surveillance using bronchoscopy, bronchoalveolar 
lavage samples and pulmonary function tests. 
From 1 st November 2007 to 1 st November 2008 all newly transplanted lung recipients 
were approached and asked if they wished to participate in the study. Patients were 
recruited even if they had undergone pre-transplant fundoplication as it was unknown 
if the lung transplant would disrupt the integrity of the fundoplication. Patients, 
therefore, had the potential to have pathological reflux in the post-transplant period. 
We were unable to calculate a sample size for this study due to the absence of current 
data. Therefore, this is a descriptive study. 
Our protocol was to assess for GORD at one, three and six months post lung 
transplantation, using a validated extra-oesophageal reflux questionnaire, manometry 
and pH/impedance measurements. These assessments were performed around similar 
time periods as bronchoscopy and pulmonary function tests. However, exact practice 
was tailored to suit individual patients. Patients were assessed on their routine proton 
pump inhibitor therapy. Routine practice was for lansoprazole 30mg once daily. If 
patients were symptomatic on once daily dose then the dose was doubled. PPI twice 
daily was not routinely prescribed as no evidence exists to suggest this reduces 
microaspiration. Results were then compared with markers of aspiration and 
inflammation in the bronchoalveolar lavage samples, microbiology, pathological 
rejection scores and pulmonary function tests. 
2.2. Ethical approval 
Ethical approval was obtained from County Durham & Tees Valley 2 Research Ethics 
Committee (Appendix 5). Trust Research & Development approval was granted by 
the Newcastle Upon Tyne Hospital Trust Research & Development Department 
(Appendix 5). 
2.3. Clinical assessment 
Patients had their case notes reviewed on enrolment to the study to establish patient 
demographics, indication for transplant, co-morbidities and current medication. The 
patients were clinically followed up for 6 months. 
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2.4. Consent & information 
Patients were recruited in the post-transplant period, once they were beginning to 
recover. Before enrolment, patients were given information sheets and an explanation 
regarding the study. They were given up to a week to contemplate the study and 
discuss this with the transplant team. After a period of time, patients were asked if 
they wished to participate in the study and written consent was obtained. 
2.5. Reflux symptom index questionnaire 
The reflux symptom index (RSI) questionnaire, which includes laryngopharyngeal 
reflux symptoms, was used. This was a straight forward 9 point questionnaire. which 
has been designed and validated by J Koufman's group in the USA at Wake Forest 
University School of Medicine (Belafsky, Postma et al. 2002). The questionnaire 
allowed patients to score their symptoms of reflux from 0-5. The 9 areas of interest 
are shown in Figure 2-1. Once completed, a total RSI score was calculated. This was 
deemed positive if greater than 13. 
·d Fieure 2-1: Reflux symptom ID ex questionnaire 
Within the last Month how did the following o = No Problem 5= 
problems affect you Severe Problem 
Hoarseness or a problem with your voice 0 1 2 3 4 
Clearing your throat 0 1 2 3 4 
Excess throat or postnasal drip 0 1 2 3 4 
Difficulty swallowing food, liquids or pills 0 1 2 3 4 
Coughing after you eat or after lying down 0 1 2 3 4 
Breathing difficulties or choking episodes 0 1 2 3 4 
Troublesome or annoying cough 0 1 2 3 4 
Sensation of something sticking in your throat or 0 1 2 3 4 
a lump in your throat 
Heartburn, chest pain, indigestion or stomach acid 
coming up 0 
1 2 3 4 
RSI 
.+8 
5 
5 
5 
5 
5 
5 
5 
5 
5 
2.6. Oesophageal manometry 
Patients underwent manometry after a minimum 4 hour fast for solids and at least 2 
hours for liquids (Bodger and Trudgill 2006). Immunosuppression medications were 
not omitted, but imbibed with a small volume of water, at least 3 hours before 
manometry. A 3.9mm single catheter, eight lumen water perfused manometry system 
was used (Mediplus Limited, Buckinghamshire, United Kingdom). This catheter had 
4 radial ports and 4 lateral ports spaced 5 centimetres apart. Only the 4 lateral ports 
were used to measure oesophageal pressures. The catheter assembly was connected to 
a standard four channel compressed air pneumo-hydraulic low compliance perfusion 
pump. Distilled water was perfused at a constant rate of 0.6mlls. This was connected 
to a Polygraf transducer (Meditronics Synectics, Stockholm, Sweden) on a Windows 
compatible desktop computer (Dresner 2001). 
2.6.1. Standard technique 
Informed consent was obtained. Patients were seated and the catheter was passed 
horizontally through the nares into the nasopharynx (Bodger and Trudgill 2006). Then 
patients were asked to tilt their head forward, put their chin on their chest and to take 
lots of small swallows via a "bendy straw". This technique, helps the catheter progress 
through cricopharyngeus into oesophagus. The tube is then passed into the stomach to 
70cm from the nares. The patient then was asked to lie in a recumbent or semi-
recumbent position, as this is the ideal position for water perfused manometry. 
Patients often had difficulty lying completely supine, as they had recently undergone 
major thoracic surgery and also many patients had not lain flat for years due to their 
respiratory co-morbidity. The manometry catheter was calibrated with the "zero" 
point being at the patient's sternal angle. These points were not thought to influence 
results significantly. The presence of all 4 channels in the stomach were confirmed by 
a positive deflection in all 4 channels in response to inspiration (Evans and Buckton 
1997). 
2.6.2. Lower oesophageal sphincter 
Using the standard stationary pull through technique (Bodger and Trudgill 2006). the 
catheter assembly was withdrawn by 1 cm every 30seconds (Zaninotto, DeMeester et 
al. 1988). Inspiration and wet swallow of 5ml were performed. As this was performed 
1 month post lung transplant, the technique was modified to suit the patient's ability 
to cope with the procedure. This did not compromise evaluation of the lmver 
oesophageal sphincter and oesophageal peristalsis. The lower oesophageal sphincter 
was defined as the high pressure zone at the lower end of the oesophagus. The length, 
resting pressure position and response to swallows were calculated manually. with the 
aid of the Polygraf computer programme. The lower oesophageal sphincter end 
expiratory pressure was defined as the difference between basal tone pressure and the 
average of the end-expiratory resting pressures found in each port whilst in the high 
pressure zone. This was measured in millimetres of mercury (mmHg). The degree of 
sphincter relaxation to a 5ml water swallow was observed (Bodger and Trudgill 
2006). The respiratory inversion point was difficult to define as patients had difficulty 
with forced inspiration and expiration. However it has been suggested that this 
represents a respiratory artefact and failure to define it did not affect assessment 
(Bredenoord 2006). 
2.6.3. Oesophageal motility 
Ten "wet" swallows were performed to assess oesophageal motility. Motility was 
evaluated for normal peristalsis, simultaneous contractions or aperistalsis. Two 
techniques were used. Initially manometry was carried out performing swallows at 
one centimetre intervals. Mean distal and proximal amplitudes were calculated as an 
average of peristaltic amplitudes between 3-8cm and 13-18cm above the lower 
oesophageal sphincter respectively. Latterly all ten swallows were performed with the 
distal port 5cm above the lower oesophageal sphincter. Mean distal oesophageal 
peristaltic amplitude was calculated based on the average of all swallows performed at 
5cm. Mean proximal peristaltic amplitudes were based on the average of all swallows 
performed at 15cm above the lower oesophageal sphincter. Traces were analysed in 
depth and divided into the following categories (Table 2-1). 
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T bl 2 1 CI·fi f a e - : ass) )catlOn 0 oesophageal peristalsis 
Normal peristalsis Normal peristalsis >70% of the time 
Mild ineffective oesophageal motility Abnormal peristalsis 30-70% of the time 
Severe ineffective oesophageal motility Normal peristalsis <30% of the time 
Aperistalsis Abnormal peristalsis 100% of the time 
Diffuse oesophageal spasm >10% of swallows simultaneous with 
mean amplitudes over 30mmHg 
Nutcracker oesophagus Mean amplitude of peristalsis 
>180mmHg 
Hypertonic lower oesophageal sphincter >45mmHg but relaxing 
Hypotonic lower oesophageal sphincter <10mmHg 
Achalasia Hypertonic LOS, absent or incomplete 
relaxations >70-80% of the time. 
Simultaneous contractions or aperistalsis 
in the oesophageal body 
(Evans and Buckton 1997; Spechler and Castell 2001; Bodger and Trudgill 2006; 
Fox, Bredenoord et al. 2008; Pandolfino, Ghosh et al. 2008) 
2.6.4. Cricopharyngeus 
The cricopharyngeus was identified to determine the length of the oesophagus. It was 
defined as the high pressure zone at the proximal oesophagus, which demonstrated 
relaxation on swallowing. 
2.7. Ambulatory impedance/pH studies 
After oesophageal manometry, combined 24 hour ambulatory pH impedance was 
performed. Proton pump inhibitors were not discontinued. 
Ambulatory impedance/pH was performed using the Medical Measurement System 
and Ohm ega Device (Ohmega Utrecht, The Netherlands). A Phersiflex Z61A \zNIS-
8R catheter was used. This is a 1.9mm catheter with 8 ring, 6 channel system with a 
single pH probe at 5cm. Channneis were located at 3,5,7,9,15 & 17cm.This allowed 
the proximal extent of the reflux to be determined. 
The catheter was connected to the Ohmega device and calibrated in a standard 
fashion. After a ten minute pre-soak the pH probe was calibrated using standard 
buffer solutions of pH 4 & 7 at room temperature. The impedance catheter was 
51 
inserted into the oesophagus using standard technique, described above (2.6.1) to 
place the end of the catheter at the upper border of the lower oesophageal sphincter 
and the pH probe 5cm above the upper border of the lower oesophageal sphincter 
(Figure 2-2) (Bodger and Trudgill 2006). 
Patients were encouraged to maintain their habitual eating habits during the pH-
impedance monitoring period. Patients were instructed to record symptoms (cough, 
something in the throat, heartburn), meals and position (erect or supine) using the 
Ohmega device. They also were given a simple, standardized patient diary to 
complete. After 24 hours the recording was complete and the ambulatory Ohmega 
device was connected to a Windows compatible computer with the MMS software 
loaded on the computer. The data was uploaded to the MMS programme. The 
electronic diary was verified with the paper diary and edited appropriately. The trace 
was then analysed manually with the aid of the software. 
Figure 2-2 Diagram of pH/impedance catheter wi thin the oesophagus and the subsequent trace 
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Legend: This diagram shows the pH-impedance catheter within the oesophagus, The 
pH probe lies Scm above the lower oesophageal sphincter and there are multiple rings 
for the impedance measurements (Z 1-6). The trace on the left hand side shows pH at 
the bottom. The sequential drop in impedance from ZI-Z6 shows a proximal reflux 
event, which is subsequently cleared by the oesophagus. 
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2.7.1. pH analysis 
pH results were analysed and values compared with normal values described by 
Johnson and DeMeester. An abnormal study was defined as a pH less than 4 for more 
than 4.5% of the duration of the study (Johnson, Demeester et al. 1974). No normal 
values exist for patients on PPI therapy, therefore standard normal values were used. 
2. 7.2. Impedance analysis 
Impedance traces were analysed visually with the aid of the software. Reports were 
verified by Dr Arjan Bredenoord, Gastroenterologist, Holland, who is a world expert 
on pH-impedance traces. Values were compared with normal European values 
determined by Zerbib. An abnormal study was defined as volume exposure > 1.2% 
(Zerbib, des Varannes et al. 2005). 
2.7.3. Comparison of symptoms to reflux events 
24 hour pH/impedance recording has the advantage of allowing the software to 
compare patient symptoms to reflux events. 
2. 7.4. Symptom index 
This is calculated using the number of symptomatic episodes associated with reflux 
events as a percentage of the total symptomatic episodes. 50% is the optimum 
threshold for a positive result (Bredenoord, Weusten BLAM et al. 2005; Bredenoord 
2006). 
2.7.5. Symptom sensitivity index 
This accounts for the limitation of the symptom index. It is calculated as the number 
of reflux events associated with symptoms as a percent of acid reflux events. It is 
positive if over 10% (Bredenoord, Weusten BLAM et al. 2005; Bredenoord 2006). 
2.7.6. Symptom associated probability 
This is a statistical attempt to utilise all the data. It is calculated by dividing the test 
into two minute intervals and determining when reflux or symptoms occur. 
The data is then evaluated using a Fisher exact test of the following 4 distributions: 
Symptoms & reflux No symptoms & reflux 
Symptoms & no reflux No symptoms & no reflux 
The test then evaluates whether the distribution occurs by chance. If the level is over 
95% then the test is positive. 
The role of SI has been verified by clinical studies and there is evidence for its clinical 
value in predicting response to proton pump inhibitor and fundoplication (Bodger and 
Trudgill 2006). Symptom associated probability utilises all parameters and provides a 
better insight into the relationship between symptoms and reflux (Bredenoord, 
Weusten BLAM et al. 2005; Bredenoord 2006). 
2. 7. 7. Overall pH-impedance analysis 
Overall analyses were interpreted to identify if patients had pathological reflux. Key 
distal reflux indices were oesophageal acid exposure and oesophageal volume 
exposure. The key proximal reflux index is proximal reflux events. Oesophageal acid 
exposure was the percentage of time that the pH is less than 4, 5cm above the lower 
oesophageal sphincter during a 24 hour period (normal <4.5%). Oesophageal volume 
exposure was defined as the percentage of time that impedance detects refl uxate 
within the oesophagus over a 24 hour period (normal <1.2%). Proximal reflux events 
were impedance events reaching 17 cm above the lower oesophageal sphincter. 
Patients were deemed to have distal reflux if either the oesophageal acid exposure or 
the oesophageal volume exposure were abnormal. If oesophageal volume exposure 
was abnormal on a background of normal oesophageal acid exposure then it was 
deemed that the patient had weakly acidic reflux. If patients had more than 17 
proximal reflux events over a 24 hour period then they were deemed to have abnormal 
proximal reflux. 
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2.8. Bronchoscopy 
Bronchoscopy was routinely perfonned at one week, one. three, six and twelve 
months post lung transplantation. It was also perfonned if there was deteriorating lung 
function, suspicion of rejection or infection. After receiving infonned consent, up to 
10mg intravenous midazolam was administered to cause adequate sedation. Topical 
application of 4% lignocaine to the nose, pharynx, larynx and below the vocal cords 
in 1 ml aliquots, was used as required to create local anaesthesia. The maximum dose 
given was 7mglkg body weight. Oxygen saturations were monitored by oximetry. 
Supplemental oxygen was administered. Bronchoscopy was then perfonned in a 
supine position via the nasal/oral route. A 4.9mm external diameter, 2mm internal 
diameter fibre-optic bronchoscope was passed through the mouth or nares. The 
endoscope is then guided through the vocal cords and trachea. The bronchial 
anastomosis was subsequently inspected and then the bronchoscope was passed into 
the lingular bronchus or the bronchus of the right middle lobe of the transplanted lung 
(Ward, Forrest et al. 2005; Stovold, Forrest et al. 2007). 
2.9. Bronchoalveolar lavage 
Bronchoalveolar lavage was perfonned in a standardized manner in accordance with 
ERS guidelines (Haslam, Baughman et al. 1999). Three samples of 60ml of sterile 
saline were injected into the lobe. The fluid was then retrieved. The retrieved BAL 
fluid sample was then split. Samples were sent for clinical microbiology and the rest 
was taken for research purposes. Microbiology was assessed in a standardized 
fashion. This is described later in detail (Section 2.11). Differential cell counts were 
made on Giemsa-stained cyto-centrifuge preparations. Cell free BAL supernatants 
were prepared by centrifugation; aliquots were snap-frozen by immersion in liquid 
nitrogen and stored at -80°C for research purposes (Section 2.12). 
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2.10. Pathology 
Transbronchial biopsies were obtained from the allografts using fluoroscopy. Fi\e to 
seven biopsies were taken at each bronchoscopy and sent immediately to pathology to 
undergo urgent processing. On arrival the samples underwent microwave fixation 
using 10% formalin. They then underwent standard histological processing using 
paraffin and then subsequent staining with haematoxylin and eosin to assess acute 
vascular and airway inflammation. These were then assessed according to revised 
standardised ISHL T criteria (Table 2-2) by two specialised pathologists (Yousem 
1996; Stewart, Fishbein et al. 2007). Samples were also stained in PAS to exclude 
viral and fungal infections and Gram stain to detect bacterial pathogens. 
At our centre, grade A2 or above is treated as being clinically significant. This would 
result in alteration in patient management, such as an increase in steroid dose. 
Table 2-2: Revision of the 1996 working formulation for the standardisation of nomenclature in 
the diagnosis of lung rejection (Yousem 1996; Stewart, Fishbein et al. 2007) 
A: Acute rejection 
Grade Rejection Histological criteria 
AO None No evidence of mononuclear cell infiltration, 
haemorrhage or necrosis. 
Al Minimal Scattered infrequent perivascular mononuclear 
infiltrates in alveolated lung parenchyma. 
A2 Mild More frequent perivascular mononuclear infiltrates 
surrounding venules & arterioles, recognisable at low 
magnification. 
A3 Moderate Easy recognizable cuffing of venules and arterioles by 
dense perivascular mononuclear cell infiltrates 
associated with endothelialitis, eosinophils and 
neutrophils. 
A4 Severe Diffuse perivascular, interstitial & airspace infiltrates of 
mononuclear cells with prominent alveolar pneumocyte 
damage and endothelialititis. 
Ax Ungradeable Ungradeable due to sampling problems, infection. 
tangential cutting, artefact etc. 
(Yousem 1996; Stewart, Fishbem et al. 2007) 
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8: Airway inflammation: lymphocytic bronchiolitis 
Grade Rejection Histological criteria 
80 None No evidence of bronchiolar inflammation. 
BIR (Bl& Low grade Mononuclear cells within the submucosa of the 
B2) bronchioles which can be infrequent & scattered or 
forming a circumferential band. 
81 (1996) Minimal Rare scattered mononuclear cells within the submucosa. 
82 (1996) Mild Circumferential bands of mononuclear cells. 
82R (B3& High grade Mononuclear cells in the submucosa appear larger and 
B4) activated, with greater numbers of eosinophils and 
plasma cytoid cells, in addition, there is evidence of 
epithelial damage in the form of necrosis and metaplasia 
& marked intra-epithelial lymphocytic infiltration. In its 
most severe form there is epithelial ulceration, fibro-
purulent exudate, cellular debris and neutrophils. 
83 Moderate A dense band-like infiltrate of activated mononuclear 
cells In the lamina propna of bronchilbronchioles 
including activated lymphocytes and eosinophils with 
evidence of epithelial damage in the form of necrosis, 
metaplasia & marked intra-epithel ial lymphocytic 
infiltration. 
84 Severe A dense band-like infiltrate of activated mononuclear 
cells in bronchi and/or bronchioles associated with 
dissociation of epithelial cells from the basement 
membrane, epithelial ulceration, fibrinopurulent 
exudates containing neutrophils, and epithelial cell 
necrOSIS. 
8X Ungradeable Ungradeable due to sampling problems. infection, 
tangential cutting, artefact etc. 
(Yousem 1996; Stewart. Fishbein et al. 2007) 
C Ch f romc aIrways reJec IOn: 0 brt f b 1 era Ive ronc lOllS 
Grade Rejection Histolo_gical criteria 
CO None No evidence of obliterans bronchiolitis. 
Cl * Obliterans Dense eosinophilic hyaline fibrosis in the sub-mucosa 
bronchiolitis of membranous and respiratory bronchioles, resulting in 
partial or complete luminal occlusion. 
.. 
*Note: Transbronchial biopsy IS an msensltlve method for detectmg obhteratlve 
bronchiolitis. The clinical use of PFTs and the Bronchiolitis obliterans syndrome are 
the preferred methods of diagnosing and monitoring chronic airways rejection. 
(Yousem 1996; Stewart, Fishbein et al. 2007) 
D: Chronic vascular rejection 
Chronic vascular rejection Fibrointimal thickening of arteries and vems. 
Diagnosed by open biopsy. 
(Y ousem 1996; Stewart, Fishbein et al. 2007) 
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2.11. Clinical microbiology 
Bronchoaheolar layage samples were processed. cultured and analysed at t:-te 
Department of ~1icrobiolog: at the Freeman Hospital using standardized techniques. 
All samples were analysed by trained staff using appropriate containment and saTet: 
procedures in accordance with Freeman Hospital accredited standard operatlng 
procedures. 
~.11.1. Culrure o(BAL samples 
On arriyaL samples were verified and were taken to the category :3 suite and placed in 
the safety cabinet. Initially samples were centrifuged for 10 minutes at 3.000r.;,.n-: .. 
The supernatant was remoyed as lignocaine is inhibitory to legionella. 20ml of sterile 
deionised water was then added to the residue and yorte:x.ed. The sample was then 
centrifuged again and the supernatant remoyed. After a further yorte>.:. the sample was 
read\ for culture. 
La\ages were then cultured neat on appropriate media by adding 10ili of sample to 
plates and spreading for single colonies. 
Patients with cystic fibrosis had their layages diluted 5 ill in 10ml sterile \\ater and 
. ~ 
then inoculated onto a chocolate agar plate for further microbial assessment. including 
Pseudomonas. Plates were then incubated as per standard protocol (Table 2-3). 
T bl 23M' b' I a e - : Icro 10 ogy protocol for BALF analysis 
Clinical Standard media Incubation Cultures Target organisms 
conditions read 
Culture neat Temp Atmosphe Time 
only (DC) re 
Horse blood agar 35-37 5-10% 24-48h Daily S. Pneumoniae 
CO2 M. Catarrhalis 
S. Aureus 
Other organisms in pure 
growth may be significant 
Chocolate agar with 35-37 5-10% 24-48h Daily Haemophilus sp 
Bacitracin CO2 Enterobacteriaceae 
Pseudomonas sp 
Capnoocytophagia 
Cysteine Lactulose 35-37 Air 24-48h Daily Enterobacteriaceae, 
Electrolyte Deficient Pseudomonas sp. 
Legionella media 35-37 CO2 10 days Daily Legionella sp Socardia 
Gram stain Any organisms and 
cellular examination 
Cultures sent to .\~l,'CObaCleria 
Health Protection 
Agency for 
tuberculosis culture 
Sabaraud medium 35-37 Air 24-48h. Can Daily Candida sp 
be extended to Aspergillus sp 
5 days Other fungi 
Cystic 
fibrosis 
patients 
Cepacia media 35-37 Air 5 days Daily B. cepacia 
B gladioli 
Mannitol trehalose 35-37 Air 24-48h Daily S Aureus 
salt agar/ aztreonam 
blood agar 
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2.12. Bronchoalveolar lavage processing 
Bronchoalveolar lavage fluid was processed to measure the volume of fluid received 
to count the total number of cells and prepare cytospins. 
The BAL fluid was stored at 4°C for up to a maximum of 1 hour before processing. In 
the class 2 cabinet the BAL fluid was filtered through a layer of gauze into 2x SOml 
centrifuge tubes. The volume was measured and recorded. Samples were centrifuged 
at 12S0rpm for 6 mins at 4°C. The supernatant was then decanted into 2x SOml 
centrifuge tubes, taking care not to disturb the cell pellet. This supernatant was 
centrifuged at 2S00rpm for 6 mins at 4°C, before being divided: 600~.d in 
microcentrifuge tubes and 4x Sml in S ml centrifuge tubes. SOml of Dulbecco's PBS 
was added to the cell pellet to give an opaque suspension and it was then mixed 
gently. The total cell concentration was calculated using an improved Neubauer 
counting chamber, counting the cells in 4 large squares. The volume was adjusted to 
give a final cell concentration of O.Smillion cells Iml. Cytospins were then prepared 
using lOOll1 of re-suspended cells at 300 rpm for 3 minutes at room temperature. 
Cytospins were then fixed in acetone at room temperature for 10 minutes and allowed 
to air dry. The remaining cytospins were air dried overnight, wrapped in cling film 
and stored at -20°C. After preparation of the cytospins was complete, the cell 
suspension was re-centrifuged. The supernatant was discarded and the cell suspension 
was stored at -20°C until transfer to -80°C freezer. 
This process resulted in: 
2Sx 600lli aliquots of acellular BAL fluid stored at -80°C. 
4x Sml aliquots of acellular BAL fluid 
1 x cytospins acetone fixed with and stained with Geimsa 
Sx cytospins air dried, wrapped and stored at -20°C 
6x cell pellets stored at -80°C 
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2.13. Biomarkers 
2.13.1. Pepsin/pepsinogen ELISA 
The pepsin assay used was developed and extensively calibrated, tested and verified 
(Stovold 2009). 1 00~1 of standards diluted in phosphate buffered saline (PBS) or 20~1 
of sample, added to 80~1 of PBS were added to coat a 96 well microplate Maxisrop, 
Nunc). PBS consisted of 137mM NaCL 2.7mM KCL 8.lmM Na2HP04. l.5 mM 
KH2P04, pH7.2-7.4, 0.2~m filtered. The plate was sealed and incubated overnight at 
room temperature. Each well was aspirated and washed with 400~1 wash buffer 
(0.05% Tween 20 in PBS pH 7.2-7.4, R&D Systems) repeating the process twice for a 
total of three washes, followed by two more washes of 1 % PBS. The plate was then 
blocked by adding 300~1 of block buffer (1 % bovine serum albumin in PBS) to each 
well and incubated at room temperature for 1 hour. Aspiration and wash were 
repeated. Primary antibody (antipepsin, Biodesign International, USA) was diluted to 
working concentration (1 in 2000) in reagent buffer (0.1 % BSA, 0.05% Tween 20 in 
PBS) and 1 00~1 was added to each well. The plate was then covered with parafilm 
and incubated for 2 hours at room temperature. Aspiration and wash were repeated. 
I 00~1 of the secondary detection antibody (horse radish peroxidase-conjugated anti 
sheep/goat antibody, Sigma, UK), diluted in reagent dilutant (1 in 10,000). was then 
added to each well. This was then covered with a new adhesive strip and incubated for 
2 hours at room temperature. Aspiration and wash were repeated. 1 00~1 of substrate 
solution (2.2' -azino-bis(3-ethylbenzothiazoline-6-) sulfonic acid) was then added to 
each well. This was incubated for 20 minutes at room temperature, avoiding direct 
light. 1 00~1 of stop solution (1 % sodium dodecyl sulphate) was added to each well. 
The plate was gently tapped to ensure thorough mixing. Optical density of each well 
was determined immediately using a microplate reader set to 405nm (Figure 2-3) 
(Stovold 2009). Negative controls were analysed. These samples were analysed 
identically apart from omitting the primary antibody. In addition a correction factor of 
(x2) was used to correct for the difference in primary antibody affinity to human 
compared to pig pepsin (Stovold 2009). 
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Figure 2-3: Standard curve of e sin ELISA 
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2.13.2. Bile salt assays 
Spectrophotometric 
Initially the Bioquant commercially available enzymatic assay (Bioquant, San Diego, 
CA, USA) was assessed. This system is based on the principle that in the presence of 
NAD+, the enzyme 3-a hydroxysteroid dehydrogenase (3-a HSD) converts bile acids 
to 3-keto steroids and NADH. The NADH formed reacts with nitrotetrazolium blue 
(NBT) to form a formazan dye in the presence of diaphorase enzyme. The dye 
formation is monitored by measuring absorbance at 540nm and is directly 
proportional to the bile acids concentration in the serum sample. 
The kit was supplied with a standard solution of bile acid- 35/lmollL- and several 
standard curves were performed. These showed that the lower limit of quantitation 
was 5/lmolil. This quantitation is contrary to previous reports from other units which 
have stated that this assay is accurate down to <O.2/lmolll (Blondeau, V. Mertens et 
al. 2008). 
Because of the large dilution of any bile acids in the lung produced by the use of 
180ml of saline in the lavage procedure, I tried to find an assay with a greater 
sensitivity. Another commercial assay which claimed a sensitivity/detection limit of 
l/lmol/l (Biostat, Stockport, UK) was assessed. This assay is based on the fact that 
3a-hydroxysteroid dehydrogenase, in the presence of Thio NAD+, converts bile acids 
to 3-keto steroids and Thio-NADH. This process is reversible. In the presence of 
excess NADH, enzyme cycling is efficient, and the rate of Thio-NADH formation can 
be quantified using photo spectrometry at 405nm (Turley, Dietschy et al. 1978). 
Reagents were warmed to room temperature before analysis. 270/l1 of reagent 1 
(which consisted of Na2HP04 15g/l, NaN3 0.3g/1, EDTA ImM and Thio-NAD 2.5g11) 
was added to coat a 96 well microplate. To this was added 4/l1 of samples, standard or 
control. In house standards were constructed from mixtures of 0.8% bile made up of 
50% cholic acid, 30% chenodeoxycholic acid, 15% deoxycholic acid and 5% 
lithocholic acid dissolved in methanol (concentrations 0-200/lmolll, range 0, 20. 40, 
100 & 200/lmol/I). Control was reagent 2, heated to denature the 3-a HSD enzyme. 
Samples were incubated at 37°C for 3 minutes and absorbance was read at 405nm. 
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BALF samples were measured undiluted. In our hands, this assay had a lower limit of 
detection of 2!J.molll (Figure 2-4). 
Figure 2-4: Standard curve of Biostat bile salt assay 
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Analytical mass spectrometry 
Because BALF bile salts were likely to be essentially undetectable by 
spectrophotometric based approaches, a more sensitive tandem mass spectrometry 
method was used at a nationally accredited external laboratory, blind to the study; 
Sheffield Children's Hospital, UK. Tandem mass spectrometry is a technique that 
allows the analysis of metabolites and proteins in blood samples. It permits 
simultaneous examination of a large number of materials. Mass spectrometry is a 
technique that measures the mass of substances (molecular weight). Tandem mass 
spectrometry involves two mass spectrometers performed in sequence. The first pass 
spectrometer tests a single molecular mass (precursor ions) from nebulised samples. 
Then these ions are passed through a "collision cell" and molecules are bombarded 
with high energy argon gas. This fractures the molecules and fragments are passed 
through a second spectrometer. Different compounds fragment uniquely in different 
ways. If a mass of a molecule and of its fragments are known then the identity of the 
molecule can be inferred (Sweetman 1996; Berger 1999; Mushtaq, Logan et a1. 1999). 
Concentrations of glycodeoxycholate, glycocholate, taurodeoxycholate, taurocholate 
glycochenodenodeoxycholate and taurochenodeoxycholate, which are prototypical 
physiologically relevant bile salts (making up approximately 95% of total human bile 
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salts), were measured (Sweetman 1996: Berger 1999; Mushtaq, Logan et al. 1999). 
Estimations of total bile salt concentration were calculated from the arithmetic sum of 
the individual bile salt concentrations. The lower limit of detection limit was 
O.l ~molll. 
This procedure was further modified to improve the lower limit of detection to 
1 nmolll as follows: 
450~1 of BALF was added to 10ml of distilled water containing 150~1 of deuterated 
taurocholate (internal standard). This solution was loaded onto a C 18SPE col umn 
(Supelco LC-18) washed with 5ml water and 2ml hexane. The bile salts were eluted 
with 10ml of methanol and evaporated to dryness. They were then reconstituted in 
1ml of 90% acetonitrile. 30~1 was injected directly onto tandem mass 
spectrophotometry with 50% acetonitrile as running buffer. The bile salts were 
measured using negative ion mode and multiple reaction monitoring scans, giving a 
sensitivity down to 1nmolll. 
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2.13.3. Interleukin-8 
A standard indirect DuoSet ELISA was used to evaluate IL-8 levels (R&D Systems. 
USA). 100Jll of capture antibody (capture antibody was antibody from R&D Systems) 
was diluted to working concentration (l in 100) in reagent buffer (0.1 % BSA, 0.05% 
Tween 20 in Tris-buffered saline (20mM Trizma base, 150mM NaCl) . pH 7.2-7.4. 
0.2Jlm filtered) and 100Jll was added to each well to coat a 96 well microplate 
overnight. Each well was aspirated and washed with 400Jll wash buffer (0.05% 
Tween™ 20 in phosphate buffer solution pH 7.2-7.4. R&D Systems) repeating the 
process twice for a total of three washes. The plate was then blocked by adding 300Jll 
of block buffer (l % bovine serum albumin in phosphate buffer solution) to each well 
and incubated at room temperature overnight. Aspiration and wash were repeated. 
1 OO~.d of standards diluted in PBS or 10Jll of sample added to 90Jll of PBS. The plate 
was then covered with an adhesive strip and incubated for 2 hours at room 
temperature. Aspiration and wash were repeated. 100Jll of the detection antibody 
diluted in reagent dilutant (l in 10,000), was then added to each well. This was then 
covered with a new adhesive strip and incubated for 2 hours at room temperature. 
Aspiration and wash were repeated. 100Jll of substrate solution (l: 1 mixture of colour 
reagent A (H20 2) and colour reagent B (tetramethylbenzidine)) was then added to 
each well. This was incubated for 20 minutes at room temperature, avoiding direct 
light. 50Jll of stop solution 3M (H2S04) was added to each well. The plate was gently 
tapped to ensure thorough mixing. Optical density of each well was determined 
immediately using a microplate reader set to 450nm. Negatives were also performed. 
These samples were analysed identically apart from omitting the primary antibody. 
The lower limit of detection from this assay was 10pglml. 
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2.14. Pulmonary function tests 
Patients underwent pulmonary function tests (PFTs) performed by clinical 
physiologists using standard European Respiratory Society guidelines (Miller. Crapo 
et al. 2005; Miller, Hankinson et al. 2005). During the test, patients were seated. A 
mouthpiece and nose clip prevented escape of airflow during expiration. After a few 
breaths, enabling the patient to relax, the patient was then asked to take a maximal 
breath in, followed by a hard, fast breath out to full expiration. To achieve accurate, 
reproducible tests the patient must ensure that the expiration is both forceful and 
prolonged. This test was repeated for a minimum of three and a maximum of eight 
times as per the American Thoracic SocietylEuropean Respiratory Society 
recommendations to ensure precision and reproducibility (Miller. Hankinson et al. 
2005). Simple spirometry was used to give a print out of volume against time from 
which the FEV! and FVC could be taken. The FEF25-75 can be calculated from the 
volume-time graph by taking the point 25% and 75% of the vital capacity and 
drawing a line between the two points. The gradient of this line gives the mid 
expiratory flow FEF25-75 . This is demonstrated in Figure 2-5. 
Figure 2-5: Volume -time graph for a normal subject 
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Figure 2-6: Volume -time graph for normal subject and subject with airflow obstruction. 
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Legend: The FEF25-75 is the flow rate over the mid expiratory flow range, from 25% to 
75% of the forced vital capacity. From this figure it can be demonstrated that the 
FEF25-75 would be greatly reduced in a subject with airflow obstruction. Thus a drop 
in FEF25-75 is diagnostic for BOS. 
2.14.1. Flow volume curves 
The flow-volume curves were measured using a Collins Owl body plethysmography 
and Raptor software using a pneumotach to give a flow signal (Figure 2-6). These 
were then integrated to give volume (Table 2-4):-
FEV I, forced expiratory volume in one second 
FVC, forced vital capacity 
FEV1/FVC, the FEV! to FVC ratio 
FEF25-75, forced expiratory flow between 25% and 75% of the FVC 
(Miller, Hankinson et al. 2005) 
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T bl 2 4 D fl .. f f a e - : e IDltIons 0 pu monary unctIOn tests 
FVC Maximal volume of air exhaled with maximally forced effort from a 
maximal inspiration, expressed in litres at body temperature and 
ambient pressure saturated with water vapour (BTPS) 
FEV1 Maximal volume of air exhaled in the first second of a forced expiration 
from a position of full inspiration, expressed in litres at BTPS 
FEVIIFVC Ratio of FE VI as a percentage ofFVC 
FEF25-75* Mean forced expiratory flow between 25 and 75% ofFVC. Also known 
as the maximal mid-expiratory flow. This index is taken from the blow 
with the largest sum of FEV 1 and FVC 
*Note this is highly dependent on the validity of FVC measurement and the level of 
expiratory effort (Miller, Hankinson et al. 2005). 
2.1-1.2. Bronchiolitis obliterans syndrome 
Bronchiolitis obliterans syndrome (BOS) scores were calculated in patients after 6 
months, based on the ISHLT guidelines (Estenne, Maurer et al. 2002), (Table 1-1). In 
summary, BOS scores can be calculated as a drop in FEV 1 from the baseline (i.e. the 
best post-transplant scores) in the absence of other causes (e.g. acute rejection, 
infection, anastomotic stricture) (Estenne, Maurer et al. 2002). However. the post-
operative PFTs often continue to rise and BOS can only be demonstrated at 6 months 
post-transplantation (Estenne, Maurer et al. 2002). 
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2.15. Methodology for analysis of gastric juice and cell stimulation 
experiments 
2.15.1. Gastric juice 
Ethical approval was obtained from County Durham & Tees Valley 2 Research Ethics 
Committee. Trust Research & Development approval was granted by the Newcastle 
Upon Tyne Hospital Trust Research & Development Department. After informed 
consent was obtained, gastric juice was collected from routine endoscopies both of 
lung transplant recipients and also from routine endoscopies on non-transplant 
patients on and off PPI. The sample population was heterogeneous with significant 
variance in demographics, pathology and individual PPI use. This method was chosen 
to maximise sample numbers and include all potential patients for analysis. Before 
use, endoscopes were thoroughly cleaned and processed in accordance with national 
British Society of Gastroenterology guidelines (Allison, Bradley CR et al. 2008) -
manual cleaning followed by automated disinfection for 30 minutes. Enzymatic 
agents (Endozime) followed by Steris Hamo P AA containing peracetic acid, 
detergent) were used to fully decontaminate the endoscopes. Endoscopies were 
performed using a fibre-optic endoscope after midazolam (l-Smg) or xylocaine throat 
spray. Gastric juice was aspirated endoscopically from the gastric lumen and gastric 
juice was collected in a trapper (Pennine Healthcare, UK). Samples were then 
purified, by filtering and removing large food particles, before being analysed for pH, 
pepsin, trypsin, bile salts and microbiology. The pepsin and trypsin activity assays 
were described below. pH was analysed using a glass electrode and a pHmeter. 
Samples of gastric juice were sent to microbiology to be cultured for pathogens. 
2.15.2. Pepsin activity assay 
This assay was previously developed and validated (Stovold 2009). It was derived 
from an assay by Hutton et al (a modification of Lin et al. (Lin, Means et al. 1969)) 
and relied on the production of new N -terminal amino groups that are formed during 
proteolytic hydrolysis of the substrate succinyl albumin. The new amino groups 
reacted with trinitrobenzylsulphonic acid (TNBS, Fluka Biochemika, Buchs. 
Switzerland), generating trinitrophenyl (TNP) derivatives. These were then estimated 
spectrophotometric ally (Hutton et ai, 1986). 200JlI of sample from gastric juice or 
standard (0-2Jlg) were added to test tubes in triplicate. SOOJlI of substrate (8mg/ml 
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succinyl albumin in HCI adjusted to pH 2 using 1 M HCI) was added to each tube and 
the tubes were mixed, covered and incubated at 37°C for 1 hour. After incubation. the 
reaction was stopped by adding 500JlI of 4% (w/v) NaHC03 followed by 500JlI 
0.05% (w/v) TNBS solution (0.05% trinitrobenzylsulphonic acid in deionised water). 
Subsequently the tubes were mixed and placed in a waterbath at 55°C for 10 minutes 
to allow the colour to develop. After 10 minutes 500JlI of 10% sodium dodecyl 
sulphate (SDS, w/v) followed by 500JlI 1M Hel was added and the tubes were mixed, 
covered and left to stand at room temperature for 1 hour. The tubes were then read on 
a spectrophotometer at 340nm. Negative controls were produced by adding substrate 
to sample immediately before the NaHC03 step (Stovold 2009). 
2.15.3. Bile salt assay 
These were analysed with the Biostat assay described in Section 2.13.2. 
2.15. -I. Trypsin activity assay 
Quantification was carried out via an N-terminal assay for proteolytic activity 
(Sunderland 2003) with the following modifications: 
For the trypsin standard (porcine, pancreatic trypsin, Fluka Biochemika), a 
concentration range of 0-2.5 Jlg/ml was used, (0-0.5 Jlg trypsin in 200JlI phosphate 
buffered saline, pH 7.4). Negative controls contained denatured inactive trypsin 
having been heat-treated for five minutes in a 100°C waterbath. The trinitrobenzene 
sulfonic (TBNS, Fluka Biochemika) acid had to be pre-washed to remove aniline 
derivatives and thereby reduce its background colour. The protocol for TNBS 
preparation from AM Sunderland (Chapter 2, Section 6, page 42) (Sunderland 2003) 
was slightly modified: One and a half millilitres of TNBS was mixed with 10mg 
activated charcoal and centrifuged at 5000r.p.m. for 10 minutes (minispin plus, 
eppendorf centrifuge). Then the supernatant was simply taken off with a Pasteur 
pipette, not being passed through a syringe filter as stated in the protocol. The levels 
of trypsin in pancreatic juice are approximately 0.3mglml. Therefore a series of 
dilutions of gastric juice (1 in 10 to 1 in 50) were made assuming a range of possible 
levels of duodenal reflux (Sunderland 2003). 
2.15.5. Microbiology 
This protocol was designed, performed and written by Dr John Perry. Clinical 
Microbiologist Freeman Hospital. lOll1 of aspirate was inoculated onto three plates of 
Columbia blood agar (Oxoid Ltd., Basingstoke, UK). The plates were incubated at 
37°C for 72 hours in three different atmospheric conditions: in air. under strict 
anaerobic conditions and under micro-aerophilic conditions. The plates were 
examined daily and each distinct colony type was subcultured on the same medium to 
obtain a pure culture for further investigation. In the first instance, pure subcultures 
were investigated using Gram stain and simple biochemical tests including tests for 
oxidase and catalase. This allowed a presumptive identification and led to further 
analysis and identification to species-level. For example, suspect Enterobacteriaceae 
(Gram negative rods, catalase positive, oxidase negative, facultatively anaerobic) 
were identified by using the API 20 E biochemical kit (which comprises 20 
biochemical tests). Similarly, suspect Pseudomonas or Acinetobacter were identified 
using the API 20 NE kit. Species characteristic of mouth flora such as Neisseria 
species and alpha haemolytic Streptococci were not identified to species level. 
2.15.6. Cell studies 
2.15. 7. Goblet cells 
The goblet cell line HT29-MTX, a human colon carcinoma-derived mucin secreting 
goblet cell line, kindly provided by Dr. Thecla Lesuffleur (INSERM U178, France) 
was grown in Dulbecco's modified Eagle medium (DMEM: Sigma) supplemented 
with 10% heat-inactivated foetal bovine serum (FBS; Sigma) at 37°C in a 10% 
C02/90% air atmosphere. For maintenance 3x10
6 
cells were seeded in a collagen 
coated T25 flask (Vitrogen 100; Cohesion™, USA) in 10ml of medium. The medium 
was changed every second day until the cells reached confluence. Once at least 80% 
confluence had been achieved, cells were passaged for maintenance, using trypsin 
0.01250/0 in 0.53mM EDTA (Sigma, UK) in Ca2+, Mg2+ free Dulbecco's phosphate 
buffered saline (DPBS) (Sigma,UK). This occurred on average every 15 days. For the 
experiments, cells were seeded and grown in 6 and 24 well plates (Sigma, UK). 0.5m) 
of cell suspension, with a concentration of 9-1 Ox 1 05cells/ml, was used in our 
experiments (Smimova, Birchall et al. 2002; Stovold 2009). Cells had been 
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characterised in the laboratory, by their resistance to methotrexate and by the presence 
of secretory granules staining positive for the mucins MUC5AC and MUC5B. 
2.15.8. Epithelial cells 
Epithelial cells were retrieved from bronchoscopy of lung transplant recipients. 
Ethical approval had been obtained from the Local Research Ethics Committee and all 
patients gave informed consent. 
2.15.9. Bronchial epithelial cell isolation and culture from brushings 
Routine bronchoscopy was performed as described in Section 2.8. Single-sheathed 
nylon cytology brushes were used to collect bronchial brushings from subsegmental 
bronchi and samples were placed in Dulbecco's PBS. These suspended samples were 
centrifuged for 5 minutes at 1000rpm and the cell pellet was re-suspended in 2ml of 
basal epithelial growth medium (BEBM); Clonetics (Cambrex), San Diego, Ca, USA) 
together with BEGM single quots (Clonetics). Penicillin 50U/ml, streptomycin 
50mglml, gentamicin 50mg/ml and amphotericin B 50ng/ml were the final 
antimicrobial concentrations in the culture medium throughout the process (Forrest, 
Murphy et al. 2005). Cells were characterised in the laboratory by the identification of 
epithelial markers including cytokeratin. 
Cell suspensions were put in to a 25cm2 dish pre-coated with collagen (Vitrogen 100, 
cohesion, Palo Alto CA, USA) and placed in a carbon dioxide incubator (37°C/5% 
CO2). After the first 48 hours a further 3ml of supplemented medium was added with 
subsequent exchanges every 48 hours, until the primary bronchial epithelial cells 
(PBECs) reached confluence. Once confluent, PBECs were passaged using trypsin, 
which was neutralised using an equal volume of RPMI supplemented with 10% of 
FCS. PBECs were then put into 10mi of culture medium to Vitrogen (Cohesion) 
coated 75cm2 flasks or to eight chamber slides (Lab-Tek, Nunc, Naperville, 1L. USA: 
Chamber-I). These were cultured to 80-95% confluence (Aseeri 2007; Brodlie 2009; 
Stovold 2009). 0.5ml of cell suspension. with a concentration of 7-8xl05cells/mL was 
used in our experiments (Smirnova, Birchall et al. 2002; Stovold 2009). 
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2.15.10. Cell passage 
As cells neared confluence in cell culture dishes, passage was perfonned. 2.5ml of 
trypsin was added and incubated at 37°C for 2-4minutes, then 5-10ml of RPM I media 
was added to re-suspend cells. Cells were centrifuged for 5 minutes at 1000rpm to 
create pellets. 12ml of epithelial media was subsequently added and mixed gently. 24 
well plates were then seeded with 0.5ml of cell suspension per well (Stovold 2009). 
2.15.11. Cell stimulation 
Once cells had reached 80-95% confluence on the 24 well plates, they were rested for 
24 hours with the addition of serum free medium (BEBM, penicillin, streptomycin, 
gentamicin without singlequots). Cells were subsequently stimulated with 
pepsin/gastric juice in resting media. 
Goblet and epithelial cells were stimulated with porcine pepsin at concentrations of 
25~g/ml, 50/lg/ml, 100 ~g/ml in 500~1 DEMEM serum free, Sigma, UK or BEBM, 
without singlequots, Lonza, Switzerland respectively). For both goblet and epithelial 
cells the experiments were carried out on two repeated cultures with five repeated 
wells, giving an overall experiment number of n= 10. Goblet cells were incubated for 
72 hours; epithelial cells were incubated for 48hours. Control stimulations were 
constructed by incubating cells in dilutant vehicle alone (resting serum free medium). 
Samples were analysed for viability at 48 hours, as it was felt if cells had not 
experienced significant death, then cells would be unlikely to die between 48-72 
hours. The lack of viability data at 72 hours would not affect the interpretation of the 
IL-8 and MUC5AC results. Media was collected for IL-8 and MUC5AC 
measurements at 24 and 48 hours from epithelial cell culture. Media was collected for 
IL-8 and MUC5AC measurements at 24, 48 and 72 hours from goblet cell culture. 
Initially we endeavoured to stimulate both goblet and epithelial cells with gastric 
juice. The goblet cell lines were infected due to contamination in the incubator and we 
were unable to carry out these experiments. 
Epithelial cells were then stimulated with gastric juice from transplant and non-
transplant patients with dilutions III ,000 to 1110,000 (gastric juice: DEMEM) in 
500~1 DEMEM serum free, Sigma UK or BEBM, without singlequots, Lonza 
Switzerland respectively) for 24 hours. Three samples were chosen. Sample one was 
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chosen as it was from a lung transplant recipient with low pH, high pepsin and bile 
salt levels and bacterial colonisation. Samples two and three were from non-transplant 
patients. Sample two was chosen as it had a high pH and was colonised with bacteria 
and fungi. Sample three was chosen as it had a low pH and no bacterial colonisation. 
These three samples were used to see if they would cause different effects on the 
epithelial cells. Control stimulations were produced by incubating cells in dilutant 
vehicle alone (resting serum free medium). These epithelial cell experiments were 
carried out on one culture with seven repeated wells, giving an overall experiment 
number of n=7. Epithelial cells were analysed for viability at 24 hours and media was 
collected for IL-8 production at 24 hours. These were analysed at this time point as 
PBECs in previous experience are more susceptible to damage compared to cell lines. 
2.15.12. Interleukin-8 
The IL-8 concentrations were measured using a commercial ELISA described earlier 
(2.13.3). 
2.15.13. Mucin MUC5AC 
IOOll1 of standards diluted in PBS or 20111 of sample, added to 80111 of PBS were 
added to coat a 96 well microplate Maxisrop, Nunc). The plate was sealed and 
incubated overnight at room temperature. Each well was aspirated and washed with 
400lli wash buffer (0.05% Tween 20 in PBS pH 7.2-7.4, Sigma, UK) repeating the 
process twice for a total of three washes. The plate was then blocked by adding 300lli 
of block buffer (1 % bovine serum albumin in PBS) to each well and incubated at 
room temperature for 1 112 hour. Aspiration and wash were repeated. Primary 
antibody (antiMUC5AC (NCL-HJ\M-45MI), Sigma, UK) was diluted to working 
concentration (1 in 150) in reagent buffer (0.1 % BSA, 0.05% Tween 20, Sigma, UK, 
and IOOll1 was added to each well. The plate was then covered with parafilm and 
incubated for 2 hours at room temperature. Aspiration and wash were repeated. IOOIlI 
of the secondary detection antibody (horse radish peroxidase-conjugated anti-goat 
antibody, Sigma, UK), diluted in reagent dilutant (1 in 10,000), was then added to 
each well. This was then covered with parafilm and incubated for 2 hours at room 
temperature. Aspiration and wash were repeated. IOOlli of substrate solution (2.2'-
Azino-bis(3-ethylbenzothiazoline-6-) sulfonic acid) was then added to each well. This 
was incubated for 30 minutes at room temperature, avoiding direct light. 1 OOlli of stop 
76 
solution (l % sodium dodecyl sulphate) was added to each well. The plate was gently 
tapped to ensure thorough mixing. Optical density of each well was determined 
immediately using a microplate reader set to 405nm (Stovold 2009). Negative 
controls were also analysed. These samples were analysed identically apart from 
omitting the primary antibody. 
2.15.14. Viability assay 
This assay has been described by Stovold (Stovold 2009). The viability of both the 
goblet and epithelial cells was measured using the Cell Titerblue assay (Promega, 
Madison, WI, USA). 
This assay relies on the reduction reactions in the viable cell reducing resazurin, a 
dark blue compound in the Titerblue reagent, to resorufin which is pink. Resorufin has 
an absorbance maximum of 573nm compared to resazurin, 605nm. Viability is based 
on a ratio of these two absorbances OD5731D605. The higher the ratio, the greater 
number of viable cells. 
Challenge media was removed from the cells and stored at -20°C for further analysis. 
Titerblue reagent (Sigma, Gillingham, UK), was mixed directly with the goblet and 
epithelial cell media (20/l1 TiterBlue for every 100/l1 DMEM, Sigma UK or BEBM. 
Lonza Switzerland) and the cells were incubated under standard conditions for 2-4h. 
Absorbance was then measured at 560nm on a spectrophotometer. Negative controls 
were also performed by fixing cells for IO minutes in ice-cold methanol prior to 
adding the Titerblue reagent. As dead cells have no reducing potential, the reagent 
should not change colour, indicating that nothing present in media alone is responsible 
for the colour change (Stovold 2009). 
A second basic method was used for several experiments. This was based on a Trypan 
blue (Sigma, UK) stain. After removal and storage of media, IOul of 0.4% Trypan 
blue was added to the cell culture for 2 minutes. One hundred cells were counted and 
it was recorded how many of these were stained with the dye. Viable cells exclude 
Trypan blue, remaining clear, whereas dead cells take up the dye and are stained blue. 
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2.16. Statistical analyses 
The relevant statistical analyses were carried out using Graphpad Prism 4.0 (San 
Diego, CA, USA). Due to the small sample sizes non-parametric tests v .. ere 
predominantly used. In chapter 3, the analyses were performed using non-parametric 
Spearman rank correlation tests and non-parametric Mann-Whitney. unpaired t-tests. 
In chapters four and six, the analyses were performed using non-parametric Wilcoxon 
paired t-tests. In chapter 5, the statistical analyses of the results of the gastric juice 
samples were performed using Mann-Whitney analysis and Fisher's exact test. The 
statistical analyses of the cell stimulation experiments were performed using non-
parametric one-way analysis of variance with a post-hoc Mann-Whitney analysis. 
Comparison of the cell viability tests was performed using a Bland-Altman analysis. 
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3. Identification of gastro-oesophageal reflux 
and aspiration in the first month post-lung 
transplantation 
79 
3.1. Abstract 
Background 
Chronic allograft dysfunction occurs frequently in lung transplant recipients. Reflux 
and asp iration may occur post-lung transplant and may be injurious to the allograft. 
Nothing is known about the prevalence of GORD and aspiration in the first month 
post -transplant. 
Aims 
This study aimed to identify gastro-oesophageal reflux and aspiration in the first 
month post-lung transplantation. 
Methods 
Lung transplant recipients were recruited over a 12 months period (November 2007-
October 2008). At approximately one month post-transplantation, patients completed 
a Reflux Symptom Index (RSI) questionnaire for symptoms of extra-oesophageal 
reflux and underwent objective assessment for reflux (manometry & pH-impedance). 
Testing was performed with subjects on maintenance PPI. BALF was assessed for 
pepsin and bile salts, IL-8 and neutrophils. Microbiology samples, rejection scores 
and PFTs were analysed. 
Results 
18 patients with a median age of 46years (range 22-59) were studied. Manometry was 
abnormal in 8/18 (44%) patients. 12 of 17 (71%) had evidence of reflux on pH-
impedance. 25% of patients had exclusively weakly-acidic reflux. A weak correlation 
existed between RSI score and proximal reflux events. Pepsin was detected in 11/15 
BALF samples signifying gastric aspiration (median l8ng/ml, range 0-43). Bile salts 
were rarely detectable, using spectrophotometry/dual mass spectrometry (2/15) 
[sensitivity 0.1 Jlmolll]. (One of these was just above the level of detection). BALF IL-
8 (1,057pg/ml Range 156-15,559) and neutrophil levels were elevated (11% Range 1-
63%). A correlation existed between number of proximal reflux events and BALF 
neutrophilia (Spearman Correlation r=0.52, p=0.03). 
Conclusion 
Reflux/aspiration IS prevalent early post-operatively and proximal reflux events 
correlate with BALF neutrophilia, which is linked to allograft dysfunction and 
mortality. 
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3.2. Introduction 
It has been demonstrated that chronic aspiration, secondary to extra-oesophageal 
reflux, may contribute to BOS and up to 75% of patients may have demonstrable 
gastro-oesophageal reflux disease (OORD) following lung transplantation (D'Ovidio 
and Keshavjee 2006; King, Iyer et al. 2009). Anti-reflux surgery may be associated in 
this population with an increased survival and improved lung function (Hartwig, 
Appel et al. 2005). More recent data stress the role of early fundoplication in 
preventing the development of BOS (Cantu, Appel et al. 2004). 
Most studies of reflux have either been pre-transplantation or at least 3 months post-
transplant. None have assessed recipients for reflux in the immediate post-transplant 
period. If the aspiration contributing to BOS begins early post-transplant, then an 
important question is whether reflux and aspiration are present within the first month 
post -transp I ant. 
This chapter aimed to identify gastro-oesophageal reflux and aspiration in the first 
month post-lung transplantation. 
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3.3. Methods 
Patients undergoing lung transplantation at the Freeman Hospital were studied at one 
month post-transplant to test for the presence of GORD. Their lung allografts were 
under standard surveillance using bronchoscopy, bronchoalveolar lavage samples and 
pulmonary function tests. From 1st November 2007 to 1st November 2008 all newly 
transplanted lung recipients were approached to be recruited into the study. 
Our protocol was to assess for GORD at one month post lung transplantation, using a 
validated extra-oesophageal reflux questionnaire, manometry and pH/impedance 
measurements. These assessments were performed around similar time periods as 
bronchoscopy and pulmonary function tests. However exact practice was tailored to 
suit individual patients. Patients were assessed on their routine proton pump inhibitor 
therapy. Results were then compared with markers of aspiration and inflammation in 
the bronchoalveolar lavage samples, microbiology, pathological rejection scores and 
pulmonary function tests as described in chapter two. 
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3.4. Results 
3.4.1. Demographics 
Forty five patients received lung transplants between October 23 rd 2007 and October 
23rd 2008. Forty patients were approached to participate (five patient died in ITU). 
Twenty three patients agreed to participate, seventeen patients declined to take part. 
Of the initial 23, 5 patients dropped out, one as he was afraid of the test, another could 
not tolerate manometry, and three gave no reason. Eighteen patients were therefore 
studied (Figure 3-1) (12 women, 6 men) with a median age of 42 years (range 22-59 
years). Indications for transplant were cystic fibrosis (10), lymphangioleiomyomatosis 
(2), severe asthma (1), asthma/COPD (1), asthma/pulmonary fibrosis (1), COPD (2). 
Histiocytosis X (1). 13 patients had suppurative lung disease at the time of transplant. 
Demographics are shown in Table 3-1. 
Figure 3-1: Consort diagram of patient recruitment 
45 patients 
5 ITU deaths 
40 patients 
17 patients 
declined ,. 
23 patients 
entered study 
5 patients 
r 
dropped out 
18 patients in 
study 
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Table 3-1: Demo2raphics of study patients 
Age 
-Median 
-Range 
Sex 
-Male 
-Female 
Underlying pathology 
-Cystic fibrosis 
- Lymphangioleiomyomatosis 
-COPD 
-COPD/asthma 
-Severe asthma 
-Pulmonary fibrosis/asthma 
-Histiocytosis X 
Transplant 
-SSLT 
-LSLT 
-RSLT 
-HLT 
42 years 
22-59 years 
6 
12 
10 
2 
2 
1 
1 
1 
1 
15 
1 
2 
o 
Legend: SSLT= Single sequential lung transplant, LSLST= Left single lung 
transplant, RSLT= Right single lung transplant HLT= Combined heart lung 
transplant. 
3.-1.2. Immunosuppression 
All patients were treated with a combination of cyclosporin/tacrolimus; 
mycophenolate mofetillazathioprine; prednisolone. No patients were gIven 
azithromycin during this study. 
3...1.3. Pre-operative diagnoses ofGORD 
Six patients have had pre-operative diagnoses of GORD. One of which had this 
confirmed by pH study and had pre-operative Nissen' s fundoplication. 
3...1...1. Proton pump inhibitor therapy 
100% of patients were started on proton pump inhibitors. The various medications and 
doses are listed in Table 3-2. 
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T bl 3 2 Pt· h·b· a e - : ro on pump m I Itor therapy on recruitment to the study 
lansoprazole 30mg od 12 
lansoprazole 15mg od 1 
lansoprazole 30mg bd 2 
omeprazole 20mg od 1 
omeprazole 20mg bd 1 
rabeprazole 20mg od 1 
3.4.5. Oesophageal manometry 
18 patients underwent oesophageal physiology tests within the first month post-
transplant. Overall 44% (8/18) had abnormal oesophageal physiology. No 
complications were attributed to manometry or pH/impedance monitoring. 
Manometry was performed approximately one month post transplant. 
Lower oesophageal sphincter 
The median lower oesophageal sphincter length was 2.75cm (2-5.25cm). Sphincter 
pressure was normal in the majority of patients (14/18) with an average sphincter 
pressure of 23mmHg (Range 9.4-91.1mmHg). One had a hypotonic sphincter and 
three had a hypertonic sphincter. The median LOS nadir pressure was 1.2mmHg 
(Range -12.3 to 21.7) with a median percentage relaxation of 93.3% (Range 69.9-
100%). 
Oesophageal peristalsiS 
The median percentage of normal swallows was 90% (Range 0-100%). In total ten 
patients had normal peristaltic activity (one had hypertonic oesophageal peristalsis, 
characterised by high pressure oesophageal peristaltic amplitudes), four patients had 
ineffective oesophageal motility (two mild, one severe and one had an aperistaltic 
oesophagus), four patients had simultaneous oesophageal contractions in >20% of 
swallows (Figure 3-2). 
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T bl 33 0 a e - : eso phagea l pe rista ltic am pli tudes 
Median Range (mmHg) I Normal Values 
(mmHg) (mmHg) 
Maximum oesophagea l 156.2 58.3-602 .7 
Amplitude 
Min im um peristaltic amplitude 18.75 0-54.5 
Average peri stalti c amplitude 67 29.3 -303.5 30-1 80 
Distal oesophageal amplitude 64.9 26.3 -482 .6 30-1 80 
(5cm above the lower 
oesophageal sphincter) 
Prox imal oesophageal 58.9 12.1- 128.6 30-1 80 
amplitude (15cm above the 
lower oesophageal sphincter) 
Median peristalti c ampl itudes are shown in Table 3-3. One of eighteen pati ents had a 
hypotonic di stal oesophagus, fi fteen had a normotonic dista l oesophagus and two had 
a hypertonic di stal oesophagus. Four of eighteen had a hypotonic prox imal 
oesophagus, fo urteen had a normoton ic proximal oesophagus and none had a 
hypertonic prox imal oesophagus. All fo ur pat ients with a hypotonic prox imal 
oesophagus had a normotonic di stal oesophagus. 
Figure 3-2: Oesophageal peristalsis 
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3...1.6. Reflux data 
18 patients underwent assessments for reflux post-lung transplant. One patient had 
their probe placed too distally. This was apparent after analysis of the tracing. The 
other seventeen were therefore analysed. 71 % (12117) had pathological GORD. 
Reflux symptom index scores 
Five patients had positive reflux symptom index (RSI) scores. Twelve patients had 
negative RSI scores. Median RSI score was 10 (range 0-32). Three patients with a 
positive RSI had pathological proximal reflux; two patients with a positive RSI had 
no pathological proximal reflux. Five patients with a negative RSI score had abnormal 
proximal reflux and seven patients with a negative RSI had proximal reflux within 
normal limits «17) (Table 3-4). A breakdown of scores is shown in Appendix 9. 
T bl 34Th d" I f h RSI a e - : e pre Ictlve va ue 0 t e score 
Proximal reflux No proximal reflux 
RSI positive 3 2 PPV=60% 
RSI negative 5 7 NPV= 58.3% 
Sensitivity= 38% Specificity= 78% 
PPV= Positive predictive value, NPV=Negative predictive value 
pH-impedance results 
All seventeen patients successfully underwent 24 hour recordings. 12 of 17 (71 %) 
patients had pathological distal reflux as determined by either an abnormal acid 
exposure or oesophageal volume exposure. A summary of median reflux indices is 
shown in Table 3-5. The patient with pre-operative fundoplication had no reflux. Of 
the 12 with reflux nine had evidence of acid and weakly acid reflux; three had 
exclusively weakly acid reflux (25%) (Figure 3-3). Eight of the seventeen had 
abnormal proximal oesophageal reflux (47%). Of these eight, seven had evidence of 
distal reflux and one had no evidence of pathological distal reflux. Most reflux events 
were in the upright position 66 (25-130) versus 11 (1-37) supine. This was true of 
proximal reflux events (upright 15 (3-47) versus supine 1 (0-17)). 
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T bl 35 K H/I d a e - ey p. mpe ance results 
Median Range Normal Number of 
values patients 
with 
abnormal 
results 
Acid exposure (%) 4.8 1-79.9 <4.5 9/17 
(percentage of time 
that pH <4, 5cm above 
the LOS in 24hrs) 
Oesophageal volume 1.6 0.71-5.48 0.4-1.2 12/17 
exposure 
(% )(percentage of 
time that impedance 
detects refluxate 
within the oesophagus 
in 24hrs) 
No of reflux events 72 27-147 (25-58) 12/17 
-Acid reflux events 25 2-90 (10-35) 7/17 
-Weakly acid reflux 38 5-140 (5-18) 12/17 
events 
-Non acid reflux events 0 0-3 (1-7) 0/17 
Bolus clearance time 15s 8-26.5s (8-13) 11117 
(secs) 
Proximal reflux events 17 4-54 (4-17) 8/17 
Aspiration 
Pepsin was detected in 11115 (73%) BALF samples- median 18nglml (range 0-43). 
4/15 BALF samples had no pepsin. When compared to our normal controls (these 
were historical BALF samples collected from four healthy volunteers at 
bronchoscopy) median 5.5 (range 0-12.6ng/ml) the median from our current sample 
was higher. This was not statistically significant (p=0.1). Using 2 enzymatic bile salt 
assays no bile could be detected in 15/15 samples. Using a more sensitive tandem 
mass spectrometry with a lower limit of detect of 0.1 ~mol/L, we could detect 
conjugated bile salts in 2/15 of the lavage samples. One of these was just above the 
lower level of detection O.2~mollL. Four "normal" BALF samples showed no 
evidence of bile salts at a lower limit of detection. 
Consequently we re-analysed the BALF samples after extraction which gave an 
increased minimum levels of detected of 0.001 ~mol/l. All 15 samples now showed 
detectable bile salts with the highest bile salt concentration present being 1.19~mol/1. 
The median value for bile salts in the 15 patients was 0.049~mol/1. which considering 
that normal serum levels range from 0-1 O~mol/l and taking into account the 180ml of 
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saline used to collect approximately 1 ml of lung bathing fluid , then values up to 
0 .056~mol/1 would be within the normal range . Only 2115 patients had abnormal 
levels of bile salts in their BALF. Four normal controls were analysed with a median 
bile salt concentration of 0.009~mol/1 (range 0.005-0.0 11 ~mol/I). 
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Legend: This figure is from an actual study patient trace demonstrating an 
asymptomatic proximal weakly acidic reflux event. The sequential drop in impedance 
from channel Z6 to ZI shows that the event reaches 17cm above the lower 
oesophageal sphincter. The pH (bottom trace) does not drop below 4, indicating that 
this is a weakly acidic event. The symptom button has not been pressed, suggesting 
this event was not noticed by the patient. 
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No correlation existed between RSI and distal reflux indices. A correlation existed 
between RSI and proximal reflux events (r=0.533. p=0.006). However the RSI failed 
to significantly predict or exclude proximal reflux in patients (Table 3-4). 
Manometry to reflux indices 
A statistically significant negative correlation existed between LOS pressure and total 
impedance reflux events (n=17) (p=0.03, r=-0.52) and LOS pressure and oesophageal 
acid exposure (p=0.02, r=-0.55) (n=17). 
Evidence ofGORD and aspiration 
Interleukin 8 was detected in 15/15 samples. Median levels (L057pg/ml (range 156-
15,559)) were greater than reported normal controls (median 27.5pg/ml (range 8.7-
84.6)) and stable lung transplant recipients (median 558pg/ml (range 36-1076)) 
(Zheng, WaIters et al. 2000). No correlation existed between reflux indices/aspiration 
markers and BALF IL-8 levels or IL-8 and neutrophil levels (Table 3-6). Cell counts 
are shown in Table 3.6. There were increased percentages of neutrophils, eosinophils 
and macrophages but decreased lymphocytes when compared to stable controls 
(Zheng, WaIters et al. 2000). A correlation existed between proximal reflux events 
and BALF neutrophils (n=13) (r=0.52, p=0.03) (Figure 3-4). No correlation existed 
between reflux indices and PFTs. 
Figure 3-4: Correlation between proximal reflux events and neutrophil counts 
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T bl 36Th d' I II d a e 
-
: e me Ian tota ce an h'l neutropl I count and IL-8 count 
1 month Normal values (Zheng. 
Walters et al. 2000) 
Total BAL cell count (cellsxl04 /ml) 15.3 (1.04-68) 14 (12-16) 
Neutrophils (%) 11 (0.6-63.2) 2.1 (1.6-2.6) 
Lymphocytes (%) 5 (0-52) 20 (14-26) 
Macrophages (%) 82.5 (20.2-97.8) 73 (66-80) 
Eosinophils (%) 5 (0-52) 1.1 (0-2.2) 
Interleukin 8 1 057pg/ml (156-15559) 27.5pg/ml (8.7-84.6) 
There was no significant difference in reflux indices in cystic fibrosis patients when 
compared to non cystic fibrosis patients. nor those with BALF colonisation when 
compared with non-colonised patients. Patients with or without A2 rejection had 
similar reflux indices. 
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3.5. Discussion 
The main findings of this study are that aspiration is prevalent within the first month 
post-lung transplant. GORD as detected by pH-impedance was prevalent at one month 
post-transplant. Thirdly, there is a correlation between proximal reflux and BALF 
neutrophilia as shown in Figure 3-4. 
The relationships learned from these findings are that GORD occurs frequently within 
the immediate post-lung transplant period and this is associated with elevated pepsin 
with the BALF, signifying aspiration. The correlation between proximal reflux and 
neutrophilia suggests that increased proximal reflux leads to increased aspiration 
causing allograft inflammation and damage. This adds more weight to the theory that 
patients with increased proximal reflux aspirate and injury their lungs. 
Only one prevIOUS study has evaluated oesophageal physiology in the post-lung 
transplant population and shows oesophageal dysfunction to be common (Davis, 
Shankaran et al. 2010). There is a high prevalence of foregut motility problems in 
patients with end-stage lung disease (Cantu, Appel et al. 2004; D'Ovidio, Singer et al. 
2005; Sweet, Herbella et al. 2006). This present study evaluated oesophageal 
manometry post-lung transplant and show almost half of the patients had oesophageal 
dysmotility which is in keeping with previous work. The high prevalence of 
oesophageal dysmotility may be related to the high prevalence of pre-transplant 
dysmotility, vagal damage or secondary to GORD and subsequent oesophageal injury. 
The RSI has been shown to be useful in predicting LPR in the non-transplant 
population. In this study, the RSI correlated with reflux indices suggesting that the 
RSI score may be a surrogate marker of extra-oesophageal reflux. One difficulty with 
its use may be the fact that many of the symptoms- cough, hoarseness, and 
breathlessness- may be attributed to pulmonary pathology as well as extra-
oesophageal reflux. This may suggest a need for further evaluation using other 
questionnaires specifically developed for the transplant population. In the lung 
transplant population, the RSI questionnaire could not predict nor exclude reflux or 
aspiration. Other methods for assessing reflux and microaspiration are required. 
A previous study has shown increased prevalence and severity of GORD post lung 
transplantation with up to 75% of patients having demonstrable reflux on pH 
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monitoring (Young, Hadjiliadis et al. 2003). This post-transplant level of GORD is 
similar to our findings with pH-impedance. In other studies, using pH-impedance, 
almost 30% of patients had exclusively weakly-acidic reflux (Blondeau, V. Mertens et 
al. 2008; King, Iyer et al. 2009). These are similar to our results where 25% of 
patients had exclusively weakly-acidic reflux. 
GORD is associated with worse pUlmonary function tests in the post-transplant 
population (Hadjiliadis, Duane Davis et al. 2003; King, Iyer et al. 2009). One study 
showed a negative correlation between FEV 1 measurements and distal oesophageal 
acid exposure (Hadjiliadis, Duane Davis et al. 2003). This study" had a longer follow 
up period(median 558days) and this may explain why no significant changes were 
detected in the current study. Proximal oesophageal reflux was associated with 
decreased lung function (Hadjiliadis, Duane Davis et al. 2003) and increased non-acid 
reflux, as detected by pH-impedance. This has been associated with increased levels 
of BOS (King, Iyer et al. 2009). The present study suggests that proximal reflux leads 
to lung injury via aspiration. 
Bronchoalveolar lavage pepSIn levels have been shown to be higher in the 
transplanted population suggesting gastric aspiration (Ward, Forrest et al. 2005: 
Blondeau, V. Mertens et al. 2008). The highest levels were present in patients with 
acute rejection (Stovold, Forrest et al. 2007). A recent study revealed a correlation 
between pepsin levels and BAL neutrophil levels- a marker of injury (Blondeau, V. 
Mertens et al. 2008). The present study shows pepsin to be an early marker of 
aspiration, detectable at one month. When compared to previously reported normal 
controls (stable lung transplant recipients), the median from the present study was 
higher, suggesting aspiration. 
Other studies have discovered bile salts in the BALF and shown high levels to be 
associated with early onset BOS (D'Ovidio, Mura et al. 2005; Blondeau, V. Mertens 
et al. 2008). A major finding from this study is the rarity of bile salts in the BALF in 
the immediate post-transplant period. This rarity may have clinical indications. If 
biomarkers develop a role in the indications for surgery, pepsin may be a better early 
marker of aspiration and injury. 
The elevated levels of the pro-inflammatory cytokine IL-8 suggests that there may be 
associated injury at this time point. Neutrophils contribute to chronic rejection and 
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elevated BALF neutrophilia has been associated with mortality (Zheng, Walters et al. 
2000). The correlation in our study between proximal reflux events and BAL 
neutrophilia suggests that reflux is deleterious to the allografts. 
There are several limitations to this study. These include the small numbers in our 
cohort. A large sample base would allow stronger conclusions to be made. The short-
term follow up to this study and small numbers prevent it from proving a link between 
GORD and BOS which only develops after 6 months. 
Most patients had pathological GORD at one month but the amount of acid 
suppression is unknown, as is the effect that this has on reflux. Factors influencing the 
efficacy of PPI therapy to suppress acid reflux include a lack of compliance. genetic 
variation, drug metabolism and Helicobacter pylori infection (Bredenoord and Smout 
2008). In this study, the effects of these complex factors is unknown. It would have 
been interesting to assess those patients both on and off PPI to assess the differences 
PPI would make. 
Further limitation lies with the analysis of biomarkers of aspiration. A greater volume 
of saline was used to carry out BAL than in previous studies (180ml versus 100ml). 
Secondly, the present results were assessed at a different time and it may take time for 
bile salts to accumulate in the lung. Assay variability is a problem and could further 
influence results. A consensus is required over how to measure biomarkers so studies 
can be compared (Robertson, Shenfine et al. 2009). This may explain the variation 
between bile salt levels reported in this study and in previous papers. However. this 
study suggests the assays used in previous studies are inaccurate. 
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4. Longitudinal changes in gastro-
oesophageal reflux and aspiration in the 
first six months post lung transplantation 
95 
4.1. Abstract 
Bac kground 
Longitudinal reflux and aspiration data is lacking in lung transplantation. This study 
was undertaken to assess the changes over the first six months post transplant. 
Aim 
The aim of this chapter was to analyse the longitudinal changes In reflux and 
aspiration in the first six months post-transplant. 
Methods 
Within the first 6 months post-transplantation, patients completed a Reflux Symptom 
Index (RSI) questionnaire for symptoms of extra-oesophageal reflux and underwent 
objective assessment for reflux (manometry & pH/impedance). Protocol was to 
undergo testing at one, three and six months. Patients were assessed on maintenance 
PPJ. BALF was assessed for pepsin and bile salts. 
Results 
Over the first six months there was an increase in reflux indices. Nine patients 
underwent assessment at one and six months. At one month 5/9 patients were positive 
for reflux at six months 8/9 were positive. Despite decrea$es in immunosuppression 
and normalising lung function there was a trend to increase in reflux parameters over 
the first six months post-transplant. Aspiration determined by pepsin in the BALF 
decreased over the first six months. 
Conclusion 
Reflux/aspiration is prevalent early post-operatively and there was an increase in 
reflux indices over the first six months. Some patients who were free from reflux at 
one month developed reflux at six months. This occurred despite decreases in 
immunosuppression and no deterioration in lung function. In several patients an 
increase in reflux parameters mirrored increased immunosuppression. Despite this. 
aspiration decreased over the first six months, suggesting an improvement in the 
defences against aspiration. 
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4.2. Introduction 
The previous work of this thesis has shown that reflux is common post-transplant and 
that it is associated with elevated pepsin, a marker of aspiration and injury. This was 
also associated with evidence of allograft inflammation. These are prominent 
findings. It is important to assess whether this situation will improve, remain constant 
or deteriorate after this time point. If they remain similar or deteriorate, then they 
remain an issue for the allograft. If they improve, then this is unlikely to be a major 
problem. Longitudinal reflux data is currently lacking, and acceptable diagnostic tests 
are required (Sweet, Patti et al. 2009). 
Our original intent was to assess patients at three time points, one month, three 
months and six months. This was universally unpopular and thus the data presented 
assesses patients at two time points- the first month and at six months post-transplant. 
The aim of this chapter was to analyse the early changes in reflux and aspiration in the 
first six months post-transplant. 
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4.3. Methods 
Ethical approval was obtained. Patients undergoing lung transplantation at the 
Freeman Hospital were studied in a longitudinal manner to test for the presence of 
reflux. Their lung allografts were under standard surveillance using bronchoscopy. 
bronchoalveolar lavage samples and pulmonary function tests. From 1 st November 
2007 to 1 st November 2008 all newly transplanted lung recipients were approached to 
be recruited into the study. 
Patients were assessed for GORD and aspiration at one and six months post lung 
transplantation, usmg a validated extra-oesophageal reflux questionnaire, 
pH/impedance measurements and BALF analysis. These assessments were performed 
around similar time periods as pulmonary function tests. Tests were performed with 
patients on their routine proton pump inhibitor. A detailed description of materials and 
methods can be found in chapter two. 
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4.4. Results 
Participation was difficult as many patients did not tolerate multiple pH-impedance 
measurements. Twenty two patients refused any measurements, five patients 
underwent one pH-impedance test, eight patients underwent two pH-impedance tests 
and only four patients underwent three pH-impedance tests. 
Seventeen patients underwent assessments of reflux at one month. Nine patients 
underwent repeat assessments of reflux at one and six months. No patient underwent 
changes in PPI therapy between longitudinal measurements. Their details are shown 
in Table 4-1 and Table 4-2. 
I 4 1 D Tab e - : h· f h d emoerap ICS 0 . patients W 0 un erwent rej>eat assessments 0 fGORD 
Patient Age Sex Indication for Type of Proton pump inhibitor 
transplant transplant therapy 
1 29 F CF SSLT Lansoprazoie 30mg bd 
2 25 F CF SSLT Lansoprazoie 30mg bd 
3 46 F COPD RSLT Omeprazoie 20mg bd 
4 32 F CF SSLT Lansoprazoie 30mg od 
5 42 M COPD/asthma SSLT Lansoprazoie 30mg od 
6 46 M Histiocytosis X SSLT Lansoprazoie 30mg od 
7 29 M CF SSLT Lansoprazoie 30mg od 
8 49 F COPD SSLT Lansoprazoie 30mg od 
9 46 M CF SSLT Lansoprazoie 30mg od 
Table 4-1 Key: CF= cystic fibrosis, COPD= chronic obstructive pulmonary disease, 
SSL T= single sequential lung transplant, RSL T= right single lung transplant 
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Pat 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Table 4-2: Longitudinal data on immunosuppression, lung function and GORD, from 
one to six months post-lung transplant 
Imm unosu ppression Lung Function 
1 month 6 month Sum I mo 6mo 1 mo 6mo lmo 6mo 
FEV} FEVl FVC FVC Ratio Ratio 
Aza 100mg Aza 100mg +1- 2.14 2.76 2.2 2.79 96 98.9 
Pred 10mg Pred 10mg 
Tacro 4/4 Tacro 4/3 
Aza 100mg Aza 100mg +1- 1.8 2.5 2.08 3.47 87 7'2 
Pred 10mg Pred 10mg 
Tacro 5/4 Tacro 5/4 
MMF 2160mg MMF 1080mg 
- 1.34 1.28 1.93 2.12 69 60A 
bd bd 
Pred 30mg Pred 10mg 
Tacro 4/4 Tacro 4/3 
MMF 1080mg MMF720mg - 0.94 2.39 1.32 2.98 71 80.2 
bd bd 
Pred 50mg Pred 10mg 
Tacro 5/5 Tacro 4/3 
Aza 100mg Aza 125mg +1- 3.7 4.43 4.49 4.5 82 98 
Pred 20mg Pred 15mg 
CyA1501150 CyA1751150 
Aza 150mg Aza 100mg - 2.45 3.17 2.6 3.83 94 83 
Pred 20mg Pred 10mg 
Cj:'A25 0/25 0 CyA1501150 
Aza 125mg Aza25mg - 3.2 5.52 3.31 5.65 97 98 
Pred 40mg Pred 10mg 
CyA 275/275 CyA1251125 
MMF 1500mg MMF 1500mg - 1.03 1.78 1.52 2.39 68 74.5 
bd bd 
Pred 40mg Pred 10mg 
C~A 1501125 CyA 1251100 
MMF 750mg MMF 1500mg +1- 2.59 3.78 3.14 4.05 82 93 
bd bd 
Pred 20mg Pred 10mg 
CyA 300/300 Tacrolll 
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Immunosuppression pHlImpedance measurements 
lrno 6rno 1 rno 6 rno 1 rno 6 rno 1 rno 6rno lrno 6rno 
Pat 1 month 6 month Sum Acid Acid Vol Vol Rfx Rfx Prox Prox RSI RSI 
Exp Exp Exp Exp Rfx Rfx 
1 Aza 100mg Aza 100mg +/- 13.3 8.4 1.64 2.13 105 108 25 27 20 13 
Pred 10mg Pred 10mg 
Tacro 4/4 Tacro 4/3 
2 Aza 100mg Aza 100mg +/- 10 17.2 0.69 2.22 35 116 7 78 2 15 
Pred 10mg Pred 10mg 
Tacro 5/4 Tacro 5/4 
3 MMF MMF - 6 0.7 1.91 2.31 93 79 17 32 7 8 
2160mg bd 1080mg bd 
Pred 30mg Pred 10mg 
Tacro 4/4 Tacro 4/3 
4 MMF MMF - 1.6 3l.9 1.13 0.96 58 77 22 11 21 1 
1080mg bd nOmgbd 
Pred 50mg Pred 10mg 
Tacro 5/5 Tacro 4/3 
5 Aza 100mg Aza 125mg +/- 13.1 23.4 3.63 1.90 111 125 42 28 10 7 
Pred 20mg Pred 15mg 
CyA1501150 CyA175/J50 
6 Aza 150mg Aza 100mg - 7.4 0.3 1.64 0.42 111 24 8 5 6 0 
Pred 20mg Pred 10mg 
CyA250/250 CyA1501150 
7 Aza 125mg Aza25mg - 4.5 13.5 1.02 0.83 69 64 34 24 0 0 
Pred 40mg Pred 10mg 
CyA CyA125/125 
275/275 
8 MMF MMF - 1.4 1.6 1.08 1.26 38 42 11 14 7 4 
1500mg bd 1500mg bd 
Pred 40mg Pred 10mg 
CyA CyA 
1501125 1251100 
9 MMF MMF +/- 1.1 5.4 0.89 1.24 63 89 14 30 12 6 
750mg bd 1500mg bd 
Pred 20mg Pred 10mg 
CyA Tacroll1 
300/300 
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Table 4-2 Key: Pat=patient, Aza=azathioprine, Pred= prednisolone, Tacro= tacrolimus, 
CyA= cyclosporin A, MMF= mycophenolate mofetil, Sum= overall changes in 
immunosuppression, FEVI = forced expiratory volume in 1 second, FVC= forced vital 
capacity, Ratio= FEVlIFVC ratio, Acid Exp= 24 hour oesophageal acid exposure (%), 
Vol Exp= 24 hour oesophageal volume exposure (%), Rfx= total impedance reflux 
events/24 hours, Prox Rfx= impedance proximal reflux events, 17cm above the lower 
oesophageal sphincter, per 24 hours. 
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Immunosuppression 
From one to six months, immunosuppression therapy remained similar in four patients and 
decreased in five patients. Of the four patients who had a similar level of 
immunosuppression: two patients had an increase in all reflux parameters. one patient had an 
increase in three parameters but a decrease in acid exposure, one patient had an increase in 
two reflux parameters and a decrease in two reflux parameters. Of the five patients with a 
decrease in immunosuppression: one patient had an increase in all four reflux parameters, one 
had an increase in three parameters and a decrease in one parameter. two patients had an 
increase in two parameters and a decrease in two parameters. One patient decreased all four 
reflux parameters (Table 4-2). This suggests that during this time point that if there is no 
change in immunosuppression, the reflux will tend to increase and if immunosuppression is 
decreased then the changes are variable. 
Questionnaire 
Two patients had positive RSI scores at one month, of these one had a positive RSI score at 
six months. Seven patients had a negative RSI score at one month. Of these seven, six had a 
negative RSI score at six months. Median RSI score was 7 (range 0-21) at one months and 6 
(range 0-15) at six months. 
pH/Impedance Results 
Five patients had evidence of reflux at one month and eight patients had evidence of reflux at 
six months. At three months, all had acidic reflux. At six months 6 had acid reflux and 2 had 
exclusively weakly acidic reflux. At one month four had abnormal proximal reflux. This 
increased to six patients by six months. 
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T hi 43 K Hr d a e - : eyp, Impe ance results at one and six months post-Iune transplant 
1 month 6months Normal values 
median & median & 
ranges (n=9) ranges (n=9) 
Acid exposure (%) 6 (1.1-13.3) 8.4 (0.3-31.9) <4.5 
Oesophageal volume 1.13 (0.69- 1.26 (0.2-2.31) 0.4-1.2 
exposure (%) 3.63) 
No of reflux events 69 (35-111) 79 (24-125) (25-58) 
-Acid reflux events 28 (3-57) 18 (4-98) (10-35) 
-Weakly acid reflux events 47 (7-84) 44 (18-72) (5-18) 
-N on acid reflux events o (0-1) 0(0-1) (1-7) 
Bolus clearance time (sees) 14 (8-22.5) 13 (8-21) (8-13) 
Proximal reflux events 17 (7-42) 27 (5-78) (4-17) 
Median acid exposure was 6% at three months and increased to 8.4% at six months (Figure 
4-1). No patients had a positive relationship between their symptoms of cough/acid in the 
throat and acid reflux episodes on SI, SSI and SAP at three months. Only one patient showed 
a positive relationship between their symptom of cough/acid in the throat and acid reflux 
episodes on SAP and SI at 6 months. None had a relationship on SSI at 6 months. 
Median oesophageal volume exposure increased from 1.13% at three months to 1.26% by six 
months (Figure 4-2) and the median number of reflux events increased from 69 at three 
months to 79 events at 6 months (Figure 4-3). Median proximal reflux events increased from 
over this period (17 to 27) (Figure 4-4). BeT was abnormal in four patients at three months 
and five patients at six months (Table 4-2,Table 4-3). Three patients showed a positive 
relationship between their symptom of cough/acid in the throat and impedance reflux events 
on SI and SAP at three month, and only one on SSI. Only one patient showed a positive 
relationship between their symptom of cough/acid in the throat and impedance reflux 
episodes on SI, none on SSI and two were positive on SAP at 6 months. 
IO-t 
Table 4-4 compares all patients assessed at one month and six months post-transplant. This 
also demonstrates that, in general, reflux indices are higher at six months post-transplant. 
This data is not longitudinal. 
Table 4-4: Key pH/impedance results at one and six months post-lung transplant (n=17 vs 0=9) 
1 month 6months Normal values 
Median & Median & 
ranges (n=17) ranges (n=9) 
Acid exposure (0/0) 4.8 (1-79.9) 8.4 (0.3-31.9) <4.5 
Oesophageal volume 1.6 (0.71- 1.26 (0.2-2.31) 0.4-1.2 
exposure (%) 5.48) 
No of reflux events 72 (27-147) 79 (24-125) (25-58) 
-Acid reflux events 25 (2-90) 18 (4-98) (10-35) 
-Weakly acid reflux events 38 (5-140) 44 (18-72) (5-18) 
-Non acid reflux events 0(0-3) o (0-1) (1-7) 
Bolus clearance time (sees) 15 (8-26.5) 13 (8-21) (8-13) 
Proximal reflux events 17 (4-54) 27 (5-78) (4-17) 
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Figure 4-1: Changes in oesophageal acid exposure (%) from one to six months post-lung transplant 
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Figure 4-2: Changes in oesophageal volume exposure (%) from one to six months post-lung transplant 
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Figure 4-3: Changes in total reflux events from one to six months post-lung transplant 
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Figure 4-4: Changes in proximal reflux events from one to six months post-lung transplant 
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Biomarkers of aspiration 
Only 13117 had BALF available at one and six months. Median pepsin levels decreased from 
23 ng/ml (range 14-83ng/ml) at one month to 15ng/ml (range 0-34ng/ml) at six months 
(p<O.OO 1) (Figure 4-5). Median bile salt levels were Ollmolll at three months and six months. 
At both time points only two patients had bile salt levels greater than O.lllmolll. There did 
not appear to be any trends between immunosuppression, reflux indices and biomarkers of 
aspiration in these patients (n=13) during these time points. 
Figure 4-5: Pepsin levels at one and six months post-lung transplant 
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Statistics 
There was no statistical significant differences in reflux indices from one to six months using 
Wilcoxon non-parametric paired t-tests. However there was a significant reduction of pepsin 
from one to six months (n=13) (p<0.001). 
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4.5. Discussion 
The main findings of this study are that over the first six months the prevalence of reflux 
increases and aspiration, as denoted by BALF pepsin level, decreases. 
The relationships learned from these findings are that despite decreasing immunosuppression 
and improvement in lung function, the prevalence of reflux increases. Surprisingly 
microaspiration improves with a decrease in BALF pepsin levels. A potential explanation of 
this finding is that over this time pulmonary defence mechanisms improve. This may be by 
allograft re-innervation, improved cough reflex (Duarte, Terminella et al. 2008) and muco-
ciliary clearance which reduce the amount of aspiration the allografts encounter. 
With impedance measurements, there is some intra- and inter-individual variability. 
Bredenoord et al evaluated 20 healthy volunteers, 2 weeks apart, and found that there was 
more variability between different subjects than within the same subjects at different times 
(Bredenoord, Weusten et al. 2005; Wise and Murray 2007). Reproducibility has not been 
assessed in the lung transplant population. Impedance monitoring has been shown to be well 
reproducible and at least as reproducible as pH monitoring (Bredenoord, Weusten et al. 2005: 
Wise and Murray 2007). This may suggest that these are real changes shown here during a 
period of dynamic anatomical, physiological and pharmacological changes for patients. 
One study demonstrated an increase in the prevalence of reflux from 35% pre-transplantation 
to 65% post-transplantation (Young, Hadjiliadis et al. 2003). Previous studies, attempting 
multiple impedance measurements, have been unsuccessful due to patients refusing multiple 
measurements. (Blondeau, V. Mertens et al. 2008) Only one study exists comparing reflux at 
two different times post-transplant. This study comparing GORD in the first year post-
transplant supports our observations (D'Ovidio, Mura et al. 2006). It shows an increase in the 
prevalence of GORD (16 out of 50 patients) at 3 months to (16 out of 30) at 12 months 
(D'Ovidio, Mura et al. 2006). Only twelve patients had multiple measurements and 
unfortunately changes for repeat measurements in the same individuals were not described. 
The current study demonstrated an increase in the prevalence of GORD over the first six 
months post-transplant despite decreasing immunosuppression and improvement in lung 
function. Although reflux increased in the absence of augmented immunosuppression, if 
immunosuppression was kept stable then reflux indices tended to increase. If 
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immunosuppression decreased then changes in reflux were variable. This suggests that some 
changes in reflux may be related to immunosuppression but other factors may playa role. 
This study tried to identify the optimum time to assess for reflux and its changes over a 6 
month period. The current data does not identify an ideal time but repeat assessments of 
GORD may be an advisable component of post-transplant follow up. This series 
demonstrates that multiple catheter based assessments are unpopular. It highlights a need for 
identifying markers of GORD and aspiration which are specific and well tolerated 
(Robertson, Griffin et al. 2009). 
Pepsin has been shown to be a marker of aspiration and of injury (Ward, Forrest et al. 2005: 
Stovold, Forrest et al. 2007). Little is known about the natural history of aspiration post-lung 
transplant and the variability of pepsin levels over time. Over the first six months. there was a 
statistically significant decrease of median BALF pepsin level. This is paradoxical as. over 
this time, GORD increased in prevalence. Several reasons may explain these findings. Given 
the strength of the p-value, biological variability is unlikely to explain this data. The most 
plausible explanation is that pulmonary defence mechanisms improve. Re-innervation of the 
allograft by the vagal nerve would improve sensation and secreto-motory function. Muco-
ciliary clearance is shown to be reduced post-transplant (Veale, Glasper et al. 1993) but it is 
unknown if this improves with time. The cough reflex has been shown to improve over the 
first year post-transplant (Duarte, Terminella et al. 2008). Combined with decreasing post-
operative pain and improved lung function, these factors may improve mechanical defences 
against aspiration. 
The main weaknesses of this study were the low numbers, poor patient recruitment and 
compliance. Further larger studies should be performed to assess whether this paradox- a 
decrease of median BALF pepsin level occurring over the time period when GORD increases 
in prevalence- is maintained. Multiple impedance measurements were universally unpopular 
amongst patients. For future studies, a recommend maximum of two measurements per 
patient should be implemented. 
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5. Analysis of Gastric Juice and Cell Stimulation 
Experiments 
1 1 1 
5.1. Abstract 
Introduction 
There is a limited understanding of the pathophysiology of aspiration induced damage post 
lung transplant. Studies are needed to assess the contents and potential damaging components 
of gastric juice. It is also necessary to understand cellular mechanisms involved in injury 
from pathological levels of injurious agents. 
Aims 
The aim of this chapter was to assess the components of gastric juice and to perform cell 
culture experiments to increase our understanding of the potential pathophysiology of 
aspiration. 
Methods 
Gastric juice samples, from both transplant and predominantly non-transplant patients, were 
collected and analysed for pH, pepsin, bile, trypsin and bacteriology. Goblet cells were 
stimulated with porcine pepsin and primary bronchial epithelial cells (PBECs) were 
stimulated with porcine pepsin and gastric juice from both lung transplant and non-transplant 
patients. Viability, IL-8 and MUC 5AC production were assessed from goblet cells and 
PBECs. 
Results 
Gastric juice samples were collected from 65 patients (56 non-transplant patients and 9 lung 
transplant recipients). 28/65 patients were on PPI. Median pepsin levels were 380/lg/ml (0-
3892/lg/ml), median bile salts levels were 50/lmolll (0-8000/lmolll), trypsin 5/lg/ml (4-
100/lg/ml) and mean pH 3.7 (0.8-8.4) levels were established. Bacteria were present in 11118 
samples (l of 2 samples analysed for microbiology from lung transplant recipients). 
Stimulation of HT29 MTX goblet cells with pepsin had no effect on IL-8 on cell viability but 
reduced MUC5AC production. Stimulation of PBECs with pepsin led to an increased IL-8 
production, but did not affect cell viability. Stimulation of PBECs with diluted gastric juice 
led to a varied response in IL-8 production, but consistently resulted in cell death. 
Conclusion 
We suggest a novel pathophysiological mechanisms linking aspiration to infection: that 
gastric juice is a reservoir for bacteria may lead to allograft infection via the direct 
introduction of pathogens. Cell work suggests aspiration may down-regulate mucus, increase 
interleukin production and leads to cell death. However. any increase in IL-8 production is 
unlikely to arise from goblet cells. We propose a subsequent model of aspiration induced 
lung epithelial injury. 
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5.2. Introduction 
There have been limitations to human and animal studies undertaken performed to look at the 
effects of chronic aspiration in lung transplant recipients (Robertson, Shenfine et al. 2009). 
Previous work has suggested that pepsin and bile are important biomarkers of aspiration. 
These biomarkers have not yet been fully validated. In our current study pepsin was elevated 
in the BALF of transplant recipients, and bile salts were rare, suggesting pepsin to be a more 
reliable biomarker of aspiration. To further assess the validity of biomarkers, gastric juice 
samples of lung transplant patients and normal controls were analysed: firstly to assess the 
gastric concentrations of pepsin and bile salts to determine whether reported BALF levels are 
feasible; secondly to obtain background data on the intra-gastric levels in both lung transplant 
recipients and non-transplant patients; thirdly to analysed gastric juice for other potential 
damaging compounds e.g. trypsin and bacteria and finally to guide cell culture experiments. 
It has been suggested that there is a link between aspiration and infection (Vos, Blondeau et 
al. 2008). This has previously been hypothesised as aspiration damaging the innate immunity 
in the lung, leading to a weakened response to infection (D'Ovidio, Mura et al. 2006). 
Another proposal is that although this may be one mechanism linking the two together, that 
the aspirate itself may contain pathogens- bacterial, viral and fungal (Robertson, Ward C et 
al. 2010). 
Currently there is a limited understanding of the pathophysiology of aspiration induced 
damage at a cellular level. Cell culture experiments (PBECs and goblet cells) with pepsin and 
gastric juice are necessary to develop our understanding of this pathophysiological process. 
Mucus homeostasis is important in health and as a defence !1gainst infection. Therefore it is 
important to study mucus production as alteration in mucus homeostasis may be detrimental 
to allograft function and health. 
The aim of this chapter was to assess the components of gastric juice and to perform cell 
culture experiments to increase our understanding of the potential pathophysiology of 
aspiration. 
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5.3. Methods 
Methods are described in detail in Chapter 2. In summary gastric juice \\ as collected at 
routine endoscopy from both transplant and non-transplant patients. Samples were analysed 
for pH, pepsin, bile salts, trypsin and microbiology. 
Cellular experiments were performed using HT29-MTX goblet cells and primary bronchial 
epithelial cells. Cultured cells were stimulated with porcine pepsin and diluted gastric juice. 
Cells were assessed for their response to this challenge with regards to IL-8 production, 
MUC5AC production and cell viability. 
1 1.+ 
5.4. Results 
5. -1.1. Gastric juice 
Sixty five gastric juice samples were collected (56 from non-transplant patients and nine from 
lung transplant recipients). The mean age of all patients was 53.lyears (Range 20-88years). 
44 were female 18 were male. Three patients did not have their gender recorded. 28/65 \\ere 
on PPI therapy. Three historical samples had been taken from patients after pentagastrin 
stimulation. There was a variety of pathology identified (Table 5-1). Several patients had 
more than one pathology present. 
bl 5 1 P . 'd 'fi d mples Ta e - : atJent category I entl Ie at gastroscopy to co lect gastric .juice sa 
Pathology Number Pathology Number 
Normal 10 Hiatus hernia 28 
Gastric ulcer/erosion 7 Barrett's 7 
oesophagus 
Gastritis 12 Oesophageal 2 
adenocarcinoma 
Peptic ulcer 5 Oesophageal 1 
nodule 
Oesophagitis 19 Pyloroplasty 1 
Duodenal 7 Gastro-j ej unostomy 1 
ulcer/duodenitis 
Lung transplant 9 Gastric polyp 1 
Mean pH was 3.74 (range 0.8-8.4). Median pepsin levels were 380llg/ml (range 0-3892). 
77% 50/65 contained active pepsin. Median bile salt levels were 50llmol/1 (rangeO-8000). 
83% (54/65) contained bile salts. Only 11165 (17%) patients had levels above 300llmoll1. 
Median trypsin levels were 5 11 g/m I (range 4-100). 100% (l3/l3) contained trypsin. A 
summary is shown in Table 5-2. 11118 (61%) had bacteria- pathogens including 
Pseudomonas aeruginosa, Klebsiella, Proteus, and fungal pathogens (candida). 
Table 5-2: Mean/median values of all gastriciuice samples 
pH (Mean) 3.74 (range 0.8-8.4) 
Pepsin (median) * 380llg/ml (range 0-3892) 
Bile (median) 501lmol/1 (range 0-8000) 
Trypsin (median) * 5llg/ml (range 4-100) 
Bacteria 11118 
*(based on an actiVity assay) 
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5 . .f..2. Comparison of gastric iuice analyses from patients on and offPPI therapy 
Twenty eight patients had samples collected whilst on PPI therapy, 37 patients had samples 
collected with no PPI or anti-acid therapy. Those treated with PPI had a higher mean pH 
(5.02) than those without PPI therapy (2.7) (p<O.OOOI) (Figure 5-1). Patients without PPI 
therapy had a higher median pepsin level 572 Jlg/ml vs those on PPI therapy 1 o 7Jlglm I 
(p=0.049) (Figure 5-2). 82% (31/38) of patients not taking a PPI as opposed to 68% (19/28) 
on PPI therapy had pepsin detected. Median bile salt levels were similar in both groups 
(70Jlmol/l vs 55Jlmolll) (p=0.97) (Figure 5-3) as were median trypsin activity levels (9 Jlg/ml 
vs 5 Jlglml) (p=0.29). A summary is shown in Table 5-3. Bacteria were present in the gastric 
juice of 4/6 without PPI and 7112 patients with PPI. This was not statistically significant on 
Fisher exact test (p=1.0). 
Ta e 5- : bl 3 D h' emograpJ lCS an d I va ues 0 fth ose on PPI versus no PPI 
NoPPI PPI 
Age 55.6 (20-81) 56 (24-88) 
Sex 
Female 25 17 
Male 9 9 
Unrecorded 3 
pH 2.7 (0.8-7.9) 5.0 (1.6-8.4) * 
Pepsin 572Jlgiml (0-3,772) 1 07 Jlg/ml (0-3,892) * 
Bile 70Jlmolll (0-8,000) 55Jlmolll (0-8,000) 
Trypsin 9Jlg/ml (4-100) 5 Jlg/ml (4-15) 
Bacteria 4/6 7112 
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Figure 5-1: pH of gastric juice onl off PPI 
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Figure 5-2: Pepsin levels of gastric juice onloff PPI 
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Figure 5-3: Bile salt concentration of gastric juice on/off PPI 
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5 . ..t.3. Gastric juice from lung transplant recipients 
Nine samples of gastric juice were obtained from lung transplant recipients (9 female) with a 
median age of 30years (Range 24-60years). 2 patients had stopped their PPJ for gastroscopy 
the other seven remained on their PPJ therapy. 
Median gastric juice pH was 3.5 (range 1.4-7.8). Median intragastric pepsin concentration 
was 3911lg/ml (Range 0-3,892Ilgll). Median intragastric bile acid concentration was 951lmolll 
(range 0-2,200llmolll). Three of eight patients had levels above 300llmollL, which has been 
proposed as the lower limit of intragastric bile salts for detection of bile salts in the BALF. 
Only 2 samples were analysed for trypsin one had 51lg/ml the other 121lg/ml. 
One of two patients had positive microbiological cultures. Pathogens grown included 
Lactobacillus and Candida species, as well as Pseudomonas aeruginosa. Two other patients 
had oesophageal candidiasis visible on OGD. There was no significant difference between 
pH (p=0.73), pepsin (p=0.88), bile salt levels (p=0.47) between transplant and non-transplant 
patients, although there was a significant difference in median age (p=O.OOO 1). Results are 
shown in Table 5-4. 
Table 5-4: Summary of analysis of lune; transplant recipient e;astnc JUIce 
Lung transplant Non-transplant 
Age 30 (24-60) 59.4 (20-88)* 
Sex 
Female 9 35 
Male 0 18 
Unrecorded 3 
PPJ 7 19 
No PPJ 2 37 
pH 3.5 (1.4-7.8) 3.7 (0.8-8.4) 
Pepsin 391 11 g/m I (0-3,892) 380llg/ml (0-3,772) 
Bile 951lmolll (0-2,200) 60llmol/l (0-8,000) 
Trypsin 8.51lg/ml (5-12) (n=2) 51lg/ml (4-100) (n-9) 
Colonised 1/2 10116 
119 
5.-1.4. Comparison of colonised versus non-colonised samples 
Eighteen samples were analysed for bacteriology (16 from non-transplant patients and two 
from transplant recipients). Eleven of eighteen (61 %) patients were colonised. Pathogens 
detected included Pseudomonas aeruginosa, Klebsiella, Proteus, and fungal Candida. There 
was no significant difference in age (65 versus 59y) (p=0.53). sex (p=0.32). or PPI use (7/11 
versus 5/7 (p=0.41) using Fisher exact test, in patients colonised or non-colonised. Median 
pH was higher in colonised samples pH 5.2 vs 2.4 (p=O.l). Of note 2 colonised samples had 
low pH 1.6, 1.7 (Figure 5-4). Median pepsin levels were lower in colonised samples 460 vs 
798 (p=0.61). Bile salt and trypsin levels were similar in colonised versus non colonised 
samples (50 vs 50 p=0.59 and 6.5 vs 5 p=0.72 respectively) (Table 5-5). Analyses were 
performed using non-parametric t-tests. 
Table 5-5: ummalYo analysIs 0 co omse gas rIC JUIce S fl' fl' d t'" 
Colonised (n=ll) Non-colonised (n=7) 
Age 65 (30-80) 59 (30-75) 
Sex 
Female 6 6 
Male 5 1 
PPI 7 5 
NoPPI 4 7 
RH 5.2 (1.6-8.4) 2.4 (1.4-6.8) 
Pepsin 460 (0-3772) 798 (0-3892) 
Bile 50 (0-2050) 50 (20-500) 
Trypsin 6.5 (4-100) 5(4-12) 
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Figure 5-4: pH of samples colonised/non-colonised 
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5 . .f..5. Cell culture experiments 
5 . .f..6. Stimulation of goblet cells (HT29-MTX) with porcine pepsin 
Results from HT-29 MTX cultured and exposed to pepsin are described below. 
Viability 
The stimulation of HT -29MTX goblet cells with pepsin over 48 hours did not lead to cell 
death at concentrations of 25 to 1 OO~g/ml (Table 5-6) as assessed by TiterBlue Assay at 48 
hours (repeated culture n= I, with repeated wells n=3, overall n=3). 
6 r Table 5- : Vlabi Ity at 48 h ours 0 f HT 29MTX blet cells stimulated with porcine pepsin - go 
Viability at 48 
hours 
Control (n=3) 100% 
25~g/ml porcine pepsin 100% 
(n=3) 
50 ~g/ml porcine 100% 
pepsin (n=3) 
1 00 ~g/ml porcine 97% 
pepsin (n=3) 
Interleukin-8 
Stimulation of HT29-MTX goblet cells with porcine pepsin (concentration 25-1 OO~g/ml) did 
not stimulate an increase in IL-8 production over a 72 hour period (repeated culture n=2. with 
repeated wells n=5, overall n=IO). Levels are shown in Table 5-7 and Figure 5-5. 
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Table 5-7 : Interleukin 8 concentration (on successive days) from goblet cells challenged with porcine 
pepsIn 
IL-8 (pg/ml) at IL-8 (pg/ml) at 48 IL-8 (pg/ml) at 72 
24 hours hours hours 
Control 136 (119-172) 144 (123 -180) 186 (153-255) 
25~g/m l porcine pepsin 139 (121 -173) 145 (124-181) 175 (153-201) 
50 ~g/ml porcine 143 (125-182) 145 (123-182) 176 (149-204) 
pep_sin 
1 00 ~g/m l porcine 144 (123-176) 147 (128-186) ] 72 (149-204) 
pepsIn 
P values on Kruskall P=0. 19 P=0.83 P=0.85 
Wallace analys is 
Figure 5-5: Interleukin 8 concentration (on successive days) from goblet cells challenged with porcine 
pepsin 
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MUC5AC 
Stimulation of HT-29MTX goblet cells with porcine pepsin (concentration 25-1 OO/lgiml) 
down regulated MUCSAC concentrations at 24, 48 and 72 hours (repeated culture n=5, \\ ith 
repeated wells n=3; overall n=IS). There was a dose dependent effect with a decreasing 
MUCSAC level as pepsin concentration increased. There was a statistically significant 
decrease in MUCSAC concentrations at 24 hours in samples challenged with SO/lg/ml 
(p=0.03) and 100)lg/ml (p=0.008) but not with 2S)lg/ml porcine pepsin when compared to 
controls. This was similar at 48 hours for SO/lglml (p=0.03), 100 /lg/ml (p=0.03), 25/lg/ml 
(p=0.22) when compared to controls. By 72 hours there was a statistically significant 
decrease in MUCSAC concentrations in samples challenged with 2S)lg/ml (p= 0.016). 
SO/lg/ml (p=O.O 16) and 100)lglml (p=0.008) of porcine pepsin when compared to controls. 
There was no statistically significant difference between the three concentrations of pepsin 
(2S,SO,100)lg/ml) at any time point (24h,48h,72h). Levels are shown in Table S-8 and Figure 
S-6. 
Table 5-8: MUC5AC concentration (on successive days) after stimulate with porcine pepsin over 72 hours 
MUC SAC MUC SAC ()lg/ml) MUCSAC 
()lg/ml) at 24 at 48 hours ()lg/ml) at 72 
hours hours 
Control (n= IS) 3.03 (1.92-4.l8) 4.13 (2.7-S.8) 4.43 (3.67-S.11) 
2S /lglml porcine pepsin I.S2 (0.6S-3.08) 2.S9 (1.36-4.87) 2.40 (1.27-4.04)* 
(n=lS) 
SO)lg/ml porcine pepsin 0.72 (0-2.81)* 1.89 (0.7S-4.1)* 2.l6 (1.2-4.01)* 
(n=lS) 
I OO/lg/ml porcine 0.48 (0- I .S6)* 1.26 (0.S-3.06)* 1.62 (0.9-3.39)* 
pepsin (n=1 S) 
P values on Kruskall P=O.Ol P=0.039 P=O.Oll 
Wallace analysis 
Figure 5-6:MUC5AC mucin concentration (on successive days) after stimulation with porcine pepsin 
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5 . .f.7. Primary bronchial epithelial cells 
5.4.8. Stimulation of primary bronchial epithelial cells with porcine pepsin 
Results were analysed from PBECs cultured and exposed to concentrations of pepsin over -+8 
hours (repeated culture n=2, with repeated wells n=5, overall n=10). 
Viability 
Cell viability was assessed by TiterBlue Assay (repeated culture n= 1. with repeated \\elIs 
n=2, overall n=2). The stimulation ofPBEC with porcine pepsin over 48 hours did not lead to 
cell death at concentrations of 25, 50 and 100Jlg/ml of pepsin (Table 5-9). 
Table 5-9: Viability at 48 hours of PBECs stimulat ed with porcine pepsin 
Viability at 48 
hours 
Control 100% 
25 Jlg/ml porcine pepsin 100% 
50 Jlg/ml porcine 99% 
pepsin 
100 Jlg/ml porcine 98% 
pepsin 
Interleukin-8 
Stimulation of PBECs with pepsin (25, 50 and 100Jlg/ml), over a 48 hour period, did not lead 
to a significant increase in IL-8 production. Levels are shown in Table 5-10 and Figure 5-7. 
Table 5-10: Interleukin 8 concentration ion successive days) from PBECs c hallenged with porcine pepsin 
IL-8 (pg/ml) at IL-8 (pg/ml) at 48 
24 hours hours 
Control (n=15) 408 (263-654) 1535 (648-2970) 
25 Jlg/ml Porcine 386 (249-755) 1728 (546-2986) 
Pepsin (n= 15) 
50 Jlg/ml Porcine 424 (305-574) 1925 (1273-2650) 
Pepsin (n=15) 
100 Jlg/ml Porcine 638 (314-1158) 2103 (920-3750) 
P~sin (n=15) 
P values on Kruskall P=0.3 P-0.7 
Wallace anaIy~sis 
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F igu~e 5-7: Interleuki n 8 concent ration (on successive days) from PBECs cells challenged with porcine 
pepsin 
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MUC5AC 
Contro l samples of PBEC ce ll s did not produce MUC5AC and stimu lati on of PBEC cell s 
with peps in did not result in the production ofMUC5AC over 48 hours (repeated culture n= ] , 
with repeated wells n=2 , overall n=2). 
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5.4.9. Stimulation of epithelial cells H'ith gastric juice 
Cells, collected at bronchoscopy, were cultured from three different human lung transplant 
recipients. These were named Cell Culture A, Band C. These cell lines were stimulated with 
three different gastric juices (Table 5-11). 
T bl 5 11 S a e - : ft· .. ummary 0 ·2as riC JUice samp es for PBEC stimulation 
Sample Patient pH of Pepsin Bile Trypsin Pathogens 
original 
gastric 
.. JUIce 
sample 
1 Lung 1.6 1346~g/ml 530~mol/ml 5~g/ml Pseudomonas 
transplant Aeruginosa: 
Candida sp 
2 Non- 5.5 3153~g/ml 600~mol/ml 15~g/ml Acinetobacter 
transplant JUDll; 
Candida sp 
3 Non- 1.7 1319~g/ml 80~mol/ml 5~g/ml Nil 
transplant 
Viability 
Viability was not calculated for cell culture A. Viability for cell culture B, was calculated 
with Trypan Blue technique (repeated culture n= 1, with repeated wells n= 1, overall n= 1). 
Viability for cell culture C was calculated with TiterBlue assay (repeated culture n=l, with 
repeated wells n=l, overall n=2). A fourth plate using cell culture B was assessed by both 
TiterBlue and Trypan Blue to compare the accuracy of these methods. Stimulation of PBECs 
with diluted gastric juice led to cell death. Gastric juice diluted to 111.000 concentration led 
to only 18-28% survival at 24 hours, 115,000 led to 32-55% survival and 1110,000 led to 50-
67% survival These results are shown in Table 5-12, Table 5-13, Figure 5-8 and Figure 5-9. 
Error bars are not shown due to the low numbers of viability assays perfonned. 
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Table 5-12: Viability ofPBECs (cell culture B) stimulated with gastric juice 
Viability at 24 Viability at 24 Viability at 24 
hours (sample 1) hours (sample 2) hours (sample 3) 
Control 96% 98% 95% 
111,000 18% 25% 20% 
1/5,000 43% 49% 55% 
1110,000 56% 62% 66% 
Figure 5-8: Viability ofPBECs (cell culture B) stimulated with gastric juice 
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Table 5-13: Viabilityof PBECs (cell line C) stimulated with gastric juice 
Viability at 24 Viability at 24 Viability at 24 
hours (sample 1) hours (sample 2) hours (sample 3) 
Contro l 100% 100% 100% 
1/1 ,000 24% 28% 22% 
115 ,000 33% 51% 35% 
1/1 0,000 66% 63% 50% 
Figure 5-9: Viability ofPBECs (cell culture C) stimulated with gastric juice 
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5.4.1. Comparison of Titer Blue and Trypan Blue viability assays 
Viability for one plate was calculated with both TiterBlue (repeated culture n=l. with 
repeated wells n=2, overall n=2) and Trypan blue (repeated culture n= 1, with repeated wells 
n=l, overall n=l) techniques to assess for any differences in the results (Table 5-14,Figure 
5-10). There was no significant difference on Bland-Altman analysis for the two different 
methods of assessment. 
Table 5-14: Viability of PBECs (cell culture B) stimulated with gastric juice assessed by Trypan Blue and 
TiterBlue assays 
Viability Viability Viability Viability Viability Viability 
at 24 at 24 at 24 at 24 at 24 at 24 
hours hours hours hours hours hours 
(sample (sample (sample (sample (sample (sample 
1) Trypan 1) 2) Trypan 2) 3) Trypan 3) 
Blue TiterBlue Blue TiterBlue Blue TiterBlue 
Control 96% 100% 95% 100% 98% 100% 
111,000 18% 24% 18% 28% 16% 20% 
115,000 46% 38% 49% 36% 42% 36% 
1110,000 62% 63% 63% 50% 57% 67% 
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Figure 5-10: Viability ofPBECs (cell culture B) stimulated with gastric juice assessed by Trypan Blue and 
TiterBlue assays 
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Interleukin-8 
Stimulation of PBECs with diluted gastric juice (1/1 ,000 to 1110,000) over a 24 hour period 
had a variab le effect on IL-8 production (repeated culture n= 1, with repeated wells n=7, 
overall n=7 from each experiment). 
In cell culture A, stimulation w ith sample 3 of the gastric juice led to an increase in IL-8 
production, whereas samples 1,2 did not have a major effect. Levels are shown in Table 5-15 
and Figure 5-11. 
Table 5-15: Interleukin 8 production from PBECs (cell culture A) challenged with gastric juice 
IL-8 (pg/ml) at 24 IL-8 (pg/ml) at 24 IL-8 (pg/ml) at 24 
hours (sample 1) hours (sample 2) hours (sample 3) 
Contro l 719 863 791 
111 ,000 570 1128 3451 
115,000 599 723 3377 
1110,000 1214 709 3941 
Figure 5-11: Interleukin 8 concentration (on successive days) from PBECs (cell culture A) challenged 
with diluted gastric juice 
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In cell culture B samples one and two led to an increase of 1L-8, sample three led to a 
decrease in IL-8 (Table 5-16, 
Figure 5-12) (repeated culture n=l , with repeated well s n=7, overall n=7 from each 
experiment). 
Table 5-16: lnterleukin 8 concentration (on successive days) from PBECs (cell culture B) challenged with 
gastric JUIce 
IL-8 (pg/ml) at 24 1L-8 (pg/ml) at 24 1L-8 (pg/ml) at 24 
hours (sample 1) hours (sample 2) hours (sample 3) 
Control 1839 1598 1719 
111,000 2697 2314 404 
115 ,000 2558 2905 699 
1110,000 5070 3851 1380 
Figure 5-12: lnterleukin 8 concentration (on successive days) from PBECs (cell culture B) challenged with 
diluted gastric juice 
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In cell culture C, stimulation with gastric juice led to a decreased IL-8 production (Table 
5-17, 
Figure 5-13) (repeated culture n= I , with repeated well s n=7, overall n=7 from each 
experiment) . This was not statistically significant. 
Table 5-17: Interleukin 8 concentration (on successive days) from PBECs (cell culture C) cballenged with 
t· . . gas flC JUIce 
1L-8 (pg/ml) at 24 1L-8 (pg/ml) at 24 1L-8 (pg/ml) at 24 
hours (sample 1) hours (sample 2) hours (sample 3) 
Control 1039 1039 1039 
111,000 1221 1120 11 39 
115,000 1189 923 81 8 
1110,000 844 923 828 
Figure 5-13 Interleukin 8 concentration (on successive days) from PBECs (cell culture C) challenged with 
diluted gastric juice 
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5.5. Discussion 
The main findings of this chapter are:- bacterial contamination is present in gastric juice: 
exposure of the HT29-MTX cell line to pepsin led to a decrease of mucin production, but did 
not result in JL-8 release or reduced cell viability: exposure of primary bronchial epithelial 
cells to diluted gastric juice led to cell death. 
The experiments reported have shown gastric JUIce to be heavily contaminated with 
organisms. The number of contaminated samples was greater than expected. This may be 
important for lung transplant recipients as gastric juice may act as a reservoir for allograft 
infection. Subsequent aspiration of gastric juice could directly introduce infection into the 
lung allograft. The reduction in mucus in response to stimulation of goblet cells with pepsin 
suggests that aspiration may degrade the protective mucus barrier lining respiratory 
epithelium. The significant cell death encountered after stimulation of primary bronchial 
epithelial cells by diluted gastric juice suggests microaspiration may be an important injury to 
lung allografts. 
An important function of gastric JUIce IS to inactivate and destroy micro-organisms 
(Martinsen, Bergh et al. 2005). The low pH and digestive enzymes of gastric juice provide a 
poor environment for bacterial growth and are often bactericidal (Gotley, Morgan et al. 1990; 
Verdu, Viani et al. 1994; Martinsen, Bergh et al. 2005). Some bacteria have developed an 
acid tolerance response and can survive in acidic environments (Martinsen, Bergh et al. 
2005). Gastric juice is normally strongly acidic with a pH of 1-3 due to hydrochloric acid 
secretion (Verdu, Viani et al. 1994). PPJ therapy increases intra-gastric pH and may 
predispose the gastric juice to bacterial colonisation (Verdu, Viani et al. 1994: Martinsen. 
Bergh et al. 2005). A pH of 4-7 has no bactericidal effect (Martinsen, Bergh et al. 2005: Zhu. 
Hart et al. 2006). One study showed PPJ therapy led to increased gastric pH and bacterial 
overgrowth. Mean bacterial counts increased from 0.47 to 5.13 xl06 cfulmL whilst mean pH 
increased from 2.51 to 5.79 (Goddard and Spiller 1996). Previous studies have suggested a 
link between PPJ therapy and pneumonia in critical care patients (Tryba and Cook 1995) and 
in patients in the community (Herzig, Howell et al. 2009). Acid inhibition alters the gastric 
flora and if this is aspirated, it may then lead to pneumonia (Vakil 2009). The current stud) 
showed bacteria, including Pseudomonas aeruginosa, in gastric juice of both lung transplant 
recipients and non-transplant patients. Of interest, this was a biofilm forming species capable 
of allograft colonisation and refractory to conventional antibiotics (Robertson. Griffin et al. 
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2009). These bacteria are likely to have entered the gastric environment via the oropharynx 
from swallowed sputum or saliva. The oropharyngeal flora may have been altered by 
immunosuppressive therapy. The importance of this intra-gastric bacterial colonisation is that 
gastric juice may act as a reservoir of infection and if reflux/aspiration occurs pathogens ma~ 
be introduced and re-introduced into allografts (Botha, Archer et al. 2008: Vos R, 
Vanaudenaerde BM et al. 2008). This risk is not altered by the original source of these 
bacteria. 
The concentration of pepsin in gastric juice has been reported as 100-600Jlglml (Wallace 
1989; Gotley, Morgan et al. 1991; Balan, Jones et al. 1996). The present study's intragastric 
results are comparable with published levels. PPJ treatment significantly lowered active 
pepsin concentrations, showing pepsin to be more active at a lower pH. The intragastric bile 
salt levels detected in lung transplant recipients were similar to normal controls. Levels of 
bile salts in BALF have been reported from 0-32Jlmol/l (D'Ovidio, Mura et al. 2005: 
Blondeau, Mertens et al. 2009). It is hard to equate the BALF levels reported with the 
described gastric levels, knowing the subsequent dilutions. Aspirates will be diluted by 
oesophageal, oropharyngeal and bronchial secretions. There will be a further dilution of 100-
200 times through the BAL lavage fluid volume. High levels of bile salts(>300Jlmolll) will be 
detected, levels lower than this will be undetectable. Only 17% (11/65) had bile salt levels 
>300Jlmolll. Trypsin is a protease secreted by the pancreas into the duodenum. In one study. 
trypsin was found in 17 of 365 gastric juice aspirates (Gotley, Morgan et al. 1991). The 
present activity assay shows trypsin was present in gastric juice aspirates but at levels a 
hundred fold less than pepsin. Thus it will be a less useful biomarker of aspiration. 
Alterations in mucus homeostasis may be problematic in lung transplant recipients (Veale. 
Glasper et al. 1993). Little has been published on down-regulation of mucus production 
which could lead to drying of the epithelial surface. Aspiration may down-regulate mucus 
production and homeostasis leading to epithelial injury, damage and increased infection. This 
study has shown mucus secretion by a goblet cell line to be down-regulated by pepsin. 
Stimulation of goblet cells with porcine pepsin did not lead to an increase in IL-8 production 
nor affect cell viability. There was a down-regulation of MUC5AC production and this may 
reduce the protective effects of MUC5AC on the respiratory epithelia. This may lead to cell 
injury and facilitate infection and colonisation. The reduction of MUC5AC may be a result of 
reduced production or as a result of MUC5AC degradation by pepsin. Ho\\ever. experiments 
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were performed at pH7.4 and pepsin has no activity at this pH. Further experimental work 
should be undertaken to reveal the mechanisms of these results. 
It has been shown that exposure of a porcine transplant lung to gastric juice increases indirect 
alloimmunity (Meltzer, Weiss et al. 2008), Cell death, induced by aspiration, leads to 
inflammation, scarring and fibrosis and the release of MHC peptides which could activate the 
indirect immune system. The current experiments show that exposure of epithelial cells to 
dilute gastric juice leads to cell death. This may explain the link between aspiration and the 
indirect alloimmune response (Meltzer, Weiss et al. 2008). Interleukin 8 is a marker of injury 
and is produced by many cells in response to injury. The biological mechanisms of BOS may 
involve elevated IL-8 (D'Ovidio, Mura et al. 2005). Stimulation of PBECs with pepsin did 
not affect IL-8 production significantly and did not lead to cell death. No measurable 
MUC5AC was produced by the PBEC in a control situation or after stimulation with pepsin. 
This is to be expected as MUC5AC is predominantly produced by differentiated goblet cells. 
It suggests, that in this submerged culture, the cells are undifferentiated and that there were 
few if any differentiated goblet cells present in these cultures. 
Chapter 3 has shown an association between proximal reflux, aspiration and BALF IL-8 
levels. If allograft epithelial cells are releasing IL-8 then other stimuli in gastric juice other 
than pepsin are responsible. 
The exposure of epithelial cells to diluted gastric juice resulted in cell death. IL-8 production 
was variable which may be partly due to the cell death. Several samples had elevated IL-8 
suggesting injury. Although there was a varied response in IL-8 production it must be noted 
that samples underwent significant cell death, most notably at the 111,000 concentration (up 
to 84%). If this is corrected for, i.e. allowing for the decrease in cell population, then there is 
a general increase in IL-8 production, up to seventeen times control levels. This suggests that 
although these samples have fewer cells, they have increased IL-8 production. However. this 
deduction must be interpreted with caution as it is unknown whether dying cells increase IL-8 
production and whether or not the process of cell death releases stores of IL-8 from inside 
cells. Of interest in cell culture A, the gastric juice which triggered the greatest IL-8 
production was the sample which tested negative for microbiology (Sample 3). 
Cell death was much greater at a 1 II ,000 dilution (80%) when compared to a III 0,000 
dilution. This suggests that even after significant dilution, aspiration still has the potential to 
be injurious. 
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Model of injury 
This study hypothesises a model of injury (Fig 5.14). Aspiration induces damage through a 
variety of causes of injury:- acid , pepsin, bile and trypsin . Aspiration introduces pathogens 
into the lung leading to infection and coloni sation. The first protecti ve layer in the epithelium 
is the mucus layer. Respiratory epithelial mucus secretion may be down-regulated by pepsin, 
exposing the epithe lium to inj ury and direct cellular damage. Thi s leads to inflammation 
induced damage, cell death and cytokine release from epithelial cell s. IL-8 release triggers 
several responses including mucus production and neutrophilia. The latter leads to damage 
through reactive oxidative species cytokines and matrix metalloproteinases p roduction. Thi s 
results in epithelial to mesenchymal transition which converts epithelial ce ll s to fi broblasts 
and subsequently may lead to obliterative bronchiolitis . The cell death leads to inflammation 
and the MHC I molecules shed into circulation could trigger an indirect immune response 
(Meltzer, Weiss et al. 2008). 
Figure 5-14: Hypothesised model of aspiration induced damage in lung allograft 
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The main weakness of this study was the relatively small numbers involved. Gastric juice 
samples were time consuming to collect and analyse. Cells were time consuming to grow. 
Our samples of gastric juice were collected after fasting. Night-time and post-prandial levels 
remain unknown. The sample population was heterogeneous with significant variance in 
demographics, pathology and individual PPJ use. These variables may affect the results of 
this study and reduce the applicability to individual populations. Using the endoscope raises 
the possibility of contamination of gastric juice samples. Current methods for sterilisation of 
endoscopes have been shown to kill all bacteria (Cronmiller, Nelson et al. 1999; Allison, 
Bradley CR et al. 2008). The risks of contamination were minimal but oropharyngeal 
contamination remains a possibility. 
To analyse pepsin, we used an activity assay. If the pepsin has been exposed to a pH >7 then 
it will be irreversibly denatured and will not be detected by this assay. These samples require 
further analysis using an ELISA. 
The goblet cell line (HT29-MTX) was derived from a colorectal cancer cell line and thus may 
be an inaccurate model. It was used as respiratory goblet cells are difficult to isolate and 
culture. This cell line has some similar properties to respiratory goblet cells and expresses 
MUC5AC and MUC5B. Thus, it is an acceptable model. Due to cell line death and problems 
with cell culture, we did not stimulate the goblet cell line with gastric juice. The effects of 
stimulating this cell line with gastric juice and pepsin cannot be compared. 
The PBECS used were undifferentiated. Differentiated cell cultures are more resilient to 
injuries (Parker, Sarlang et al. 2010) but are more difficult to culture. Results from in vitro 
experiments cannot always be extrapolated to an in vivo environment. 
Cell death was assessed by Trypan blue which relies on cell counts and could be open to 
human error. An experiment comparing this with the assay based TiterBlue modeL revealed 
that there was no significant difference between the two methods and a simple human 
observation method did not consistently over or under read cell viability. This simple, quick 
test could be used as an indicator of cell death to direct future experiments. 
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6. Effects of anti-reflux surgery on reflux 
symptoms and quality of life in lung transplant 
recipients 
1-+1 
6.1. Abstract 
Introduction 
Gastro-oesophageal reflux disease (GORD) has been suggested to be a risk factor for BOS 
post-lung transplant. Anti-reflux surgery has been perfonned in some patients and may be 
associated with improved lung function and survival. Little has been published on the effects 
of this on symptoms and quality of life of laparoscopic fundoplication in adult lung transplant 
recipients. 
Aim 
The aim of this study was to evaluate the effects of anti-reflux surgery on reflux symptoms 
and quality of life in lung transplant recipients. 
Methods 
Between 1 st June 2006 and 1st October 2009, all lung transplant recipients undergoing anti-
reflux surgery were studied. Patients were operated on for symptomatic GORD or for GORD 
with decreased lung function. Quality of life was assessed before and after surgery using 
Gastrointestinal Quality of Life Index (GIQLI), DeMeester and Reflux Symptom Index (RSl) 
questionnaires. Body Mass Index and pulmonary function were followed up from transplant 
to the current date. 
Results 
Nine patients (3 male/6 female) with a median age of 41 years (range 24-57years) were 
operated on during this period. Laparoscopic Nissen fundoplication was the procedure of 
choice. There was no peri-operative mortality and no major complications occurred. Median 
hospital stay was 2 days (range 2-4 days). 7/8 patients were satisfied with the results of 
surgery 6 weeks post-operatively and 4/5 at six months. There was an improvement in 
median RSI, DeMeester and GIQLI scores at six weeks and this was maintained at six 
months. Median BMI decreased from 22.5 (range 18.5-29) pre-fundoplication to 21.1 (Range 
17.6-29.4) at six months post-fundoplication (p=0.0012). Median FEV j was 2.35L pre-
operatively and 2.68L at latest follow up (median 174 days post-fundoplication (range 68-
1082days)). 
Conclusion 
Fundoplication was associated with an improvement in reflux symptoms and overall quality 
of life in this population. 
J-e 
6.2. Introduction 
The earlier chapters of this thesis have focused on the deleterious effects and high prevalence 
of GORD post lung transplant (D'Ovidio and Keshavjee 2006; Robertson. Griffin et al. 
2009). Anti-reflux surgery may be associated in this population with an increased survival 
and improved lung function (Davis, Lau et al. 2003; Cantu, Appel et al. 2004). 
In routine patient populations fundoplication has been shown to improve symptoms and 
quality of life. Little evidence exists to support a benefit of this therapy on symptoms and 
quality of life in lung transplant recipients. For this study three validated questionnaires were 
used- (DeMeester, GIQLI and RSI questionnaires). 
The DeMeester reflux regurgitation questionnaire IS a validated straightforward tool 
(DeMeester, Wang CI et al. 1980). It is based on a score of 0-3 for symptoms of reflux, 
regurgitation and dysphagia. The higher the score, the worse the symptoms are. 
The RSI (Figure 2.1) is a 9 item questionnaire which assesses both oesophageal and extra-
oesophageal reflux symptoms. It is easily administered and highly reproducible. The higher 
the score, the worse the symptoms are. A RSI score of greater than 13. is abnormal (Belafsky, 
Postma et al. 2002). 
The GiQLI was chosen as it is a straightforward quality of life questionnaire which addresses 
both global symptoms of well-being and also gastrointestinal focused questions (Kirk 1986; 
Eypasch, Williams et al. 1995). It allows us to look at the effects of fundoplication on quality 
of life without too much focus on the transplant process. The questionnaire is made up of 36 
questions, 17 physical (8 related to upper gastrointestinal symptoms) and 19 social. Each 
question is scored from 0-4. The higher the GIQLI score the greater the quality of life. 
There have been reports of weight loss after anti-reflux surgery in both non-transplant 
(Neumayer, Ciovica et al. 2005) and the transplant community (Burton, Button et al. 2009). 
This study also assessed Body Mass Index (BMI) pre and post-operatively. 
The aim of this study was to evaluate the effects of anti-reflux surgery on reflux symptoms 
and quality of life in lung transplant recipients. 
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6.3. Methods 
Between 1st June 2006 and 1 st December 2009, all lung transplant recipients undergoing anti-
reflux surgery at the Northern Oesophago-Gastric Unit were studied. Surgery was considered 
for patients with symptomatic reflux alone, refractory to PPI therapy. or for reflux associated 
with deteriorating lung function. All lung transplant recipients, in our unit, are routinely 
prescribed prophylactic PPI therapy to prevent steroid induced ulceration. 
Reflux status was assessed by oesophageal manometry, pH-impedance (Ohmega, MMS 
System, Utrecht, The Netherlands) and endoscopy. Patients underwent a thorough pre-
operative assessment to ensure fitness for surgery. Patients were followed up clinically with 
emphasis on lung function, satisfaction and quality of life and BM!. Patient satisfaction was 
assessed by directly questioning of patients. Lung function was assessed in accordance with 
American Thoracic Society/European Respiratory Society guidelines. The RSL DeMeester 
reflux questionnaire and GIQLI questionnaires were completed pre-operatively. 6 weeks and 
6 months post-operatively. Patients were asked about satisfaction at 6 weeks and 6 months 
post-operatively. 
Statistical analysis was carried out usmg non-parametric paired t-tests (Wilcoxon) with 
Graphpad Prism software (San Diego, CA, USA). 
Laparoscopic Nissen fundoplication was performed. Access to the abdominal cavity was via 
4 ports and an epigastric stab incision for the Nathanson retractor to retract the liver. Initially 
the oesophageal hiatus was dissected to mobilise the oesophagus. The posterior vagus was 
preserved and a window was created behind the oesophago-gastric junction. The posterior 
crura were repaired to tighten the hiatus, and a loose 3600 wrap was tailored with 3 sutures. 
One further suture was used to anchor the wrap to the oesophagus and right crus. 
Percutaneous endoscopic gastrostomy (PEG) fistulae were repaired when present. They were 
divided with an Endostapler. The PEG wound was then excised and the deficit in the 
abdominal wall and skin were closed. Local anaesthesia was inserted into the peritoneal 
cavity and infiltrated in the wounds. 
6.4. Results 
6. -1.1. Demographics 
Nine patients (6 women, 3 men) with a median age of 41 years (range 24-57years) underwent 
fundoplication. Indications for lung transplant were cystic fibrosis 5. COPD/asthma 1. 
pulmonary fibrosis 2, Pulmonary fibrosis/asthma 1. Eight underwent single sequential lung 
transplant, 1 had a right single lung transplant (Table 6-1). Indications for fundoplication 
were heartburn (n=5) or heartburn and extra-oesophageal symptoms (n=4). Symptoms 
occurred despite PPI therapy. PPI used included lansoprazole 30mg od (n=1). 30mg bd (n=4) 
(one of these patients also took ranitidine 150mg nocte), rabeprazole 20mg od (n=2) and 
esomeprazole 40mg bd (n= 1). Median pre-operative BMI was 22.7 (range 18.5-29). 
Table 6-1: Patient demographics 
Age 
-Median 41 years 
-Range 24-57 years 
Sex 
-Male 3 
-Female 6 
Underlying pathology 
-Cystic fibrosis 5 
-COPD/asthma 1 
-Pulmonary fibrosis 2 
-Pulmonary fibrosis/asthma 1 
Transplant 
-SSLT 8 
-RSLT 1 
-LSLT 0 
-HLT 0 
1-l5 
Oesophageal physiology 
All patients underwent oesophageal physiology measurements. All (9/9) underwent 
oesophageal manometry (n=9), one of 9 had pH monitoring (n= 1) whilst 8/9 had combined 
pH-impedance (n=8). Results of these tests are shown in Table 6-2. One patient v.ho 
underwent surgery had a nonnal DeMeester score and acid exposure on PPI therapy. The 
decision was made to operate as they had symptomatic reflux, oesophagitis and abnormal 
volume exposure on impedance measurements. 
T bl 62 R It f ti d r a e - : esu S 0 j!l'e- un oplIcatlOn lUvestigatlOns 
Oesophageal physiology Median Range 
Lower oesophageal sphincter 
pressure 13 9.3-26 
length 2.5 1.5-3.5 
Mean distal peristaltic amplitude 47.9 75.4-165.9 
Peristalsis 
normal 7 nla 
abnonnal 2 (NSD, SOC)* nla 
Reflux indices 
Acid exposure 17.2 1.6-33.1 
DeMeester score 61.1 7.5-115.2 
Oesophageal volume exposure 1.58 0.5-3.84 
Total reflux events 68 21-125 
Proximal reflux events 19 3-78 
FEV 1 (% predicted) 87.8 33.4-139.5 
*NSD= Nonspecific dysmotility, SOC= SImultaneous oesophageal contractIOns 
6.-1.2. Morbidity and mortality 
There were no deaths or serious post-operative complications. One patient developed minor 
post-operative dysphagia which increased their post-operative stay by 2 days. Barium 
swallow revealed no significant hold-up and symptoms subsequently settled. 
146 
6.-1.3. Overall satisfaction 
Overall 8/9 patients were satisfied at 6 weeks and 7/8 patients were satisfied at 6 months. At 
six weeks one patient was unsatisfied due to dysphagia. At six months one patient was 
unsatisfied due to pain at the site of her PEG fistula and abdominal bloating. 
6. -1. -1. Quality o(li(e 
Overall there was a statistically significant improvement in symptoms and quality of life 
scores over the first six months post-fundoplication (Table 6-3). 
Table 6-3: Median (and range) quality of life questionnaire scores ~re & f d post- un ophcatlOn 
Pre-operative Six weeks Six months 
GIQLI 106 (65-132) 118 (63-133) 128 (75-142) 
DeMeester 4 (1-6) 1 (0-4) 1 (0-2) 
RSI 15 (8-23) 3.5 (2-18) 2 (0-18) 
I-P 
6.4.5. Reflux symptom index questionnaire 
Pre-fundoplication R SI was positive on 6/8 patients and thi s decreased to 1/8 being pos it ive 
for RSI by six weeks and 117 being pos itive at six months . The median RSI impro ed from 
15 (range 8-23) pre-operat ively (n=8) to 3.5 (range 2-18) at six weeks post-fundopl ication 
(n=8) (p=0.008) and 2 (range 0-1 8) at six months (n=7) (p=0.0 16) (Figure 6-1 ). There was no 
statistica l di ffe rence between RSI scores at six months and six weeks (P=0.44). The 
improvement in RSI score was th rough an amelioration of both heartburn and extra -
oesophageal symptoms. 
Figure 6-1: Graph ofRSI score ove r the first six months post fundoplication 
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6.4.6. DeMeester reflux questionnaire 
There was an improvement in median DeMeester reflux questionnaire score from 4 (range 1-
6) pre-operatively (n=9) to 1 (range 0-4) at six weeks (n=9) and 1 (range 0-2) by six months 
(n=8) ( 
Figure 6-2). There was a statistical significance between pre-operative scores and six weeks 
(p=0.039) and pre-operative scores and six months (p=0.023). There was no significant 
difference between scores at six weeks and six months. (p=0.63). 
Figure 6-2: Graph of DeMeester reflux questionnaire score over the first six months post fundoplication 
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6. 4.7. Gastrointestinal quality ofli fe index 
There was a statistically significant improvement in median GIQLI score fro m 106 (range 65 -
132) pre-operatively (n=9) to 118 (range 63-13 3) at six weeks (n=9) . This was 128 (range 
109-134) by six months (n=8) (Figure 6-3). There was a sign ificant difference between 
GIQLI scores pre-operatively and at six weeks (p=0.001 ) and six months (p=0.023). There 
was also a statistically significant improvement from six weeks to six months (p=0 .003) . The 
improvements were in both physical and social categories. Seven points of the overal l med ian 
improvement of 22 points were in social functioning, but the predominant improvement was 
via amelioration of physical symptoms. 
Figure 6-3: Graph of GIQLI score over the first six months post fundoplication 
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6.4. 8. Body mass index 
Median BMI decreased from 22.7 (range 18.5-29) pre-fundoplication to 2 l.] (Range] 7.6-
29.4) at six months post-fundop lication (p=O.OOl ) (F igure 6-4) . Four patients kept a steady 
weight and five patients had a decrease in weight post-fundoplication. 
Figure 6-4: Graph of BMI sco re over the first six months post fundoplication 
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6.4. 9. Lung (unction 
Patients were followed up for a median of 174 days post-fundoplication (range 68 -1 082da s). 
Median FEY 1 was similar pre-fundoplication 2.3 5L (range 1.03-5.12L) and post-
fundop lication 2.68L (O.79-5.03L) (Figure 6-5). This was not statistically significant 
(p=O .38). Pre-fundoplication, five patients had no evidence of BOS, whil st the remaining four 
patients had BOSp (n=l) , BOSI (n=l ), BOS 2 (n=l ) and BOS 3 (n=l) . One patient had a 
worsening BOS score from BOS 2 to 3 during follow up . The patient with BOSp had a 
reversal of this to BOS O. All other patients remained stable. 
Figure 6-5: Graph of PFTs pre and post fundoplication 
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6.5. Discussion 
The main findings of this study was that in lung transplant recipients, anti-reflux surgery 
improves both reflux and extra-oesophageal reflux symptoms; there was an improvement in 
quality of life after surgery; in the first six months post-fundoplication BMI decreased. 
Anti-reflux surgery improves both reflux and extra-oesophageal reflux symptoms. The 
subsequent improvement in quality of life was derived predominantly from an improvement 
in physical symptoms but also an improvement in social functioning. This suggests that 
fundoplication is of benefit to lung transplant recipients. The improvements in extra-
oesophageal reflux symptoms suggest that these patients suffer from laryngopharyngeal 
reflux. The decreased BMI within the first six months post-fundoplication is of unknown 
significance. 
The Duke University Transplant Group have published several papers(Lau, Palmer et al. 
2002; Davis, Lau et al. 2003; Cantu, Appel et al. 2004; O'Halloran, Reynolds et al. 2004; 
Balsara, Cantu et al. 2008), with results suggesting that anti-reflux surgery may lead to 
increased survival and improved lung function post-transplantation (Cantu, Appel et al. 
2004). The limitations and flaws of their studies are described previously. No conclusions can 
be drawn on the effects on lung function from this study. 
Anti-reflux surgery in the lung transplant population has been shown to be safe (O'Halloran, 
Reynolds et al. 2004). Only one post-fundoplication death has been reported.(Burton, Button 
et al. 2009). This study reports no mortality or major morbidity to date. Post-operative stay 
was longer than for non-transplant patients. This may be partially due to the fact that 
transplant patients travel greater distances for surgery and can remain in hospital due to 
logistical reasons. 
Fundoplication is associated with symptomatic improvement in the non-transplant population 
(Korolija, Sauerland et al. 2004; Yano, Sherif et al. 2009). It is recommended that 
questionnaires are completed between 1-3 months and then at one year post-operatively 
(Korolija, Sauerland et al. 2004). The present study assessed patients at six weeks and six 
months to obtain quality of life data at both short and medium term follow up. Only one study 
has previously assessed the effects of fundoplication on reflux symptoms in lung transplant 
recipients (Burton, Button et al. 2009). This paper did not use validated questionnaires and 
the results are therefore of limited value. The current study has demonstrated an improvement 
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In reflux and extra-oesophageal reflux symptoms usmg validated questionnaires, the 
DeMeester reflux questionnaire and the RSI. 
Fundoplication has been shown to improve quality of life in the non-transplant population 
(Korolija, Sauerland et al. 2004; Yano, Sherif et al. 2009). In one previous transplant study_ 
three quarters of patients had an improvement in quality of life scores. 88% rated the results 
of their surgery as excellent or good(Burton, Button et al. 2009). However. this used non-
validated methods of assessment. The current study has shown that patients are generally 
satisfied with their procedure and there is an improvement in quality of life. The GIQLI 
questionnaire was used as it is validated and recommended for the assessment of anti-reflux 
surgery by the European Association for Endoscopic Surgery (Korolija, Sauerland et al. 
2004). 
It is well known that BMI decreased post-fundoplication, due to early satiety. This normally 
stabilises within the first six months. One previous study has shown this in the lung transplant 
population. The present study concurs with these results and shows a decrease in median 
BMI from 22.5kg/m2 to 21.1kg/m2 in the first six months post-fundoplication. The clinical 
significance of this is unknown, as the current study does not demonstrate whether this 
weight stabilises or undergoes further deterioration by one year. This requires further follow 
up. 
This study has several limitations. Firstly, the numbers involved are small. The patients had a 
variety of indications for surgery, making the patient sample diverse. Secondly, 
fundoplication was performed at different times after transplant and no patients were operated 
on within 90 days, the suggested optimum time for therapy. No control group was present to 
compare symptoms or lung function and the study wasn't randomised. The overall follow up 
is limited and thus reduces the conclusions that can be drawn from this study. 
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7. Summary 
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7.1. Summary 
Background 
-Chronic microaspiration, secondary to extra-oesophageal reflux, may contribute to 
bronchiolitis obliterans syndrome post-lung transplant. 
-Up to 75% of lung transplant patients have demonstrable gastro-oesophageal reflux disease 
on pH monitoring. 
-Elevated biomarkers, pepsin and bile salts, have been documented in the broncho-alveolar 
lavage fluid post-transplant, suggesting microaspiration. Elevated pepsin is associated with 
acute rejection, and elevated bile salts have been linked to BOS. 
-Early anti-reflux surgery may lead to increased survival and improved lung function, 
through preventing microaspiration and allograft injury. 
-Little has been published on this topic and the current data is limited and flawed. 
Results 
Chapter 3 
-GORD occurs frequently within the immediate post-lung transplant period. 
-This is associated with elevated pepsin in the BALF, signifying aspiration. 
-A correlation exists between proximal reflux and neutrophilia suggesting that increased 
proximal reflux leads to aspiration. This leads to allograft inflammation and damage. 
-Bile salts are a less prevalent biomarker of aspiration. 
Chapter .f 
Despite decreasing immunosuppression and improvement in lung function, the prevalence of 
GORD increases over the first six months post-lung transplant. 
-Microaspiration improves as suggested by a decrease in BALF pepsin levels. 
-A potential explanation of this finding is that over this time point pulmonary defence 
mechanisms recover. This may occur through vagal re-innervation of the allograft, improved 
cough reflex and muco-ciliary clearance. These factors may reduce the amount of aspiration 
the allografts encounter. 
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Chapter 5 
-Gastric juice may be colonised by pathogenic organisms. 
-This may be due to the raised pH created by PPJ therapy. 
-This may be important for lung transplant recipients, as gastric juice may act as a reservoir 
for bacteria. Subsequent aspiration of gastric juice could directly introduce infection into the 
I ung all 0 graft. 
-MUC5AC levels were reduced in response to stimulation of goblet cells with pepsin. This 
suggests that aspiration may degrade the protective mucus barrier lining respiratory 
epithelium. 
-Cell death was encountered after stimulation of primary bronchial epithelial cells to diluted 
gastric juice. This suggests microaspiration may be an important cause of injury to lung 
allografts. This cell death could release MHC peptides from allograft epithelial cells which 
could activate the indirect immune system. This may explain the link between aspiration and 
the indirect alloimmune response. 
Chapter 6 
-Anti-reflux surgery is safe in selected lung transplant recipients. 
-Anti-reflux surgery improves both reflux and extra-oesophageal reflux symptoms in lung 
transplant recipients. 
-The subsequent improvement In quality of life was derived predominantly from an 
improvement in physical symptoms but also an improvement in social functioning. 
-BMI decreases over the first six months post-fundoplication. This is of unknown clinical 
significance. 
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7.2. Future Work 
More work is required to increase our understanding of microaspiration in these patients at a 
clinical and cellular level. 
Clinical 
-A larger study of reflux and aspiration should be performed with long-term follow up, to 
establish whether early GORD and aspiration is associated with BOS. 
- A larger study of changes in GORD and aspiration over the first six months should be 
undertaken to assess whether the paradox of improving aspiration, despite worsening GORD 
is maintained. 
-BALF pepsin levels should be collected and analysed at 1 year to establish whether 
aspiration further improves or is maintained at this time point. 
Laboratory 
-More gastric juice samples should be collected from homogeneous populations of patients. 
-Gastric juice samples should be collected at differing times from the same patients to assess 
variability. Samples should be collected from patients both on and offPPI therapy to assess 
the effects of PPI on colonisation. 
-In lung transplant recipients gastric juice microbiology should be compared with BALF 
microbiology to assess whether the same bacteria are present in both samples. 
-Goblet cells should be stimulated with diluted gastric juice and also other individual agents 
which could be injurious (e.g. bile salts and trypsin) to assess the individual effects of these. 
-Experiments should be repeated using a differentiated epithelial cell culture. 
-Epithelial cells should be stimulated with individual components of gastric juice which could 
be injurious (e.g. bile salts and trypsin), to assess which component causes cell death and 
elevated IL-8. 
Surgery 
-Many unanswered questions remain about the role of laparoscopic fundoplication in lung 
transplant recipients. Does surgery improve lung function and survival? When is the optimal 
time for intervention? What are the optimum selection criteria for surgery? 
-Individual units researching this topic should collaborate and undertake a large multi-centred 
randomised controlled trial of laparoscopic fundoplication in lung transplant recipients to 
answer the above questions. 
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measurement and markers of aspiration in the detection of extra-oesophageal 
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2008: £35 ,000 : Fellowship from the European Society fo r Organ Transplantation-
Clinical Research Grant for: 
The role of oesophageal impedance measurement and markers of aspiration in 
the detection of extra-oesophageal reflux disease and in the development of 
allograft dysfunction in human lung transplant recipients. Written and submitted 
by myself. Awarded to myself directly_ 
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Correspondence ESOT 
Dr. AG.N. Robertson 
Dept. of Cardiopulmonary Transplantation. Cardiothoracic Centre. Freeman Hospital. '\e\\ castl upon 
Tyne, E77RN, nited Kingdom 
andrewgnrobertson@ doctors.net.uk 
Groningen. :vla~ :20 lh . 2008 
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JCRG 08 .006 
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During the last ESOT Council Meeting all app licants fo r the ESOT Junio r Clinical Re earch Grant 
were presented and di scussed . We are delighted to inform you that you have been a\\'arded the E OT 
Junior C linical Research Grant. The grant consists of a tota l anlou nt of 
€ 35 .000 . 
It is very important, that you will inform the ESOT Treasurer Prof Dr. H.J. Schl itt. Department of 
Surgery of the Uni versity of Regensburg, Germany, phone + 4994 1 944680 I. about the bank 
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A report about your research project in relation to the ESOT Junior C linica l Research Grant is required 
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grants in the future . In case of a published arti cle, the E OT Junior Clin ica l Research Grant should be 
mentioned in the acknowledgements. All grant recipient will be mentioned du ring the nex t E OT 
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On behalf of the ESOT Council , 
yours sincerely, 
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Secretary General of ESOT 
Cc Professor H.J . Schlitt. Treasurer ofESOT, 
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Netherlands 
Te lephone *3 1.50.36 14430, Telefax *3 1.50.36 11 745. E-mail j.t.uildriks~chir.umcg.nl. Web it http: \\ \\ \\ .e -ol.org 
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Appendix 3: OESO Award 
2008: OESO 9th World Congress: Research Grant Award. 
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This project has been accepted for and included in the National Institute of Health 
Research UK-Clinical Research Network (NIHR CRN ID:6486) with myself as stud) 
co-ordinator. 
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NIHR eRN '~l:kj 
National Institute for NIHR Clinical Research Network 
Coordinating Centre 
Health Research 
lItnership with 
20th February 2009 
Professor S M Griffin 
Northern Oesophago-Gastric Unit 
Royal Victoria Infirmary 
Newcastle upon Tyne 
NEl4LP 
Dear Professor Griffin 
NIHR Clinical Research '\et\\ork 
Coordinating Centre 
Fairbairn House 
71-7 5 Clarendon Road 
Leeds LS2 9PH 
Tel: 0113 3.+3 231.+ 
Fax: 0113 3.+3 2300 
Email: info a ukcm.org.uk 
\\ "\\\\ .crncc.nihr.ac. uk 
Re The role of oesophageal impedance measurement in detection of gastro-
oesophageal reflux disease in human lung transplant (NIHR eRN ID: 6486) 
Thank you for completing the minimum dataset for the above study. I can confinn 
that the study is eligible for, and has therefore been included on, the National Institute 
for Health Research (NIHR) Clinical Research Portfolio. The record for this study 
can be viewed on the Portfolio Database at 
http://www.ukcrn.org.uklindex/clinical/portfolio new.html. 
Benefit of inclusion in the NIHR Portfolio 
Inclusion in the NIHR Portfolio of studies ensures your study can access NHS 
service support and research infrastructure support in England (i.e. support to 
help with study promotion, approval, identification of eligible patients, recruitment, 
and follow up etc). This support is now flowing through the Comprehensive Clinical 
Research Network to the 25 Comprehensive Local Research Networks (CLRNs) 
across England. Funding allocations to the CLRNs include an activity-based 
component driven by the data which are held on the UKCRN Portfolio Database and 
it is therefore essential that your study record is kept up-to-date. Please contact us as 
soon as possible via email (portfolio@ukcrn.org.uk) if any changes are required. 
Collecting your accrual data 
In order to ensure that your study remains on the NIHR Portfolio and receives 
appropriate support through the relevant Comprehensive Local Research Network(s), 
the UKCRN Coordinating Centre must collect accrual data for the above study from 
April 2008 and then each month on an ongoing basis. 
If you haven't already had the opportunity to send this data to us, \\e would be 
grateful if you could do so as soon as possible. Accrual data should be supplied via 
Directors 
Protl!ssor Peter Sc'lb: 
Protl!ssor Janet Darb) shin: 
~ :::::..,~- -:; •• ~~. ~...;.. -",:y.cz;.j System and we will be contacting you in the near future 
to talk you through this process. Further information and data templates for uploading 
accrual data can be found on the UKCRN website at: 
http://www.ukcrn.org.ukJindex/clinicallportfolio newlP accrual.html. Please contact 
us (accrualrci<ukcm.org.uk) if you have any queries about the process. 
We would also encourage you to provide data on accrual prior to April 2008 in order 
to contribute to the CCRN "baseline" and to provide information on the overall level 
of recruitment into this study. This can be submitted in a simplified format, simpl) 
stating the total number of patients recruited prior to April 2008. 
Additional and new studies 
Please note that some new studies funded by NIHR Partners (as defined in the 
Eligibility Criteria) might need to undergo a further adoption process prior to 
inclusion onto the Portfolio (e.g. if individual studies are part of a programme grant). 
All new "non-automatic" studies (those funded by non-UK governments, e.g. EU. 
NIH, and industry-supported, non-industry sponsored - IITs) will also need to 
undergo a full adoption process. 
UKCRN is keen to ensure that all studies which are eligible for inclusion into the 
NIHR Portfolio are identified so that they can be supported through the 
Comprehensive Clinical Research Network. If you are aware of any other potentially 
eligible studies which are recruiting or actively following up patients from April 
2008, and which have not yet been confirmed as being on the Portfolio, we would be 
very grateful if you would let us know. Further details are available at 
http://www.ukcrn.org.ukJindex/clinicallportfolio new.html. 
Thank you for your support in this exercise which will be critical to the successful 
development of the national Comprehensive Clinical Research Network. Our aim is to 
ensure the provision of high quality infrastructure to support clinical research in the 
NHS and support the delivery of your study. 
Please do not hesitate to contact me if you require any further information. 
Best wishes 
Dr Sam Taylor 
Portfolio Lead 
NIHR Clinical Research Coordinating Centre (NIHR CRN CC) 
Fairbairn House 
7 1-75 Clarendon Road 
Leeds 
LS29PH 
Tel: 0 I 13 343 0403 
Fax: 0 I 13 343 2300 
Email: s.taylor@ukcrn.org.uk 
www.cmcc.nihr.ac.uk 
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'l' Projec t reference number Irom above REC: 07 H0908J70 
Submission date: 04.'102007 
--------------__________ -1 
A 1 Title 01 the research 
he role 01 oesophageal Impedance measurement In detection of gastro-oesophageal rellu, dIsease 
~ uman lung HdnSP1o' 1\ recipients 
'"9 Transplant: fe!'., .. x Impedance 
A2. Chief Investigator 
TiUe: Professor 
SClname Gr;ttln 
Post· PrOfessor of GastrOlnlestlnal Surgery 
Quahhcatlons' MD. FRCS 
Organlsalloo 
Work Address' 
PoSI Gode 
E .. ma,1 
Telephone' 
NCIr1hern Oesophagogastflc UnJI, Royal \"CIOr;a Inf,rmary 
1\1:' 4LP 
Mlchael.Gnffln@nUlh nhs.u' 
,440 191 28202:'4 
.44,0 t91 2820237 
A "'i) 01 a current CV (maxImum 2 p.l)c':' 01 A4J lor the Cellellnvestlgator must be submmf'o With me apphca/Jon 
r-
i A3 
I 
I 
Proposed study dates and duration 
Sla'l 'J" 
E~o oate 
Duration' 
o ~uu' 
2)10 
y,",,,s 3 Months' 0 
5 AS 121·J,l 
Date 0·\ 10/2007 Reference 07'H090870 
\~ Primary pu;po;'" of the r~search, I TIC/( .]s .lporopo3Ie; o Con,cnerCial product de.elopmen! and or licenSing 
o Publicly tunded tnal or SCientifIC Investigation 
~ Educ atlonal qualificatIOn 
o Eslab s~ '9 a dataoase data slorage faCility 
o )1 e' 
A6, Does .his research require site-specif.c assessment ISSA ,? (AdvICe can be founo ,n the gUidance notes on Ih,s IOPIC 
" Yes an appllcalron lor SSA should be made tor each research s,te on the S,te-SpeClf,c Iniormar.an form and submlrted to 
I''', releva or 'a' '.11 Research EthiCS Committee D<; 'IOF apply fa! SSA at sires other /han the lead sire unlll Ihe mam 
app/lc 1/10'1 ~a5 been booked lor re"i'!,' and validaled by Ihe ma'~ Research EthiCS Commnee 
.--= 
,-----,-'''--'-''-'- .- ---------------------------1 
\ '.".J,)I'" H / .liP' ~" J' to proceed ,',,'1' /he research will De reqUifed trom the /,';8D office lor each NHS careorgamsa/IOn In 
I '" 1),eI research oroced"" ,s are undertaken TIlls applies whelher or not the research IS eKempt tram SSA ".,0 appilC.atlOns In 
! t" ',)3"') waleS and Scotlar d should be made uSing 'he S,le-SpecdlC '"forma/IOn Form 
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, A 7 What IS the princIpal research questIon ob/ectlve? '.!.,sr oe In language com.,rehenslble to a lay per5Of1 
1 he aIm of fllIS study IS '0 evaluate srudy how frequently gast,o-oesophagea, reflu. dIsease, GORD, occurs 
after lung transplant and !s role In Ihe aev£"opment of chrome lung dysfunction whlCI, IS progressIve loss of 
lunq fUII,e!lon alter lung Iransplantatlon tAanr pallents after lung transplant suffer from gastro-oesophageai 
reflui disease (GORD) "llch IS when the stomach COrle"l, and acid lrom the stomach 'eak up Into Ihe 
gullet (oesophaguS) Tnls mill cause heanburn ana other symptoms It not fully knowr Nhether Ih,s reflu. 
d1Sf'ilS8 IS relaled to the d",(,ay 01 lung funClion 
A8. What are the secondary research questions Objectives? (1/ aPIJliCilble. must be In language comprehens>ble /0 a 'ay 
:-erSjm, 
1 he ,;e,;ondary research oblecliVes are 10 assess the e'fects 01 tuncL';:lllcalion surgery on reflu, and on lun\) 
fupctlon Fundoplicatlon IS an Operdl,()n per10rmed to lighter. Ihe lONer oesophagus ana prevenl reflux 
Ie.)"''') up Irom the stomach. 
----------------- . 
A9. What IS the scientific justification lor Ihe research" What IS the background? Why IS th,s an area ot 
importance? 'Musl be in language comprehenSIble 10 a lay person. I 
BACKGROUND 
Lung transplantation has been performed since' 96:- Compared 10 other Irar'splanted organs survIval IS 
poor. 0"'1 41' ,01 pallents are DriVe 5 years after thelf transplant ThiS IS commonly due 10 ChronIC lung 
dy,.,tuncllor' after Ihe Iransplant (DavIs, 2003) 
SCIENfiFIC JUSTIFtCATlorJ 
It IS thought Ihat chrOniC aspiraliOn of stomach contents '11a, contnbute !o chroniC tung dyslo'leliOn 
(P'OqlC'SS"C' toss of lung functJOn). ThIS IS a fatrl,! 'eeeni concepi ana was f"st descnbed In 1990 There is a 
high incidence of GORD atter lung transplant. ThiS IS related to vanous faclors Includmg damage [0 the nerve 
suppll'ng Ihe stomach dunng surgery. antI-reJection medication. and the high InCldence 01 GORD before 
surgery 
One ot the proposed mechanisms for Increased reflux In pOSI transptanl pallents IS de',,) eO empty,ng of Ihe 
stomach An ,ncrease rn the volume of the stomach IS known to cause rellux Into the gulle[ "!h" nerves at'! 
,j;""",1"o "I Ihe I,m" Of transplanllhls would promote delay,·rj Slomach e~'p!y n\} and ~·':I. be a Slgnilicani 
contflbullng laclors 10 reflUX after sul'JE", 
Posl-Iransplanl !nere an; Imparred lUng defence mechanIsms cough and clearance 01 mucous and Spll 
t.'I,(OUS clearance has been shown to be less than 15% 01 normal after a Iransplanl These lactors 
predispose the new lungs to damage 
Post, ;;p.:-,IIIV['. pat'en!s are pul on antl-ae,o Iherapy ThiS reduces symptomatic heanburn. and the aCid 
levels III reflux. but not reliuxed matenal Iisell, which can slilt damage the lungs Impedance IS a small deVice 
It",al CJf1 be placed in the gul101 !O measure reflux whether It IS acid or not It IS an exclling fie" lecMology 
WhfCh is more accurate than current acid d<:lectlon studies ',V,se.2007) These non acid reflux events may 
contnbute to Ihe development of chrOniC lung dysfunction The use oflhls lechnology enables us to study 
reflux in a "reat ille slluallon", unlIke prevIous studies .,',ero: 3011 ·acrd Iherapy has been discontInued 
"rhflclally, fo' acid mOflllonng studIes (DaVIS. 2003) TIle older lechr,'qcJp. Will miss episodes 01 non-acid 
reh,l<, 
fhere IS ,lXlsllng research Inl,) aSp."alion of stomach conlen:s ,n lung Iransplant patlenlS and subsequent 
lung aYS'IJ'ICI'on. worldwide and also from thiS unit There have been some h'gh prollie publiCatIOnS from thIS 
cenlre (SIOvold. 2007. Ward. 2005). Our prOject Will brtng state of the an oblecllve measuremenls 01 reflux 
and Will compliment eXlsI:n\) we," on measurements of asp" allon Irom our laboratory 
TO accurately quantitate ",,' levels at peps," bel!1g ~,~·-aleo Into the lungs. the ELISA used musl be 
callbraled With human pepSin The only source of r,urnan pepsin IS gastnc Juice Therefore la~lng gaslnc fUlce 
,s an essen,,;,1 pa" ollhls stud, 
II,l"c)RTANCE 
I hiS IS a very Important tOP'C 1 _\'o ,e, papers puOlished In 2003 by DaVIS and ,n 2007 Oy Stovold. suggest 
NHS REC "l>pllcatlon Form· Ve-sl,,' 5.5 7 
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Ihe follo .... ,ng (al Iha! anti-reflux surger, may lead 10 Increased su""val and Improved lung funct,or ,fie' 
iUl1splanl, by prever :"'9 lung aamllG" !hroug"' 'f,'IJ' and Ibl that gaslflc refluxa!e IS reaching Ihe 
transplanted lung ana ,s harp'I,,"!O lung function 
Ho,''',,:, !hlS IS unclear and lhe relaDonstJ,p oe',,~~·, 'ellux disease and ChroniC lung dysfunction needs to De 
defmeo AIt~'ouQll there are suggestions that lundopr,callon surgery has Improved lung functIOn a'~d SUf\llval 
Ihe slUO,es have been small and retrosp€"!lve Further research IS needed 
Relerences 
. A. SlovolO I A ~ orres!. P A Corns, u r" r., jfpr-'I J A Smith, S Decalmer. G E: Johnson. J H, Darll 
JP Pearson and C, \'I·"d PepSin a blOma""'" of gaslrrc aSp"atIOn In lung allografts Am J Resprr Cq 
Care I.l,l(j 2007 VOl 175 1298-1303 
,,, 'se JL MLrra, JA UtrllSlng me,!,channel Inlralumlnallmpedance for (j,a9"<>5Ing GERD a rev.,"" 
DIseases of the !:.sophagus 2007 Vol 20:83 .. 88 
WI"') C. ForresllA, Brownlee :A Johnson GE. 1.L'phy u'.' Pearson JP, 
Dark JH. Corns PA, PepSin' '" act", ti In bronchoalveolar lavage flUid IS suggestrve of gaSlrrC asprralron In 
lung allografts. Thorax 2005: Vol 60(10):872-4 . 
-DaVIS RD. lau CL, Eubanks S, 1.1esSler ""'. HadJriladlS D, Sleele I,\~ Palm.-' 9.1 Improved Lung Allograft 
F ,'",1'00 after lundopllcalioo In patients ,,'!" gastroesophageal rei:", disease unoergoing lung 
IransplaniallOn Journal 01 Thoracl( ,Cardlovascular Surgery 2003, VOl' 2'0 3) 533-542 
-------------------------------------------------------------
A1O-1. Give a lull summary of the purpose, design and methodology of the planned research, Including a brief 
explanation of the theoretical Iramework that Informs It, It should be clear eractly what wrll happen to the research 
participant. how many times and In what order. 
1 hiS section must be completed In Innguage comprellenslDie to the ta, person It must also be sell-standtng as 1/ will be 
replrcated In Jf', appllc.Jf.Ons lor sIte spec,l,c assessment on the Site-Specific Informa/lcn Form Do not slmpl, rr>prOOUce Or 
refer to lI1e protocol. Further gUidance IS available II) the guidance notes 
PurPOSt' & Theory 
largely asymptomatic slomach reflu, is presenlln mOSI pallenls aller lung 
rranSplanlallon, Subsequent asprration of siomach contents InlO Ihe lung can be detected usrng approprrale 
D'omarkers and reduces lung funCllon F')"d~~'lCalive surgery reduces reflux dIsease and bIological mar~ers 
of asprral,r,l1, With Ihe consequence of Improving survival and lung 1.lnclron 
Our alms are' 
- To measure pH'lmpedance In a siudy of lung transplant 
recipients. to UDjecl1veiy assess reflux dlseasc' 
, To see ,I Impedance can replace pH mOnrlonng In relic' pallenls 
To measure patlenl s,''"'P!O'TS of reflux disease, uSing a spcClllc questIonnaire, 
To compare objective assessment of reflux disease (Impedance) With pat len! 
expenence of symptoms Iquestlonnalre) 
_ To compare objecwe and clinical assessments of reflux and symptoms With rnar,,,rs 01 asprratlon In the 
flUid removed from the lungs Ipepsln, bile salts) and clinical and pathological changes In lung funcllon 
_ TO evaluate the e"eel of fundoplicallon surgery on the above 
Pallents undergOing lung Iransplantahon althe Freeman Hosp',la' "',,1 be studied 10 les! '01 the presence 01 
rell". Thell ",nq" will be under surveillance uSing bronchoscopy la leSllo lOOk InSide the lungS), lIuld 
samples wll be taken from Ihe lungs and lung funcllon lests w ; be per10rmed. T hiS IS alreaOy routine 
prachce 
Ove' an 18 monlh P6f1Od a group of 40 new lung Iransptant r"lllents WIll have r(iv' and acid levels 
measured II' Ihe gullet uSing a small probe passed through In" nose, al 1 3 and 6 monlhs POSI transplant 
ThIS .... ,rl be pertorrned J'"mc-dJ.llel, before the bronchoscup, and a flUid sample on each occaSIon Pal,enls 
w,l, be approached 10 be recruited mlo the sludy by Dr Robe'lson, dV"'9 Iherr posl-operallve stay, once Ihey 
are beginmng ," recover from surgery and returning 10 health Overall there ,', 'I be no ,",',., VISI!S but the 
palrenl s one monlh, 3 rnonlh and 6 mo,)!I, VISII WIIII.)st tor 2 days as opposed 10 one day, DUlIng thIS I,me 
pallents "~I receive Iree accommOdallOn ,n the available TranSplanl accommodalion allhe "'eeman 
Hosp'lal 
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The e_tra procedure ~ec~rmed IS calleo an IIT1pedance test Each pahent "'I" u:)dergo this prOCedure 3 times 
at t month 3 month and 6 mon:n post-Iransplant Impedance IS a new teslll0 'Iears Old' Stm,iar to a 
stal'oard pH cattlcter It consISts of a thin "ailed tube i2mm 'n d'ameten WhlCe Ii 'I be plJCM '''rougn the 
"ostnllnto the gullet to look for ren" ';>r a distance of J~cro(lmately ~'. :.m Tne tube CO'1SlStS 01 a serres Of 
small rings N"'ch detect chan~es of resIStance' ·:'o'Ieen \nese "ngs uQulOS have le.- 'eslstar>ee gases hay,," 
a hrgh reSistance ThiS deVice '" able 10 0",:,,·;1 changes In resIstance ad ·.;:nous pomts along Ihe tube -~'s 
enaOles thiS deVice to dlshngUtsh beINB"" I .• ",,, c ... s and retlu. events, determine tne composltlO~ 01 the 
reflux event (gaSJloquldi and the level of ref tux Impedance deVices have been.n use lor over 10iea's ana 
the deVices used III the stud f h,,,,? b»en uSed In the UK for 3 years ,n bOlh c"",cal and researCh se~: rrgs 
Impedance deVices are uSed routinely t~roughout t'C.? LK andN0'idN,de Ij>< centres InClude GlasgG" ",0,,, 
Inhrmary. LJmvensty College Loodon HOSD,tals, Noltlngham ',',nchester I paedlatr,cs , and Plymoulh We als~ 
use tn,s deVice clln,cal , ~t Ihe Northern Oesophago-Gastnc Cancer U,,!\ in the Royal Victoria In'"mary 
The oevrce used IS CE marked In hne "'Ith European s:a'mards and Is manufactured to comply ""t~ Ih€' 
E.uropean 1.led,cal DeVices Dlfecllve (93.42 EEC) and the'efore does not requlf€ 1,lc'-A approval 'here IS a 
completed Pre Purchase '~uesllonna"e (PPD from Ardmore Healt'lCare LtC that confirms Ih.s compliance 
The deVice rtselL has been operallonally chec~ by tne electron,c department on receipt and has Ot:en placed 
on the r,,'wcastle Upon Tyne Hospitals Trust asset register !Trust Safety ',"mber Safety Informat,on tor 
Impedance- 155951) 
There ","I no dietary restrrchons dunng II1IS study and pallents "'III be encouraged to try to have a . nOI mal d 
diet as posslbte t('l I :'w a "real III,,' assessmenl of Ineir 1~lu, 
The role of relbx clsease In toe dP""iop",(·nl of chroniC lung j;slo' ,'Ion after lung transplant is 
controversiaL Although there IS a gro ~ Ing OOd I of eVidence to suggest a link. thiS has not been dehn,t,vely 
proven. 
Similar tests for reftL' disease are c[,rrccl". roullne practice at several lung transplant centres (Du~e s 
Centre, k;rth Carolina. USA SI LouIS. Mlssoun, USA Great Ormond SI, Londonl They are also rout,nely 
done for patients at the RVI sutfenng from reflux Inslead of an old- ';Js",loned probe ::4 hr pH) a newer more 
accurate probe ,\,1: be used (Impedance· rhls ",iI: be poSitIoned W In the help of a Sllg~lIy larger tube 
Imanometry) placed Into the gullet through 1.1'0 nose. ThiS targer tube ""II be in place for about 10-20 
minutes, "allents \V"I also be asked to hilin a ~uesl'onnaire to see If they have symptoms. 
Lung fl,,:o samples ,\ ' be analysed as routrne pract.ce and also as comparabte with current research. 
The degree of relllD detected ' "~". often. hOW severe. and ",hether II IS aCId or noli IV " be ,:,)'Cpared With 
molecular measures of reflUX [ ne deteCl!on of pepsin !a protel/) made In the stomachl and bile salls ifrom 
the liver and small intestine) In Ihe IUflg f'L,d and the preseflce of cells of Inflammation In Ihe lung IIwd sample 
., ',t be used to assess I'le relevance of the detected retlc. episOdes 
Patients Wlh Significant I.'li.;. at :he 3 month assessment IV Ii be oHered anll-reflux surgery as pan 01 tre" 
clinical managemenl at the Royal V,ctona Infirmary All pal erlS Will have a 6 moo!n Impedance p"rtJfI')ed 
Those patients MIO deCIde to have surgery ""II be Included In the loIlO'~ -up 
L UII<1 Sunveiliance 
Ro~i,ne lung surveillance ",I, be performed by the resp"ato', phYSICians speCialiSing tn pulmonary 
Iransplant This ""I be u',der""en uSing bronchoscopy. At bronchoscopy. thc'c are normally IIUld samples 
and b'op",", laken E.vldence ,,I rejectIon trom bIopSies, assessment of lung t,u,d lor mfectlon. an ar:I",'5 of 
Inllammatlon cells Will be used 10 assess II e status 01 th", graft These are routine measurements 
Some extra bronchoalv.,oiar lavage samples ",III be taken and al'al,sed to look lor the presence 01 peps,q 
bile aCids. (eVidence of stomach COfllE'nts enterrng the lungS) and prOduct,on of an Inflammatory ru'ec:ule 
called ,nlerleukrn (lL)-8 ThiS means Ihe bronChOSCOpy w<li ,as' abOJI 5 rnmutes longer than norma, 
Pulmonary Funcllon Tests ,,<II oe stUdied as part of routme follow up ,ncluding FEVl fVC r~r.~" :' 
spirometry wltf) exprratory flo", volume loops 
Results "'Iii be studied to see ,I there IS a link Det",een severe refiU' 01 SlOmach contents and lung 
dysluncllOn 
Those -'.tIl Slgn,ilcant reflux at 3 months ",;II be offered the opportunrty to undergo surgery 10 stop :t'em 
refl'",~ al the ROydl VictOria IIli,,,nary 10 Iry to prevenl the development of bronchiolitiS obliterans and thus 
Improve survlvat ; 'lIS IS alsO rouM" prac:,ee at several lung transplant centres worldWide, 11,,1 IS a 
controverSial Issue Currently apart from Great Ormond SI. no other UK lung transplanl unrt IS perform,ng tnts 
procedure Ho· ..... -'ver !/lere lS some eVIdence to suyges! that tnls Improves pallent survIval 
Res,,!I< '" t then be analysed to see ,1 :here IS a I '·e. betweer retlu, lung flUid samples and lung 0,51'",,' r 
The measures 01 pepsin (8 protein found ,n the stomach) causmg lung damage have been 51"0""" to be 
ImportanIIStovOld). Much research has been performed ,n general on pepsin and also on ItS role 01 In lung 
d,sease by Professor Pearson. Pepsin levels are measured uSing a standard ,,1 called an ELISA 1 he 
~HS REC ApplicatIOn Form Version 5 5 9 
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EUSAs are designed 'G cheO, for p:p&ln derived from IhC slom3ch of pigS, nol huma% I! "0~1d tne'efo'" 00 
of ~Ientl"( "k"»SI to assess these detectIOn ·~s usmg human pepsm ThIS would be oot3'ne<l from san-pies 
'rom ',.' ne washolJ1S of pat rer t~ stomachs al SCheduled endoscopies of non-transplant patients The 
patient s management NJ/J not oe altered In any way as the endoscopy IS perlOfmed for ci,mcal reasons 
and the washoc.ls of Ihe stomach are to enat>'e Ihe surgeon 10 \,;0. at Ihe In$joe of Ihe stomach dun"9 the 
procedure The flwO IS normarty discaroed after !t,~ prOCedure It COuid pe usee 10 e.tract human pepsin and 
Ihen our assay could be evaluated, ThiS collection of numan peps,n WOUI(] Oe uSed to see If Our assafs are 
accurate in aetectmg human san,p '~S and thus are ~>entJflcally accurate 
Al0-2. In which parts 01 the research have patients, members 01 the public or service users been Involved? 
o As lser -researchers 
o A' members of a research projer.r grou~ 
o As JOI'S0t to a proJcct 
o As members of a departmental or other wider rAsear::~ strategy group 
o tJJne of the above 
Please provide bile! details 11 applicable: 
~-; 0-3 ~~~-;;;-the research lead to the development 01 a new producl!process or the generallon 01 intellectual property? 
L __ O_=~ __ O~.~_~ r'_"'_s_u_re __________ , ___________ _ 
I. A 11 Will any mterventlon or procedure, Which would normally be consIdered a part of rouline care. be Withheld trom 
: the research partlclpanls? 
,Yes • ", .. () 
r' ,-----,,------
\ A 12, Give details 01 any clinical Inlervention(s) or procedurels) to be received by research panlClpants over and above 
I those which woutd normally be considered a part 01 routine clinical care., These Include uses of medlcmal proou,"c v I aevlces Oll>er medIcal treatments or assessments. menIal health ;nterven/lons, ImagIng Investlgallons and 1"l<mg sam~ PS 
~ human bll "OOlcal mateflal I 
-----_ .. 
----
- ---
c~--
" ---------" i 
I 
Average time Oelails 01 additional intervention or Additional Average number per partiCipant taken procedure. who will undertake it, and Intervenllon (mins'hours1daysi what tralnmg they have receIved. 1---- - ~------- --
1 Routine Care Research I~ -- --------
" i r}, : lomet(~' J' 1(1 Irr·pl.?d(j'1Ce teSting Will be I' 
I perlormeo I rne oesophageal laDor atory 
of the [,,,"hem OesophagogaSlr,,· Unrt 01 
Ihe Ro/al Victoria I,,'rmary oy the rl meal 
research fellows. I\drnely Dr And":.,, 
I Robertson a clinical research fellow ana 
(I:h'r 3 3.,day SpeCialty Registrar iST1) I~ General 
Surgery, who has completed a foundation 
programme and has experience In 
Inserting nasogaslnc lubes Hf' IS pelng 
trained In manOrrielry, pH SluOles and 
''Tpeeacce bi 1.1, Sultan a Speoalty 
Registrar (ST31 In General Surgt:' I 
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A 13 Give delalls of any non-clinical research-relafed inlervention(S) or procedurel S I. (These ,p,;JuOe mIen. "..-5 
"on unlca oOServa/lons and use of ques(tonnilJres I 
I Average 1 Average lime Details 01 addilional Intervention or procedure, who 
Addillonal Interv ention number per taken will undertake It. and whal training they have 
partlclpanl I mm~ nours'days I receiVed. 
I Pallents ", I be asked 10 It" ,n a slra'gh: forward 
3 12 hou' '-1uesllOnnaire ~ J. og al symploms of retl". d,sease 
, 'c' heartburn cough, discomfort wo,ISI eallngl 
Othe' (.J le~,! onna re 
A14. Will Individual or group Interviews questIOnnaires discuss any 10pics or Issues thaI might be senSI\lve, 
embarraSSing or upsetting, or IS It possible Ihal criminal or other disclosures reqUiring action could ta~e place dUring 
the study (e.g, during Interviews group discussions, or use of screening tests lor drugs)" 
OVes • iw 
~-------------------------------------------------.-----
I/)e Inlormatlon Sheet sl.ould make It cleat under whac CJlCumstances acMn may be :.1_"v t ,.~"" ;, ;;;;;;,;.~'" ... , "',"00 0' "rt.'"",oo '0 ""'"" '0' "" "",''''",0 
6 monlhs 
I 
i 
I ... ' . , ' "1 
I A16, What are Ihe potential adverse effects, risks or hazards for researCh partiCipants either from giving or Withholding I 
'I medications, devices, ionising radiation, or from other interventions (including non-cllnlcaf)? ' 
l M;Hw"el", and Impedance are low r51< prOCedures, !,lany patients undergo manometry and pH studies ian o,j-Iashloned measurement Similar to Impedance) .v,~hout experiencing any comp"cat,I)ns The main r,s~ IS of Olscomlort 10 the nose, throat or guller 
A17, What IS the potential for pain, discomfort, dIstress, inconvenience or changes to lifestyle for research 
participants? 
r I,f' main polential lor distress to participantS IS trom the manometry test. ,," en lasts about 20 min uk, i I)" 
I '''f cause a scomfort to the nose. throat or gullet impedance causes less discomfort as II IS a smaller tube 
A18, What 's the potential for benefit to research participants? 
EVidence has shown 'halll severe reflux IS detected and Ireated w'th anti-relit.> surgery, then pat,ents have 
Improved lung function and sUfVlval Eallf lung dyslunctoOn has been reversed I"rough surgery Studies have 
shown surgery 10 have no mortality and a small amount of complicatiOns Several ant,-reflll' operations have 
been succe~tully pertormed here on lung l';;r'spl"n~ pat,ents 
'-----.-~--... ,,----------------------------
A 19 What is the potenllal for adverse effects, fisk s or hazards, pain, dlscomtort, distress, or Inconvel1lence to the 
researchers themselves? "I anyJ 
None ThiS IS a low riSk Investigation 
r~~. HoW will pOlentlal participants In the study be (I) identified, (iI) approached and (iii) recruited? 
! lIVe aeralls for cases and controlS separately • "opropnate 
40 patlenls Wll0 "av~ undergone lung IranSpl;Jrl at the F"'E'man ",[1 be approached and recruited Into thiS 
;,I,;d, after Informed consent IS obtained to obtaJn 30 completed pallents. 
NHS REC ApplicatiOn Form· VprSl("15,5 11 AS t214,1',1 
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'--;out,ne endOS,~0Pf patients at the Royal VK:tofla Infirmary Nc'.c.::l~:..~-e Gener;"1 .,.., cO'~ 3~prJached random;, 
'" '0 w,li be recn .. ,led 10 donate gastrIC JUICe 
A21 Where research participants Will be recruited via advertisement, give specific details. 
~ ~. 01 Applicable 
/1 clPI'IIC80Ie enc})se a com' 0' rile advertlsemenc raOlo scnptwebSltevldeo lor teleVISion (WIth a vefSlOfl num!>er ana Gale. I """"" " .... , __________ ---.: ________ -=--____ =-=-=-= __ =--::.::.:..:=-::::.=~_..J 
A22. What are the principal inclusion cfltena?' Please i[,S/"I" 
Patienl who have r.ad a recenl Lung Iracsplant at the Freeman Hospltai. 
t. , ·transp',ar'l patIents undergoing routine endoscopy 
._-----,,-----_._ .. - -,. 
r A23~·..;;~~~·are the principal exclusion criteria? P,ease /us/lfv 
I Patient "hO have not undergone a lecenl iung transplar:1 
",_ .. _-----,,_ .. _-------------------
" A24, Will the participants be from any 01 the following groups? T!c~ as .!I'" 'i .1'" 
Dc 1(1"" unoer h 
o Adults ",,1" !al nI °Il oiS30"·tles 
o Adul;S ""r.o are U :;0 ISCIOUS or very :;c\.erc.) III 
o Aduns "he '~':e" lermlnal Illness 
o Adults In emergency slluallOns 
o Adults "'.ie, memal illness (particularly If detained under r.~e'~ltal Health legls'atlonl 
o Adults "".t· Den· nl a 
o Young Ot'enders 
o Adults 111 Scotland who are unable 10 consent for Inernselves 
o Healtll)' Volunteers 
o Those who could be conSidereD 10 11ave a particular!, depenoent relationshIp With the mvestlgator. e.g, Ihose In care 
hOmes. medical students 
B Other vulnerable groups 
Jus(JIy therr inclUSion 
ThiS study is deSigned to look at rteflu, n the lung transplanl populatIon and Its role m the development of 
chroniC a'loq,;,II cI,slunCiion. I/,S therelore necessary to Include these patle,,1S ,. II" stvl, There may l)e 
palenllal healtrl beneills for ~"r'" .;,J1lr, of the study 
o No partiCIpants from any 01 the above groups 
----------'-------------... 
~HS REC Application form -- Version 5.5 12 AS 121447/1 
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A25 WIll any research partIcIpants be recruited who are involved In ~"stJng research or have recently been Involved In 
a ny researCh prtor to recruitment? 
• Yes ",at Known 
nor,. > In ongoing sluOy ot chron,c lung aisfunctlon after lung Iransplant at the Freeman Hospital whoeh has 
It ":r",,,1 approval ThIS stuat seeks 10 aoo on one minor chmcallnvestlQatJon ana comome thIS w,tr routIne 
nla agemect to gain an dnae rSl3!ldlng of ,,·':ux dIsease and lung dysfunctIOn 
A26. W,ll Informed consent be obtained from the research participants? 
• Ye~, 0'.0 
/I Yes, gIVe details of M\:' .vli : ,- ,? consent and how It ,',.11 be done GIVe details of any particular steps 10 provloe ,nformatID" 
(m aCj(jrt'Qn to a 'A'iiie," mformatlOn SheeT) e g. VIdeos. Inreract!ve rnatenaf 
II part.e'pJf'/s are to be recrUIted from any of the potenllaii, >ulnerabfe groups listed 1(' ".:'4 giVe OetaJls of exIra sleps tJI<er; 
to assure thelf protectIon. Describe an, arrangements 10 be made for obtaining consent from a legal representatIve 
II consent IS not to be obtamed. please e';Jlam M,y not 
Infor"""J Consen~ will be '?k,or, by Dr And(€,<, Robertson. ClinICal ResearCh Fellow",," the a,d 01 the enclosed 
IIllorm d!,on sheets Pallents 1'0'111 be encouraged to diSCUSS partlc.pallon .. ",., all members 01 Ine transolant team 
CopIes of the ,',erie" informaI<o" and ali other explanatory malenal sho(;/o accompan,' thiS applicatIOn 
I A27. Will a signed record ot consent be obtained? 
• Ye~ O~.-
II Yes. allach a copy of me inlormatlon sheet to be used. ",(11 a verSJon number and oate 
r'" ~ .. '."" .... ", "".'''''''.' ",,' ,.~ 'oc'" .... "" ,. "., ". ,. , ... ,~ .. ,", I 
s~:~w~~e_ks to 1 month ___________________ ~ 
r
A29 What arrangements have been made tor partIcIpants who mIght not adequately understand verbal eXPlanatlonSlr 
written mtormation given In English. or who have special communicatIon needs? Ie g translatIon use ollnterorelers elc 
rt/celve a yllg t/ansplar1\ Translators and Interpreters will be used 10 Inform patlenls whO cannot understand , l All ,I I p, I ents need to understand and retam ""planations from a :,ansp,ant perspect.ve u be able to ~ngl sn --~~- ----- -~---' 
A3D. What arrangements are In place to ensure participants receive any information that becomes avaIlable during the 
course of the research that may be relevant to their continued participallon? 
Patient will have regular contacI wllh the Iranspla"1 leam 
L-_________________ ~ ___ ._ 
13 
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Online Form 
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A30-1 What steps would you take if a participant. who has given informed consent loses capacity to consent (luring 
the study? ,,0 one oc/,On only 
Ie participant would be withdrawn from the study Data or tissue Whlct, ,s r,ol 'denlihable to the rasearcn team ma, be 
Ined ""i 'del'I,/'able data or hssu~ .'ould be anonymlSect Or disposed 01 ' 
he participant would be wIthdrawn trom the stuay ldentlhae,e data or tiSSue al'eaa, cQ<!ectea w,lh:onsenl waul(] be 
0': :.1,' led and used ~r, 'he Stu1 1 
The participant ,. ,10 conl,nue to be Incluaed In Ihe study 
'- ';,' appl'cable ',['<'0' med consenl ~,' not be soug~1 from any part'Clpants in IhlS rasearer 
, -- -----~ -------- ~------ ----- - - " 
\
' A31 Does thiS study have or require approval 01 the Patient Information AdVISOry Group (PIAG) or other bodies WIth a 
similar remit? see 'he gV'Ci3PCf? notes) 
I 
V Yes • 1\0 
l _________________ , ___________ _ 
I ~;;;;:_~-i-I-I the research participants' General Practitioner [and or any other health professional responsible lor ihelr care) be Informed that they are taking part In the study? 
• Yes ONo 
If Yes, enclose a copy of the rn/orma/lon sheet letter for the GP,,0eall', pro/esslonal ... ',th a versIon number and date 
A32b, Will permission be sought from the research participants to Intorm their GP or other health profeSSional betore 
thiS IS done? 
• Yes ONo 
If !Vcl Ic' elth.·, Question. expl,IIn why not 
II Should t e made Glear In the L\ went m/orm<111on sheet tf the research partiCipant's GP />ealth profeSSIOnal Will be In/ormed 
A33 Will Individual research participants receive any payments for taking part In this research? 
OYr • No 
I A34, Will Individual research partiCipants receive reimbursement 0/ expenses or any other Incentives or Denelils for 
I taking part In thiS research? 
I • Yes 0 ~~O 
If Yes, ,'odlc',lIe ,10W much and on ",'n.lI baSIS thiS has been uL'C-oc-d 
Pal,ents Will not be foreseen to have to m.1i,e extra journeys to ~'t'wcastle as Ihe .mpedance measurements w.1I 
COI"CI(/(, With their cliniC VISitS. Accommodation w,.! be provided free of charge An al'OW3rcL' Will be made for 
meals aunng thelf e,!.a day stay in Newcastle Pal<ents will be Inlormea that if ar'. unforeseen (:'p0 I1 ses allse 
retaled to partiCipation In Ine study full reimbursement "'," be gIVen 
A35 Insurance'indemnity to meet potential legal liabilities 
NHS REC Appi" it',,,, " Form - Version 5,5 14 
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~ Relerences I{l this quesllon to'.HS ,ndemmty SChemes mciude eq""aent SChemes p'o>lded b. Heailr and Persz:' J 
SOCIal ServICeS (HPSS; ,n Norrnern treland 
AJ5-1 What arrangements Will be made tor insurance and'or indemnity to meet the potential legal liability at the 
sponsor(5) for harm to participants arising from the managemenl 01 the research? 
l:i.i..:1l;:. t,'h 'f' '." ,', orgamsallon hilS agreed 10 act as Ihe sc'onsor, Indemnlly is provided thrO"O"'I,HS SCllemes Ind'CJle,'~" c 
aI";" e. Iho re 's no need to prOVide documenta", eVidence;. For all olher sponsors, descflbe the arrangements and prOy1de 
P'IIOel ': . 
• r ai!:) IIId nnlty scheme 1/'; appl" 
Oth fl5uranCC or indemn,!! arrangement:; "'! apply ~g'Y~ aetaJls 0>2,0'" 
: Pled>.' enchst' a 'i), 01 relevant documents 
--------,----------------
: A35-2 What arrangements will be made tor Insurance and or indemnoty to meet the potential legal liability ot the 
! soonSQr(Si or emp/oyer(s) for harm to participants arising trom the des ian oltbe research? 
I 
i ~ W"ew 'esearchers w," substantive ',,is employment contracts have deSigned rhe research Indemn,t)' IS prov,oro 
Ilhrough \H~ SChemes. Indicate Ii this applies ,there is no need 10 provide documentary eVidence) For other prO/ocol aut/'ors 
, "g r;ompany emplc, ,,,,''; Un/I prs",' membersj describe /Ile arrangements and prOVide evl(Jence 
• NrS iI,dem"')) scheme ,\ apply to all protocol aulhOrs 
o Oll1er Insurance or Indemn,ly arrangements Will apply 'give details below 
\ 
f---------I Please enClose a COpy 01 relevant documents, 
, A35-3, Whal arrangemenls will be made tor Insurance and or Indemnity to meet the potential legal liability 01 
, IOves/lOators collaborators and, where applicable, Site Management Qrganisations, arising Irom harm 10 participants in 
the condu,,1 01 the research? 
i 
I 
::L.:k. Whefe II,,, ;Jar"'.:'I',~nts are NHS paI1e"ls, IfIdemn,ty IS pr,JVldeo t',rough NHS scllemes or through prolesslOna/,ndemftl'y 
mO/cate" tn/S lPP' /0 tIre whole of the 51",:1, ithere IS no need 10 prov,de documf"larv evidence) Where non- 'l,H::; sites are 
to be IfIc/uded tn ,he research, ,nCluomg prIVate praClices, deSCribe the arrangements Wh'ch Will be made atlhese sites and 
pr )VIde eVidenc£ 
• " ~artlclpan!s w,lI be recru,led al 1.11: SI!es and I,HS Inaemnlty scheme or professional Indemnr.y Will apply 
\"J -!PSPd'cl, ,ncludes non, ~I" ,sites Iglve deta,ls of Insurance (f,o."T,n,!y arrangements for Ihese Siles belOW) 
, '-Iease enclose 3 cop, 01 re/evaN dOCuments, 
A36 Has the sponsor(s) made arrangements for paymenl 01 compensation tn Ihe even I 01 harm to the research 
partiCipants where no legal liability arises? 
) Yes • ~,c; 
/I res, [7'\ e details 0/ the compensatIon pO',cy 
C=:c;;S,' enclose a COpy or relevant documents 
NHS REC ApplicatiOn For'TI - Version 5.5 t5 
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A37 How IS It Intended the results 01 the study will be reported and disseminated? f,e' as aoprop"3te. 
~J Peer reviewed sClenltfic Journals 
LJ Internal repor1 
I~J COfitmence prcSenlai,on 
~,~ Other publl".1',on 
o Submission to regutatory authonltes 
Online Form 
o Access 10 I,).v data and ng"., to publish freely bl all investigators In stuO, or by Ic:Jependent Steenng Committee on 
behalf of all Inves' ,qatars 
o w"n·,,,,, feedback to researcr. participants 
o Presentation to panlc.pants or relevant communlt\ d'OuPS 
o Other,none e g Cochrane Revl{:w UOIverSlty Library 
, A38, How will the resultS of research be made available to research participants and communities Irom which they are 
, drawn? 
fhe results of research .', I be made available t"rough presentations and pubhcat,ons 
L ______________ _ 
r--------------------------------------~ 
A39. Will the research involve any ot the followmg activihes at any stage (Including Identification of potential research i 
participants)? riO, as appropriate} 
o Examlnahon of ~ ,,(tcal records by those outSIde the NHS, or ""thin the NHS by those wno would not normally ,,,IVI 
access 
o Eif'ctrOOIC transfer by magnetic or optical media, e-mail or compuler networ~s 
o Shannq 01 dala {,ill', other organisations 
o f:xport 0f data outSide tne European Union 
o Use of personal addresses, postcodes faxes, e-malls or telephone numbers 
o Publication of dnact quotations Irom responder, IS 
o Pubhcahon of data that might ailOw Idenllflcatlon of ,nd",duals 
o Use of audlo,vlsual recording deJCo'S 
l~ Storage of personat data on any of the follOWing: 
o 1.1-,lnual files Including' -rays 
. .-.: NHS computers 
o Home or other personal computers 
o Un"Iers"v computers 
o Prrvate company computers 
o Laptop computers 
I 
Relevant sectrons of pallen!s' medical notes and data collected ov,ng the study, ma,! be iooked at by 
respons.tlle IndiViduals from regulato'y authOn1:es or from the M-:o, Trust. where It IS ,elevant J 
A40, What meas~;:s have been p~t In place to ensure confidentiality 01 personal data? Give details ot Whethe~a;y 
encryption or other anonymlsatlon procedures have been used and at what stage 
The Coldlcon Pnnclpals Will be adhered to 
NHS Hlel. Application Form VerSIO'l 5 5 16 
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. A41 Whe-r-e-";;I~t;e-a-n-al~~;~~-f-th-e-d-a~ from the study take place and by whom will 11 be-U-n-d-e-rt~ken~-------l 
AnalysIs of the data tram the st~dy Will be undertaken Oy the researcn team from the Newcastle lJDO~ T yne , 
Hospital Trust alld the UniverSity of '·~e'.castle 
\ A42 Who will have control ot and act as the custodian for the data generated by the study? 
Professor Cords I'. Professor Gill! G 
: A~3 Who Will have access to research partiCipants' or potenllal research partiCipants' health records or other personal 
Informalion? .v'v",> access IS by Individuals au/side the normal ctmlC.3l team. JUSI.', and say wnetne':onsenr WIll be soughr 
h,' C III ca . earn w'e research team. personnel from regulatory authorrhes or from the sponsor ,e the 
rst Patle1ts will be Informed of thiS and consent ",I, be sought. 
--------.----------------
A44. For how long Will data from the study be stored' 
GIVe details of where they Will be stored. wllO w·11 have access and the custodial arrangements for the oata 
_ dliG T ranspla:Jl Pallent Details w,1I be stored in the Department of MeSp,raIG' I 'S' JIClne Freeman Hosp,la: 
I ~'-W("S'Jc under the guardlansr"p of Professor Corns DetailS of the Impedan~c measurements ",.11 De stc,reo 
the Northern Oesophago-Gasl11C Unit. Royal VlelO'la Infirmary under the guardianshIp 0' Professor Gr·ffICI 
A4S-1. How has the SClent,IIC quality of the research been assessed? ,TICk as appropr:iJle 
o Indepeoaent e)(ternal reVfI?W 
D ReVIew '''''~''''' a company 
o ReView ",th,n a mUlt,-centre research g'ouP 
D ReView'", ,H,I] Ih· Chief Investigator'S inst I.JliOn or hOst orgaf1lsalion 
~ 'kV'8W Within the research team 
, .. j >'kv:ew 0-, educational supervisor 
DOtMr 
JUSf,f, and descflbe the reVle" process and outcome /I rhe rev:6''' has been undertaken bur no/seen by the researcher 
gIve l1f.NdlJ$ of the body w'/·c t ) has unde rla;'.en the ~D.IC.'v 
ThiS potenfial project has ,.!rl(Jergone reView by the research team. edlicapOnal supe'>lsor and the Urwerslty of 
~""C.1',1" All Involved r'd"'" deemed thiS to be an Important area of c!ln.cal 'esE'arch Wlttl potential benefit lor 
palientS rhlS prOject has been accepted for a MD theSIS pending ethical approval. 
A4S-2. How have the statistical aspects ollhe research been reViewed? T c, as appropflatel 
D Rp"ew by Independent statiStiCian commissioned ~'i funde' or sponsor 
D (;Ult" :e"ew by ,ndependent statistiCian 
o ReView by compan', statlslJClan 
D Ht'vlew by a statistiCIan Within the Ch,ef Invesligator s ,nSlltuflon 
D Rev'~w by a statiStiCIan WIthIn the researctl team or mult,-<:entre group 
! .. J ReVIew by educational supervIsor 
D Other ,,"""W by ,nd,,,dual With relevant statistICal expertIse 
NHS hI.· -. Application For." - V"'SI"', 5 5 17 
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Date )·1 10'2007 Onlr'le Form 
In ail cases gIVe details Dele .... ai/he Indl'lldual responSible lor rev ev.ng the stausllCa' aspects It aeNlce has been D'c,.>ded 
In OOr;{J,jJ_."!ce gIve deld,j,> ,}t the aepa'la (~nl and mSfl'd,on concerned 
Department' 
InS~ilur,on' 
v\<~"k A.jd~ess 
PoslC{)de 
Telephone 
F.p 
Forename,'IM,aIS 
Professor Paul 
~)'-'[JJrtment of i-olr.;s;::'Ja10r~ 1.~; ,ine 
Frp..l--<nar HospI!al 
High Heaton 
"~(''''l_astle upon T yne 
NE77DN 
01912127462 
Paul.CorriS@ncl ac '" 
Sumame 
Corns 
Please e'lC/OSP a ccp, of .In'l avaIlable comments or repfirrs from a srar.sffClan 
I A48. What IS the primary outcome measure for the study? :J 
! The >Jflll,"f'f ou\corne measures for the s'.udy are U11pedance measurements. (he presence at reflux 'Yid_"~rs 
In the lung flUid and lung ',>,'1Ctlon resul1s , 
A49 What are the secondary outcome measures? 'anyl 
L The secondary outcome measures lor the study are !ung i"nclion and patient SUfYl','al 
ASO, How many participants will be recruited? 
If there IS more lIlan one group. stale ho:>, 'nany participants ...",,' be recruited In each group. For Interndl'andl studies, say "c~ 
man', partlclpan/s Will be recrUited In Ihe UK and In tolal 
Up to 4Q to get 30 completed evaluated patients 
Th 5 IS baSed 0 ,"(fOer of patle''/'o transplanted per year. 
" ~ lormal S</mplE SI. 'e calcula/lon w" used indicate !JaW thiS 1'1.'1> done. givIng sufl'Clent mformatlOn 10 Jusflfy and 
'~,'r{(I(1Ce me Cllculillion 
L __ ~ _____ , _____ _ l" W;" """,,,.,,, "" "'oc",'" ,. ~,."" " ~,,~, 
OVes • No 
---------------------------rS3 Describe the methods 01 analysis (statlstlcat or other appropriate methods. e.g. for qualltalive r .. search I by which 
NHS RE:C Application Form VerSion 5.5 18 AS 12'~~71 
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Reference 07 HOC,j8 70 OnlIne F0r~ 
\ 
the data will be evaluated to meet the study oblectl~es. ~
, The results Will be anal ysed tl\ the research team anO a statlshclan "'''i tle Involved 
------------------------_ ..-
i AS4 Where wlllIhe research lake place? T c. as appropnate) 
I 01;K 
o atner states In European UnIon 
o ~ner countries In European E:conomlc Area 
D~ 
/I Other. give details 
ASS Has Ihls or a similar application been pre~lously relected by a Research Ethics CommIttee in Ihe U,", lhe European I. 
Union or the European Economic Area? 
\'es • f\' 
._ .. --_._ .. _---------------------------
AS6 In how many and what type of host organisations (NHS or other) In the UK IS II intended the proposed study WIll 
lake place? 
InalC lte rne rype CII organisation by tlcJr.mg the box and gIVe approximate numbers I' ,nown 
o Acute teaChing ~;HS Trusts 
o ACL'I!.' I,H" 'rusts 
'\Lmber at 
~)'qanlsa[lons 
o NHS Primar" Care Trusts or local Health Boards In Wales 
o N,I", Trusts pro~ldlng mental nealthCare 
o r,w· Health Boards tn Scotland 
o HPSS Trusts If' "-"nl""'l Irelano 
o GP Practices 
o eif·' Care [rusts 
o Social care organisatIons 
o Prisons 
o Independenl hospitalS 
o tel", "IIonal estabhsl1ments 
o l'ldep<"·lue'lt research Jrllts 
D Other (give detailS; 
Other 
1 ~57' Whal arrangements are In place lor monItoring and auditing the conduct o. the researCh" Monl:ortng Will be performed by the Stud) Sponsor I e 1he Trust ----------------~ 
NHS REC Application Form· Version 5.5 19 
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A57a. Will a data monitoring committee be convened? 
., y, a. 1;3IIS Jr me 7Jbershrp 01 the data mom/Dong commrNee U!AC i 1/5 stanaard operating procedures and summan~ " 
reports of IIcr analyses 10 the Llr. 'c mus/ be 'or ... arded to the \HS Research EthICS CommrNec wnJCh gIVes a '3.C)ur3C1e 
ODin en 'Jf the .'Lie1, 
What are the criteria lor electively stopping the trial or other research prematurely? 
n3 
I A5S Has external lunding lor the research been secured? 
) Yes • N(, 
" No, what arrangements are being made to cover any costs 01 the research? II no externallundrng IS being sought 
please say so: 
ThiS prOJecl Will have mlmmal costs as !',ere IS Iree par:erl accommo<l<lIion for transplant paM')IS at the FrEeman' )SP la 
'j r.e main costs W"; be for the person COllecltng the data and the Impedances catheters Grants are currenll. a velY 0 
sought 10 help cover mese costs 
.-.. -----------------------------
Ii A59 Has the lunder 01 the research agreed to act as sponsor as set out In the Research Governance Framework? 
• Yes 
i 
I Has the employer 01 the Chiellnvestlgalor agreed to act as sponsor of the research? 
I 
I 
,. Y~" (, tJ J 
Lead' s;o~sor rmu~; ve completed In all cases I 1-·_··-_ .. _-_·_··--'------------
· ._ ..... _: _. " ... "._ •• ",)n willen w,iI act as the iead sponsor 'or the research 
Necastle Upon Iyne NHS Foundation T'JSI 
Status 
-- -- ~ 
• tJH~ or HPSS care organisation C Academic 0 Pharmaceutrcal,ndustry "\"<:81 deVice Ind~stry 0 Other 
/I Olher. please' SpeCifY' 
AdOress' 
Posl Code 
relep!10ne 
Fax 
/,\"I"le 
[ .. mail 
Rlil.' Clinical ResearCh Facll,ty ~T Floor Leales W,ng 
Royal Victorra Inf,rmar, 
Newcastle upon Tyne 
NEt ~lP 
Sponsor's UK contact point for correspondence with the main REC (must be completed rn all cases) 
NHS REC Appll,'J:lo') Form .. Version 5,5 20 AB1214471 
~') 
.'-
r·,flO[)I! 
m,11 
Co-sponsors 
t- ---.--.---~---". 
Reference 07 H0908?O 
Surname T Ol1lce 
Cllnocal Research f~~l': I ty ~;'h Flcu: ceazes ':1' 
Royal Victoria Inhrmar~ 
Newcaslle upon Tyne 
t,[, 4lP 
0191 282 5959 
Amanda~ T orliCe@ICI)lh nhs uk 
I 
Are there any co-sponsors for this research" 
OYes • ~~(, 
Onhne Form 
-----~ 
------------------- ~---~ I, A60 Has any responSibility for the research been delegated to a subcontractor? ('Yes • NO 
Ir;~-~;i;;-~~~~Idual fe~e~;~h~;S receive any personal payment over and above normal salary ;~; undertaking this research? 
I o Yes • No 
------------------------~ 
A62~ Will Individual researchers receive any other benefits or incentives lor laking part in this research? 
o r'es • r.,· 
J 
___________ ~ _______________ ------.J 
r~~63~ ~;;I-t~e host organisation or ~he researcher's department(s) or on5tltutl~nlsl receive any payment or benefits '" 
I I excess 01 the costs of undertaking the research? 
I I O,'e. • No 
__ J 
--~---------~--------------~~----~------
-A64. Does t~-e Chief Investigator or~any o~he~;nvestl~-;~~-collaborato;~-~~-;;-~y direct personal Involvement (e q I 
financial. share-holding, personal relationship etc) in the organisations sponsoring or funding the research that may 
give rise to a possible conflict 01 Interest? 
QVes • t,· 
__ . __ ...J 
NHS HEC ApphcallOn Form -- Version 5~5 21 AS 121447 1 
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-----_._-------------------------------------, 
! A65 Research reference numbers: (g,ve any 'e/evant references lor your studyl 
I 
Apphcanl's organlsat,on'S own reference number e 9 R&D (,f ava,lablel 
Sponsor :, p'otocol number 
,. UflOi:l !:i relerence numoer 
Int!?maIiO' ·31 Standard Randomlsed Controlleo r flal I • Jmber (ISRC 
L._~r0":'CI webs/Ie' _n_l_a _______________ _ 
na 
na 
A66. Other key InvesligatorS/coliaborators (all grant co-aopflc:JIIls or protocol co-,)u!hors should DC I,stedl 
'OS! 
:.),j~j If ca'I'- IS 
)rQa' IIsat on 
Wort Address' 
PostcOde 
Telephone' 
r-ax 
E-mail 
T,lIe. Professor 
Post· 
QualificatIons' 
Organisation' 
Work AddresS 
PoslCOde 
Telephon~ 
~a, 
T,I'e Dr 
Post. 
Qualifications. 
Organlsallon 
Wor~ Address 
PoslcOde 
telephOne 
Fa' 
E-mail' 
Forename Initials Paul Surname Carr,s 
Professor of ThoracIC r.1Mlctne 
DepartlT'''''1 01 Resplfatory MedIcine. Freeman Hosp,la 
Freeman Hospital 
H,gtl Heaton 
NI:;/~c..1srif;, upon Tyne 
r,t:77DN 
. ~-I (01191 21 :74t.~ 
PauLCorns@ncl.ac uk 
Forename'lnttlalS JOhn 
Professor 01 Card,othoracle SJ'ger i 
Regional Cardlothoraclc Centre 
The Freeman Hosp,ta, 
Freeman Road 
H,gh Heaton Newcastle cpon Tyne 
t,l: 70N 
0191 223 '~-i' 
0191 233 1152 
JH.Dark@ncl.ac u, 
Forename'lnrhals Andrew G t\ 
Clinical Research Fello" 
Northern Oesophago-Gaslr", Cancer Un,1 
Royal \ .c'.Jria In'"mTY. 
Queen '1.(IO'la Rd. 
Newca~!ip upon 1 i'le 
NE1 ~_P 
07.--1385 i)-I6ti 
andrewgnrobertson@aJc",rs o'g 
Sumame' Dark 
Surname Robertson 
NHS REC ApplicatIOn Form - Version 5.5 22 
Date 0.1 10/2007 
r,Ue Or 
Post 
QuaIJ1~cat:ons 
Organ",,], C;' 
','/: '. Address 
Postw:)!' 
Telephone' 
r a,. 
MODd.; 
E-mail 
Title: Professor 
Post 
(.1:J;;Iiihcatlons· 
Orgamsalton 
'v'-',,:,.rk Address 
Postcode 
t e1cpnone 
F Jx 
',,100,:(, 
"lie Or 
Posl 
Oual'I' 
Orgamsahon' 
Wr", Address' 
Poslcode 
'I elephone' 
Fax 
Mobile 
E [,lel,1 
Rel/i',nee 07 HO'J.18 70 
Forename InItials Andrew Surname Fisher 
ClinIcal Sen'or Lecturer ;n Resp;raro'y Med,c,ne 
Oepanmenl of Resplfatory 1»:tw:tne, Freeman HospItal 
"'('eman HOspital 
Hl{Jh Healon 
New"",t;r: upon Tyne 
r,~t: 7 70"" 
0191213~ii'j3 
a,1 f,sher@ncLac Uk 
P'ofessor of /~Clecular PhysIOlogy 
Ir'51,t!)te for Cell ano Ll recular BloscJ,',;es 
rhe I.I,:! ;al SChool 
University oll\W"C;]S"e upon Tyne 
Framhngton Ploce, Newu,tlEo 
/~l,:: ,IHH 
,44 (0) 191 222699 
• ~4 (O) 191 222 -42 
J,P Pearson@ncl.ac,uk 
Forename/ln'tlals Chflstopher 
Lecturer In Respifalorfn;a,(I~e 
The Medical School 
Unrvers,ty 01 Newcastle upon 1 1''0 
FramLnqlon Place. 
rkWC1S110 upon Tyne 
tJf:24HH 
Chfls,ward@nci ae '>" 
Surname Pearson 
Surname 'lid'] 
------- , ,~-~,-----, '~-~--~ 
Onhne Form 
I A67, What arrangements are being made for continued provISion of the mtervention for participants, If appropriate, 
once lhe research has finished? \fal apply to In)' c/lmcal intervention, Includmg 3 drug medical ,x.,ce mental fled/lh 
!fliervenlion, complemenldl, therapy pflYSIO/llPUP> , (j,f'/3') mampulallOn, hlesryle change, elC 
Tile f'j:,'I'k'" ,,)esophago-Gaslnc Unit has faclllt,es to study retlL' ,n Its oesoo"a~-::l1 laboratory and has the 
facliJJ!(~s to perform an!! - ('tJUX surgery 
NHS REC Appheatlon Form Version 5,5 23 AB'1214471 
Date 04 to'2007 Reference 07iHO"tCl8,70 O'1hne Form 
I i A6S What are the main ethical Issues with the research? 
Summanse me main Issues from the pa rl'2Danl s pam/ 01 view and sa;' "~,' VOL prc;:;cc,:' to aaaress them 
The main Issue ... ,w, thiS research IS the add "y'i of a mmOt monl\onng procedure to me rQuline management I 
and the use of human samples In the laboratory, However analySIS 01 these samples MS prevIouSly re.~,yeo I
ethiCill approval S,n1llar ,,,,flu, studies are pe~omled on othe' units as part of routone cilnlcal practICe 
Indicate a'i, Issoes on w'lIch you 1,",Uk:i welcome aaVICf) from the erhlcs commltree 
Ques/lonls) rj (j'sab/ed 
NHS REC Application Form Version 5 5 2-1 
AB 121447 1 
36 
r A;~ Ol;e -detailS -; t~ edu~~;onal course or degree lor which IhlS research IS bel~;~~~~~-~', 
I r .. a me 0 1 -:.1 ide'l' 
I Dr A b--'\fi l j t ... Robertson BSc,Hons) MBChB Hons) 
I J,,,,, and level of course,degree 
r",o-e 01 educal,anal establ'Shment 
I,. I • ". and contact details of educal10nal superVisor' 
Professor SM Gr.!!,,·. 
Professor of Gastromtestlnal Surgery. 
Northern Oesophago-Gastric Unit 
~O'l(}1 V:c\orl?i Int:rmar i 
',,14LP 
Email: miChael onffln@nuth.nhs.uk 
Telephone 01 '11 282023-1 
! 
\ 
_.----. __ ._--'--------------------------, 
A 71 Declaration of educational supervisor 
lave read and approved both the research proposal and thiS application I J' the ethICal reVIew, I am satisfied that Ihe SCientifiC 
content ,.1 Ihe research IS satisfactory for an educal,onal quailflcal10n at thiS level I undertake to fulfil the responSlblill1eS of a 
sUpe';<SOl as set out In the Research Governance FrB"'"""" for Health and Social Care 
Punt Narr,(~ Professor ',/.1 Gntfln 
Date 16108:2007 idd mm,yy,y 
A one (Ufi£' SI)~lf"3" 0' /he supervlsor's CV Sllould be subm'rred w·rn Ille application 
NHS RteC Application Form VerSion 5 5 25 AS 121"4~ . 
Da\(: 04 10)2007 
: 
Give details ot the medical devlce(s) to be used in the study 
De'lCe le: c' pi on 
• .'. ~n ul.cture· 
use 
... en~ I" It tm Ie since 
dey ce came II Itt Jse 
Impedance Catherer & Ambulatory Recording DeVIce 
Arcjrnore Kealthcare Umlted.I,1,dlcal "',,~sc','menl Systems 
DelectlOn 01 gastro-oesophageal rell", olsease 
3 fears ' Does the device have a CE ma"? • 'Ves 0 N,) 
~ .... 
: . F.)' 311 products wl/t· CE mark please anacfJ mslruc/!ons for use L---~ ________________________________________________________________________ ~ 
2. Does ~.~ study mvol"., ~use 01 a new medical device or new implantable matenal or the use ot ~~ eXlsling productl 
outSide the terms ot Its CE market Intended purpose? 
l 
OVes • No 
In addition to the Instructions for use, the lollowlng details should be provided where applicable: 
Descnptlon 01 I ''''w device. maler,als. method of use or operatron and a summary of the '"ten Oed purpose 
r;CI"posllion Of any ne" Implantable malenals. Including summary of biocompat,b""; ',"dlngs from studies 10 dale 
II already C Ec marked, a summary of any proposed changes to the CE m",,"'d in l(·ndea purpose 
:mIJt,(j,,,,~,, IS a new test (10 i'oars old). Slmllar 10 a slandard pH catheter. It consists at a tI',n walled tube 12mm 
In diameter) W['';;'' will be placed through the 11051,,1 into the gullet to look for rellux lor a d.S:JI'Ce o! 
approximate I .. 45cm. ThiS tube IS connecled to a small har.d·~I;e'd be, whoct) records the ,nlormalJon Tr~ ',it;': 
conSists 01 a serres at small nngs "r,d :Jerf:!..: changes of resistance between these flngs cJd,ds have iJ'" 
'es,slance gases have a hlgll resistance I "'S deVice IS able to detect changes In reSistance ad vanous po,1 1,. 
along the lube ThiS enables Ih,s deVice to d'51,ngulsh between ': N:, lows and refiu' events. delermlne the 
compoSllior of the ref!·.J> eV01'1 igas'llquld) and Ine level of reflux Impedance deVICes have been In use lor over 
10 years and 11e deVICe'S used In the study have been used In the UK for 3 years In both cl;n,cal and research 
settings. Impedance deVices are used routlllely throughout the UK and ... orlowlde UK centres Include Glasgow 
Royal Int,fn)ar'l UniverSity College Landon Hospitals. r ,,'1 ngram 1.1anchester IpaedlatflCS) and P,ymouth We 
also use thiS device clinically at the r,r,rthem OesOPhago-Gaslnc Cancer Unit In the Royal V,ctona Infirmary 
The deVice used is CE marked In line with European standards and is 'T'd"013':',"'(:d 10 comply With '.I~rc 
Europeal 1.,I"d,',,'" DeVices Directive (93 42 EEC) and therefore does not lequrre ',"iRA approval 'nere IS a 
completed Pre Purchase OJeSlionnalfe I PPO) from Ardmore Healthcare Ltd that confirms thiS cOI'~".nce 
The deVice ,I"", has been operal,onally Check by the electronic depat1ment on recelpl and has been placed on 
lilf' "' .. ·.vcastle .p,," Tyne Hospitals h"51 assel ';>9 ,,~, ,Trust Safely I',i'loer Salel, Informallon lor 
ImpedanCe- 155951, 
3, For electrical devices give summarised details ot acceptance and safety testing 
., ",.:, lestlr' ." , .. ·en periorrned by Jeff Stephenson, Electromc Services Ollrce r at the Royal Vrclona 
Illilfl1'a: y i he deVice IS CE marked in hne W,lh European stanaaros and IS manu'actured to comply w'," Ihe 
European MedIcal DeVices DlfeC1lve 193,4<' E:f:C A Pre Purchase OuestlonnalfC (pPU trom Ardmore 
H"", "care Ltd ',as been completed 10 conl"m thiS comphance 
W,ti'. regard to Ihe deVice Itself, lt haS been operatlo",Ji, check b)' '.I)e eleClrOniCS depat1menl on receipt and 
nas been placed on the Trust asset register. 
nust Salety NU'11ber S31elV InformatJon for tmpedance~, 155951 
I, 
N'-lS REC Applh ,Ilion Form - Version 5,5 26 
AS ~ 2"::' , 
38 
Date 04'10'2007 Reference 07 H0908 70 
,----------"- '----_.---'--------_._--_.--.-
4 Is a medical device or other commercial company arranging this trial? 
• No 
ai Is this Inal a clinical InvestigatIOn requlflng notlhcatlon to the l.ji'IRA? 
t:ll D('h I',~ company have a r. lice of r,o Objection from H"e MHRA? 
H;,s 1.1,·,,;, approval been applcd for but rOI yet received? 
') Ves • t<.c; 
• Yes ,) t-..c 
OVe,; • No 
Online Form 
'b:' An <1ppltcal/oll :,~/., be '~:·i.!e pnor 10 recelpl 01 a vahd \.1 ce [I No Ob/ecllon Irom MHRA The Nollce .... 1/ be ISSued sub/eel II~ lie sponsor subsequem,J' rece/vmg a lavourable oprnron There /5 no reqUirement lor a valtd ,',Y'ce 01 '\. Ob,eClronlo be 
l,',,,-,vlded to le,e,'an: ethics commll/ee belore the research can be given a !avcurable OPlnton _____________ J 
is. Have any of Ihe medical devices been transferred from one organlsallon (legal entity) to another lor the purpose of 
Ii this tnaf? 
I 0 V~.s • 1' ... ;, 
i G,V( oela;'s 
I 
'---- --- ---.-
[
6 In cas~~·~f'-~~~I~ment or medical devices, what arrangements have been made with Ihe manufacturer to provide 
Indemnity? 
n€ Manufacturer has Insurance to provide Indemnity. 
[E;~~se <1-" I' 01 .. !I (e,e.anl correspondence ,', ,'" a version number and date 
NHS HEC Application Form VerSion 5 5 27 ABt21-l471 
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Dale 01 10;2007 Ref8'ence 07 HOC,( ': 70 Online Form 
1 What types 01 human tissue or olher biological matenal will be included on the study? 
In , Flu d Ga~!rIC JUice 
,2 Who w!" collect the samples? 
L',"q flUid Will oe collected at routine brorc~osDPI by one of the respirator, pI1,:>IClacs Gastnc JUice "'" be 
CCI!lf!ct("1j i)tt['f routine endoscopy t r one IJt the surgeons. 
: 3, Will the samples be: (TICk as appropnare) 
'l"J Obtained p mal'll for research purposes? 
B ' ,,~, c " ",eft over from tissue taken In the course of normal clinical cale lor diagnostic Of1heUD",,' c purposes:' 
4, Will informed consent be obtained from donors for use 01 the samples: 
If, ths research? 
Or. 
In future r~5eafch? 
OYes • I,,) 
,-----------------------------------------------~ 
Will the samples be stored: 
,n fully anonvmlsCd lorm? lIink to donor bf( "en) 
OYes • N') 
., ',' , 'v"'I" ,sco for n? Iinkeo to donor but oonel not ,demtl,abte to researcherS) 
• Yes Orh 
tl Yes, sa, ", ",j will have access to /I1e code and personal m/ormatlon about the Oonar 
,-"ng flUid samples are Siored as P')'" of another prOject NI','Ch has full eth,ca' approval. Access.' 'be through 
Professor CorliS as parl of an ongoing stud,! ,r-.RES approved I Into chrOniC lung (16'"" ':,0" The storage 01 
mese samples is not directly related (0 n1ls researCh 
In a form In ",I:r,h the donor could be IdentIfiable 10 researchers? 
• Yes ONo 
/I Yes, please jUstl')' 
! 
L ThiS storage IS part of .1lloH1er rescarcl' project and nas fe': ethical appIJv:, It IS nol directly hnked 10 Ihls proposal. The "between pa:rcn\S and samples allo.,s a correlallon betM'" tr,e clinical picture and laboratory Siud,es. Othe'wlse thiS Informahan IS anonymous and protected 
-----------' 
16, What types ot test or analysis will be carried out on the samples? 
I 
";1'" REC ApplicatiOn Form - Version 5.5 28 
'---1 
AS 121~~7 1 
-w 
Date ')4 1012007 R(>!"'C;'lce 07 H090870 Onh~e Form 
L Samr,If'; will be analysed to 100~ for evidence of stomach confects and ma',f"S ollc":af"1ma!lon In Iun:~fiU.a 'p"r,Slnblle aCid levels) Gashrc sar' ~','-'s will be useo 10 lest our laoo. ralory -,easuremenlS of reps' ,1 slomach protein I -- . 
\ 7. WI:I ;~e research involve the analysis of human DNA In the samples? 
()Ves • r<.v 
._--------,-----
'8. Is 11 possible thaI the research could produce findings 01 clinical significance lor indIviduals? ,1.'.1. mclude relatIVes as 
"eN as donors) 
L~ ___ . __________ _ 
---------------------------------------
9. II so, will arrangements be made to notify the indiViduals concerned? 
'JNo 
"ND please !uSld, "Yes. s.)y V,I",! arrangements will be made a~J gl.£1 detaIls of the S~PiXJrt or counsellmg servICe 
Pal' ~ts are In regular contacr ,v'I· the transplant team and are very well sJoponed 
----------~--
\
10, Give details 01 where the samples Will be stored. who will have access and the custodIal arrangements 
Samples will be stored In the Freeman Hospital Lung Transplant Human TIssue Bank Access Jc:J custOdial 
arrangements are through Professor Corris. This IS not Olfc,ctly related to this Prolect. 
11 What WIll happen to the samples at the end of the research? 
o LJes truchon 
r8nS!er to research tissue bank 
It the oanK IS In I: rg'and. IVales or NO'1.oem Irelana a licence Irc'" the Hj,,,,,.,r {,ssue Aurhoflty Will be rC'QJlr60 to Slore the 
1155"" for posSiblE further research I 
o Storage ov research learn pending ethical approval for use In another project 
~Unles5 In£> researcher holds a licence from the Human Tissue Aurhoflty. a furlner application lor etnlc.al reVI' .v should De 
suo '"1160 b['.'OI.O rile end of thiS prOJeel ; 
o Storage by research team as pan of a new research tissue ~.I'·' 
(The t,lck Will reqUJre a licence from the Human Tissue AuthOflly A separate applicatIOn tor ermca' rr-. "A 01 the tissue barr. 
,'.'1.1, also be submil/ed , 
Please Y"" further details of me proposed arrangemenrs' 
SamplCs .\'II, be siored In the F,eeman Hospital. Lung Transplant Human Tissue Bank In line With prevIOus 
ethical approval. ThiS slorage IS not relared to thiS curren! research project Lung Ilwd samples analySed as pan 
of thiS research prOjec' "II be oestroyed aller analySIS Gaslflc flUid samples Will also be destroyed 
~H'" REC APP:Ili!lIUil Form Version 5.5 29 AS 12~~-l7,1 
.+1 
Date '1410,2007 Onhne FCl'~ 
Declarallon by Chief Investigator 
The mformation In th,s form IS accurate to the best of my ,~o,,'edge ana beliel and I take fuji respans.b!lity 10' : 
2. I undertake to ab,de by the ethical principles under'yIng Inr; Declarallon of Hels,,,. and good praCllce guoCle!,nes on 
the proper conduct Q' 'es'!alct 
3. If the researCh IS ·-'rp'oved I unde'I,]"C to adhere 10 IhE stuo, protocol. the terms o' me full appl,callOn 01 "'~dC" lhe 
mam REC has gIven a favovabl" opInion and any cor,dltions set out by the main REC In glvmg Its fJvourabie 
opinion 
I undertake: to seek an ethIcal opinion from lhe "la,'l REC before ImplemN,I--lg substantial amenoments to the 
protocol 01 to the terms of Ihe full application of which the main REC has given J !] • Jurable opinIOn 
f> I undertake to submit annual progress repons selling out the progress of the research 
6 I am '''', I' ')f my responSIbility to be -'I' to date and comply With II'~ reqUirements 01 the la ... and relevanl 
gUidelines relaling to secunty and co:o'dentlallty of pattent or on-,er personal data IncludlOg the need to register 
." "", necessary ",th the appropnate Data Protection OffICer 
7 I ,.nJerstand IhAI research records·data may be Subleel to Inspechon !~r audit purposes If reqUIted In future 
8 I understand that personal dale about me as a researCher", thiS application Will be held by Ihe relevant RECs and 
thel( operational managers and that th,s Will De managed according to t"e pnl1C1ples established In the Data 
Protection Act. 
9 I understand that the 'n~olmallOn contained In thIS apphcahon. al1Y s"oporllng documentahon and ali 
correspondenceMth NHS Research Ethics Committees or theH operallOnal managers relatlOg to the application 
',i' , be helo Of the main REC until at least 3 '(ears after the end 01 the stuOy 
1,1" be disclosed to t"e 01,era:")',,1' managers or the aPPolntinq body for th .. qEC n order to checr- that Ihe 
appllc.at,on '>,IS been processed correctl/ or to Iro:esl>gate any complaint 
_ 1.1 'f be seen by auditors appointed by the NatIonal Research EthiCS Service to undertake accreditation ot tne 
RbC 
\\,,,, De subject to the prOVISions of tne "reedo,," of Information Acts ana may De disclosed '" response to 
requests made under the Acts except w',ere sl~!;;tory exemptIons apply 
Llpll,lnOJi - please liCk as appropflate 
o I would be content I,), members of other RECs to have access to le,e ,nformatlon :n the applicalion 10 conl:dence for 
training purposes All personal Identdlers and references to sponsors, funders and researcn Units "OI"ld be removed 
Signature 
Print Name Professor S M,chael Griffin 
Date 04!tO,2007 (dd!mm Y'f'i r 
---------------
\,H:-- HF,; Appile,'lllo" Form - Version 5 5 30 AS 121447 1 
Oa',· 04 102007 Onlt'le Form 
Declaration by the sponsor's representative 
Illhere IS mo": than one sponsor. 1"IS declaration should be s'9neO on behall 01 tne co-sponsors 0, a represenUrrve;)' !'i' 
wnsar namma/ed to lake the ,ead lar Ihe REC applicatiOn 
I confirm thatlllc~ as appropnalej 
l~ This research proposal has been discussed .,,!~ the Chr:' :nvestlgator and agreement In ~"nc·ple to soonso' 
the research IS In place 
. ".: An lppropnate process 01 SClenuhc ';'Ilique has demonstrated that thiS research proposal 1$ ""'Jrthwhde ano J' 
high SClent,/lc qualoty , 
l~ Any necessar I Indem~.tJ or Insurance arrangements. as descflbed In questIOn A35 "",j. he ,. place before th'$ 
research sta'IS 
o ArrangE'menlS "",II be In place before T.e study starts 1 J' Ihe researen leam to access resources and support to 
deliyer the ",search as proposed 
:';j Ar' ''''W,men!s to allocate responslbdrtles for :he management. monltonng and reporting of the researC' .\ I be 
111 place beifAe the research starts. 
o The duties of sponsors set out In the ;"'HS Research Governance Frameworl< for Health and Sooal Care WIll tw 
undertaken In re:fJ1·on to thiS research." 
. hot apphcarM, 'G student researcn (except doctoral researchi 
., f,.c, ar,p'lCable to rescarCI' outside the scope of the Research Governance Framr,,,,,ork 
Amanda lortlce 
Post Research Operations 1.1,nager 
Organisation N"iVcastie Upon Tyne Hcsp,tals NHS Trust 
NHS REC App",',}'ton Form - Version 5 5 31 AS 121447 1 

lO October 2007 
County Durham & Tees Valley 2 Research Ethics Committee 
Professorial Lnit of Surgery 
Lniyersity Hospital of'\orth Te.:s 
Piperimowle Road 
Stockton-on-Tees 
TS198PE 
Telephone: 016~2 62~16~ 
Facsimil.:: 016~2 62~16~ 
Professor S Michael Griffin 
Professor of Gastrointestinal Surgery 
Northern Oesophagogastric Unit, Royal Victoria Infirmary 
Queen Victoria Rd 
Newcastle upon Tyne 
NEl4LP 
Dear Professor Griffin 
Full title of study: The role of oesophageal impedance measurement in 
detection of gastro-oesophageal reflux disease in human 
lung transplant recipients 
REC reference number: 071H090S170 
Thank you for your letter of 04 October 2007, responding to the Committee's request 
for further information on the above research and submitting revised documentation. 
The further information was considered at the meeting of the Committee held on 08 
October 2007. A list of the members who were present at the meeting is attached. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised. 
Ethical review of research sites 
The Committee has designated this study as exempt from site-specific assessment 
(SSA. There is no requirement for [other] Local Research Ethics Committees to be 
informed or for site-specific assessment to be carried out at each site. 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out 
in the attached document. You are advised to study the conditions carefull y. 
45 
The final list of documents reviewed and approved by the Committee is as follO\\ s: 
Document t'ersion Date 
Application 5.4 17 August 2007 
Investigator CV 
Protocol 1 23 August 2007 
Participant Information Sheet: Collection of gastric fluid samples 2 04 October 2007 
Participant Information Sheet J 04 October 2007 
Participant Consent Form 2 04 October 2007 
Participant Consent Form: Collection of gastric fluid samples 2 04 October 2007 
Response to Request for Further Information 04 October 2007 
Table of events 
revised pages of application form 
R&D approval 
All researchers and research collaborators who will be participating in the research at 
NHS sites should apply for R&D approval from the relevant care organisation, if they 
have not yet done so. R&D approval is required, whether or not the study is exempt 
from SSA. You should advise researchers and local collaborators accordingly. 
Guidance on applying for R&D approval is available from 
http://www.rdforum.nhs.uklrdform.htm. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
Feedback on the application process 
Now that you have completed the application process you are invited to give your 
view of the service you received from the National Research Ethics Service. If you 
wish to make your views known please use the feedback form available on the NRES 
website at: 
https:llwww.nresform.org.uklAppFormlModules/FeedbackiEthicaIReview.aspx 
We value your views and comments and will use them to inform the operational 
process and further improve our service. 
071H0908!70 Please quote this number on all 
correspondence 
With the Committee's best wishes for the success of this project 
46 
Yours sincerely 
Kate Williams 
Deputy Chair 
Email: leigh.morgan@nth.nhs.uk 
Enclosures: 
Copy to: 
Standard approval conditions 
Ms Amanda Tortice, R&D Department, 4th Floor. Leazes Wing. 
Royal Victoria Infirmary, Newcastle upon Tyne 
47 
The Newcastle upon Tyne Hospitals 'rl:fj 
LRF'I 1\ '1% 
2ill!()7 
I h\ndrc\\ (,l\ Roberts< In 
( Ii 11 iedl research Fellow 
~llrth~rn Oc~()phagu-(J~l'llll Cancer Unit 
R\'! 
Dcar Dr RohcI1"<l1l 
Trust Approyal for R __ ,O Project: ,B68 
NHS 11 
Royal VictOria I,d""" 
Queen 'v "t,)r ~j R' 
r '.·\'icdstle upor, ",' , 
Titll' of Projcct: The role of Ol',oph:q.!l'al impedance I1Il'a\Url'llll'nt ill dctl'l'tion of 
gastro-oesophagl'al reflux disea,l' in human lung transplant 
I'rincipalll1\ l',tigator 
Funder (propo'l'd): 
"'ponsor (proposed): 
recipic'nh 
Or ,\ (; '\ Robertson 
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Study Code: 
Patient Initials: 
Study Title: 
The Newcastle upon Tyne Hospitals ~ 
NHS Trust l!1J.tJ 
Patient Information Sheet and Consent Form 
Freeman Hospital 
High Heaton 
Newcastle upon Tyne 
NE77DN 
Subject Number: 
The role of oesophageal impedance measurement in 
detection of gastro-oesophageal reflux disease in 
human lung transplant recipients. 
Name of Researchers: Professor Paul Corris, Professor Michael Griffin, Professor John 
Dark, Dr Jim Lordan, Dr Andrew Fisher and Dr Andrew Robertson 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
What is the background and purpose of the study? 
Rejection is a major problem for lung transplant recipients. This can occur at any time after 
a lung transplant; some patients develop chronic rejection soon after the transplant while 
others may go many years without it developing. The earliest sign of the start of this 
rejection is a drop in lung function, which can be measured with a simple blowing test. This 
early drop in lung function is often termed Bronchiolitis Obliterans Syndrome (BOS). All of 
the causes of BOS are as yet, not fully understood. One possible cause is now thought to 
be backflow of stomach contents into the lungs (known as reflux disease). 
This backflow is most likely to be a low-grade, which means that patients will not always 
notice this. It is enough, however, to cause the airways to become inflamed and, if left 
untreated, to cause scarring. 
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It has been shown, in several studies here and in other lung transplant units, that contents 
from the stomach. can flow backwards up the gullet and reach the transplanted lung. This is 
bad for lu~g function. It has also been shown that anti-reflux surgery, which is surgery to 
prevent this backflow, may lead to increased survival and improved lung function after 
transplant, by preventing lung damage. 
We are now conducting a study that will, hopefully, answer the question as to how 
important this backflow is in causing rejection in patients who have had a lung transplant. If 
this is the case then surgery could be performed to prevent backflow and perhaps rejection. 
This study will involve placing a thin tube through your nose into the gullet to measure this 
backflow. This tube is called an impedance catheter. The tube will be inserted into the 
gullet for 24 hours to measure the amount and severity of backflow you are experiencing. 
All patients in the study will have this test performed to determine whether they are 
suffering from backflow and how severe this problem is for them. 
Why have I been chosen? 
You have been asked to consider taking part in this study because you have had a recent 
lung transplant. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to 
withdraw at any time and without giving a reason. A decision to withdraw at any time, or 
a decision not to take part, will not affect the standard of care you receive. 
If you decide not to take part in this study your management will be routine and your 
treatment will not be changed in any way. 
What will happen to me if I take part? 
Following the discussion and consent for the study, when you will be given the opportunity 
to ask questions: 
o You will be asked to fill in a simple questionnaire to see if you are experiencing 
symptoms of backflow (e.g. heartburn) . 
o The impedance catheter will be placed in your gullet for 24 hours before your routine 
bronchoscopy to assess for the presence of backflow. To insert the impedance catheter 
another 10 minute study is performed on your gullet with a slightly large tube to work out 
where to place the catheter. 
These impedance measurements would be performed the day before your routine 
bronchoscopies at 1, 3 and 6 months. If you were found to have severe backflow ~r early 
signs of rejection at 3 months you would be offered the opportunity to undergo anti-reflux 
surgery to prevent this backflow. 
What do I have to do? 
It is important that you attend your study visits - these will be the day before your routine 
bronchoscopies which are performed to check up on your new lungs. 
We would .ask you to keep a .not~ of any adverse events that may happen and note if you 
are prescnbed any new medication during the study. 
What is the technology that is being tested? 
An impedance catheter is a new technology that assesses reflux disease. It is made up of 
small monitors along a fine tube that can detect the changes in electrical resistance present 
in liquids and gases. Thus it can detect the presence of gas and liquid in your gullet and 
whether you are swallowing this gas/liquid or whether it is travelling in the wrong direction. 
With your consent, your family doctor will be informed that you are taking part in this study. 
Your participation in this study will be written in your hospital notes so that all hospital staff 
will know that you are in the study. 
What are the side effects of any treatment received when taking part? 
No new treatment is being given during this study therefore there are no side effects. 
What are the side effects of any study procedures? 
The possible side effects of the manometry and impedance catheters are discomfort to the 
nose, throat or gullet. These are normally related to the manometry test which only lasts 
10-20 minutes. 
What are the other possible disadvantages and risks of taking part? 
There are no foreseen disadvantages or risks of taking part. 
What are the possible benefits of taking part? 
We cannot promise the study will help you but if you are found to have severe reflux 
disease or worsening lung function, then you will be offered surgery. This has been shown 
in several studies to improve lung function and survival. The information we get might help 
improve the treatment of other lung transplant patients and people with chronic rejection. 
What happens when the research study stops? 
At the end of the study you will continue to be monitored in the transplant clinic. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (Contact 0191 2231148). If 
you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure 
Complaints can be sent to: 
The Complaints Officer, Freeman Hospital, Newcastle. NE7 7DN 
Will my taking part in the study be kept confidential? 
By agreeing to take part in this study you are consenting to the study staff collecting 
personal data about you, including the following: 
• Your date of birth 
• Your sex 
• Your race or ethnic origin 
• Details of your medical condition e.g. reason for transplant, transplant date etc 
The data will be collected and entered onto a secure database. Access to this database 
will be password protected and only available to your doctors and the research staff. All 
data stored on the computer will be coded, your name will not appear - you will be given a 
unique study number under which all data and test results will be entered. 
Your data, and the data from all the patients taking part in this study, will be analysed to 
see whether the presence and severity of backflow of stomach contents has an effect on 
your lung function and on the markers of inflammation that are being looked at from the 
samples taken during your bronchoscopy. 
Your medical records may also be looked at by representatives of regulatory authorities 
and by authorised people from the Trust to check that the study is being carried out 
correctly. All will have a duty of confidentiality to you as a research participant and nothing 
that could reveal your identity will be disclosed outside the research site. 
All the information about your participation in this study will be kept confidential. 
If you agree, we will notify your GP that you are taking part in the study. Participation in the 
study will also be noted in your hospital records so that anyone who treats you will be 
aware that you are taking part in the study. 
What will happen if I don't want to carry on with the study? 
Participation in any research study is completely voluntary and you can decide to withdraw 
from the study at any time. You may decide that you don't want to have the impedance 
measurements performed. If you do withdraw from the study any information collected may 
still be used. 
Withdrawing from the study will not affect the level of care that you get from your doctors. 
What if something goes wrong? 
In the event that something does go wrong and you are harmed during the research study 
there are no special compensation arrangements. If you are harmed and this is due to 
someone's negligence then you may have grounds for a legal action for compensation 
against Newcastle upon Tyne Hospitals NHS Trust. The normal National Health Service 
complaints mechanisms will still be available to you. 
What will happen to the results of the research study? 
The results of this study will be published in a medical paper but your identity will not be 
revealed. This study is expected to go on for two years so any publication may not take 
place until 2009. 
Your transplant doctor will be able to tell you the severity of the backflow of stomach 
contents during the study. If this is abnormal you will be able to discuss the treatment 
options available to you with your consultant. You will be able to find out the overall results 
of the study, if you wish to know them, once the study is completely finished. 
Who is organising and funding the research? 
This study has been funded by the Newcastle upon Tyne Hospitals NHS Trust and will be 
overseen by the Newcastle upon Tyne Hospitals NHS Trust. 
Who has reviewed the study? 
This study has been reviewed by the County Durham & Tees Valley 2 Research Ethics 
Committee. 
Contact Details: 
For further information about the study you can speak to one of the consultants, 
Prof Corris, Prof Griffin, Dr Fisher or Dr Lordan. 
Alternatively you can speak to the Research Fellow: 
Andrew Robertson Tel: 0191 2820240 
In case of an emergency you can contact the transplant registrar on call. 
Thank you for taking the time to read this information sheet. 
If you decide you would like to take part in this study, you will be given a copy of this 
information sheet and a signed consent from to keep. 
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TABLE OF EVENTS 
Visit 1 Visit 2 Visit 3 Visit 4 
Screening 
Week1-4 1 month 3 months 6 months 
Study 
Discussed / X Information 
sheet given 
Informed X Consent 
Medical History X 
Routine Flow 
Volume & X X X 
Bronchoscopy 
Heartburn X X X questionnaire 
Impedance X X X 
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Diagram of Impedance catheter which is a few millimetres in diameter. 
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The Newcastle upon Tyne Hospitals ~ 
NHSTrust 
Freeman Hospital 
High Heaton 
Newcastle upon Tyne 
NE77DN 
Patient Consent Form 
Study Code: 
Patient Initials: Subject Number: 
Study Title: The role of oesophageal impedance 
measurement in detection of gastro-
oesophageal reflux disease in human lung 
transplant recipients 
Lead Investigator: Andrew Robertson (Clinical Research Fellow) 
Name of Researchers: Prof Corris, Griffin, Dr Fisher and Lordan 
Please initial in the box 
1. I confirm that I have read and understand the information sheet dated. D 
4th October 2007 (version 2) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals 
from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to 
have access to my records. 
4. I agree to my GP being informed of my participation in the study. 
5. I agree to take part in the above study 
Name of Patient Signature Date 
Name of Person taking consent Signature Date 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical 
notes. 
D 
D 
D 
D 
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Study Code: 
Patient Initials: 
Study Title: 
The Newcastle upon Tyne Hospitals ~ 
NHSTrust 
Patient Information Sheet and Consent Form 
Freeman Hospital 
High Heaton 
Newcastle upon Tyne 
NE77DN 
Subject Number: 
Collection of Gastric Fluid Samples for analysis and to 
assess its damaging effects on the human lung 
Name of Researchers: Professor Paul Corris, Professor Michael Griffin, Professor J 
Pearson, Dr Andrew Robertson 
You are being asked to allow your doctor to keep fluid samples removedfrom the stomach at 
endoscopy. Before you decide if you are willing to take part, it is important for YOli to understand 
why the fluid samples are being collected, what this involves, how the information gathered will be 
used, and the possible benefits, risks and discomforts associated with the procedures. Therefore 
please take time to read the following information carefully and discuss it with others if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take as much time 
as you want to decide whether or not you wish to take part. 
Thank you for reading this. 
What is the background and purpose of the study? 
Your doctor will be one of the investigating doctors in a study of gastric juice and its role in 
damaging the human lung. 
Why have I been chosen? 
You have been asked to consider taking part in this study because you are scheduled for 
an endoscopy. You are being asked to allow your doctor to take your gastric secretions 
and send these to a laboratory in Newcastle. Your stomach's juice will be analysed and 
assessed for its role in damaging the human lung. 
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Do I have to take part? 
~o. It is. up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to 
with.d~aw at any time and ~ithout giving a reason. A decision to withdraw at any time, or a 
decIsion not to take part, Will not affect the standard of care you receive. 
If you decide not to take part in this study you will not be disadvantaged and your medical 
treatment and care will not be changed in any way. 
What will happen to me if I take part? 
You are already scheduled to undergo an endoscopy. During the procedure any fluid of the 
stomach is sucked out to allow your doctor to look at the lining of the stomach. Rather than 
being placed in a clinical waste bin, some of this fluid would be kept for analysis at the 
laboratory and used in experiments. This retaining of samples does not affect the 
endoscopy being performed by your doctor. 
What are the possible side effects, risks and discomforts associated with this? 
There are no anticipated side effects, risks or discomforts over and above the risks of 
endoscopy, which will be explained to you. 
What are the possible benefits of taking part? 
This study will not directly help you but will be of use to the scientific community. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (Contact 0191 2829697). If 
you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure 
Complaints can be sent to: 
The Complaints Officer, Freeman Hospital, Newcastle. NE7 7DN 
How will my personal data be used? 
The samples will be collected anonymously. No personal information will be collected for 
this research process. 
What if something goes wrong? 
In the event that something does go wrong and you are harmed during the research study 
there are no special compensation arrangements. If you are harmed and this is due to 
someone's negligence then you may have grounds for a legal action for compensation 
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against Newcastle upon Tyne Hospitals NHS Trust. The normal National Health Service 
complaints mechanisms will still be available to you. 
Who has reviewed the study? 
This study has been reviewed by the County Durham & Tees Valley 2 
Research Ethics Committee 
Contact Details: 
For further information about the study you can speak to one of the consultants, 
Prof G riffi n 
Alternatively you can speak to the Clinical Research Fellow: 
Andrew Robertson Tel: 0191 2829697 
Thank you for taking the time to read this information sheet. 
If you decide you would like to take part in this study, you will be given a copy of 
this information sheet and a signed consent from to keep. 
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The Newcastle upon Tyne Hospitals ~ 
NHSTrust 
Freeman Hospital 
High Heaton 
Newcastle upon Tyne 
NE77DN 
Study Code: 
Patient Initials: 
Study Title: 
Patient Consent Form 
Subject Number: 
Collection of Gastric Fluid Samples for 
analysis and to assess its damaging effects 
on the human lung 
Lead Investigator: Andrew Robertson (Clinical Research Fellow) 
Name of Researchers: Prof Corris, Prof Griffin and Prof Pearson 
Please initial in the box 
1. I confirm that I have read and understand the information sheet dated. D 
2ih April 2009 (version 4) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
2. I agree to take part in the above study 
Name of Patient Signature Date 
Name of Person taking consent Signature Date 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical 
notes. 
D 
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Extra-Oesophageal Reflux Study 
Reflux Symptom Index Questionnaire Response Form 
Patient Initials: 
------
Screening NumU!b~eo!Lr-=-: ____ _ 
Date: I 1 ___ -
Within the last Month how did the following problems affect you o = No Problem 5 = Severe Problem 
I 
Hoarseness or a problem with your voice 0 1 2 3 4 5 
Clearing your throat 0 1 2 3 4 5 
Excess throat or postnasal drip 0 1 2 3 4 5 
Difficulty swallowing food, liquids or pills 0 1 2 3 4 5 
Coughing after you eat or after lying down 0 1 2 3 4 5 
Breathing difficulties or choking episodes 0 1 2 3 4 5 
Troublesome or annoying cough 0 1 2 3 4 5 
Sensation of something sticking in your throat or a lump in your 0 1 2 3 4 5 
throat 
----- --
Heartburn, chest pain, indigestion or stomach acid coming up 0 1 2 3 4 5 
RSI 
--
_____ ____ _ ___ L 
(d 
DeMeester Reflux Questionnaire 
1) In the last 2 weeks have you suffered from heartburn (i.e. a burning sensation in the 
chest)? 
grade 0, no grade 1, occasional grade 2. reason for grade 3. 
symptoms episodes medical visit interference with 
daily activities 
2) In the last 2 weeks have you suffered from regurgitation (acid or stomach contents 
coming up into your throat, mouth or lungs)? 
grade 0, no grade 1, occasional grade 2, predictable grade 3. episodes 
regurgitation episodes on position of of pulmonary 
straining aspiration, 
nocturnal cough or 
recurrent 
pneumOnIa 
3) In the last 2 weeks have you suffered from dysphagia (difficulty swallowing or 
food getting stuck)? 
grade 0, no grade 1, occasional grade 2, require grade 3, episodes 
dysphagia episodes liquid-to-clear diet of esophageal 
obstruction 
Overall are you satisfied with your operation? 
YIN 
Comments: 
The Gastrointestinal Quality of Life Index (GIQLI) 
1. How often during the past 2 weeks have you had pain in the abdomen? 
all of the time most of the some of the a little of the never 
time time time 
2. How often during the past 2 weeks have you had a feeling of fullness in the upper 
abdomen? 
all of the time most of the some of the a little of the never 
time time time 
3. How often during the past 2 weeks have you had bloating (sensation of too much 
gas in the abdomen)? 
all of the time most of the some of the a little of the never 
time time time 
4. How often during the past 2 weeks have you been troubled by excessive passage of 
gas through the anus? 
all of the time most of the some of the a little of the never 
time time time 
5. How often during the past 2 weeks have you been troubled by strong burping or 
belching? 
all of the time most of the some of the a little of the never 
time time time 
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6. How often during the past 2 weeks have you been troubled by gurgling noises from 
the abdomen? 
all of the time most of the some of the a little of the never 
time time time 
7. How often during the past 2 weeks have you been troubled by frequent bowel 
movements? 
all of the time most of the some of the a little of the never 
time time time 
8. How often during the past 2 weeks have you found eating to be a pleasure? 
never a little of the some of the most of the all of the time 
time time time 
9. Because of your illness, to what extent have you restricted the kinds of food you 
eat? 
very much much somewhat a little not at all 
10. During the past 2 weeks, how well have you been able to cope with everyday 
stresses? 
extremely poorly moderately well extremely well 
poorly 
11. How often during the past 2 weeks have you been sad about being ill? 
all of the time most of the some of the a little of the never 
time time time 
66 
12. How often during the past 2 weeks have you been nervous or anxious about your 
illness? 
all of the time most of the some of the a little of the never 
time time time 
13. How often during the past 2 weeks have you been happy with life in general? 
never a little of the some of the most of the all of the time 
time time time 
14. How often during the past 2 weeks have you been frustrated about your illness? 
all of the time most of the some of the a little of the never 
time time time 
15. How often during the past 12 weeks have you been tired or fatigued? 
all of the time most of the some of the a little of the never 
time time time 
16. How often during the past 2 weeks have you felt unwell? 
all of the time most of the some of the a little of the never 
time time time 
17. Over the past week, have you woken up in the night? 
every night 5-6 nights 3-4 nights 1-2 nights never 
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18. Since becoming ill, have you been troubled by changes in your appearance? 
a great deal a moderate somewhat a little bit not at all 
amount 
19. Because of your illness, how much physical strength have you lost? 
a great deal a moderate some a little bit none 
amount 
20. Because of your illness, to what extent have you lost your endurance? 
a great deal a moderate somewhat a little bit not at all 
amount 
21. Because of your illnes, to what extent do you feel unfit? 
extremely unfit moderately somewhat unfit a little unfit fit 
unfit 
22. During the past 2 weeks, how often have you been able to complete your normal 
daily activities (school, work, household)? 
never a little of the some of the most of the all of the time 
time time time 
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23. During th.e past 2 weeks: how often have you been able to take part in your usual 
patterns of leIsure or recreatIOnal activities? 
never a little of the some of the most of the all of the time 
time time time 
24. During the past 2 weeks, how much have you been troubled by the medical 
treatment of your illness? 
very much much somewhat a little not at all 
25. To what extent have your personal relations with people close to you (family or 
friends) worsened because of your illness? 
very much much somewhat a little not at all 
26. To what extent has your sexual life been impaired (harmed) because of your 
illness? 
very much much somewhat a little not at all 
27. How often during the past 2 weeks, have you been troubled by fluid or food 
coming up into your mouth (regurgitation)? 
all of the time most of the some of the a little of the never 
time time time 
28. How often during the past 2 weeks have you felt uncomfortable because of your 
slow speed of eating? 
all of the time most of the some of the a little of the never 
time time time 
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29. How often during the past 2 weeks have you had trouble swallowing your food? 
all of the time most of the some of the a little of the never 
time time time 
30. How often during the past 2 weeks have you been troubled by urgent bowel 
movements? 
all of the time most of the some of the a little of the never 
time time time 
31. How often during the past 2 weeks have you been troubled by diarrhoea? 
all of the time most of the some of the a little of the never 
time time time 
32. How often during the past 2 weeks have you been troubled by constipation? 
all of the time most of the some of the a little of the never 
time time time 
33. How often during the past 2 weeks have you been troubled by nausea? 
all of the time most of the some of the a little of the never 
time time time 
34. How often during the past 2 weeks have you been troubled by blood in the stool? 
all of the time most of the some of the a little of the never 
time time time 
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35. How often during the past 2 weeks have you been troubled by heartburn? 
all of the time most of the some of the a little of the never 
time time time 
36. How often during the past 2 weeks have you been troubled by uncontrolled 
stools? 
all of the time most of the some of the a little of the never 
time time time 
Calculation of the score: 
most desirable option: 4 points 
least desirable option: 0 points 
GIQLI score: sum of the points 
I 
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Appendix 8: JAG Accreditation in Endoscopy 
JAG 
" ,:ISCH \ (J I 
I dec/are thdf Dr Andrew Robertson 
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Difficulty 
Excess 5 wallowing 
Clearing throat or food, 
your postnasal liquids or 
H oa rs'eflle5 s th roat drip pills 
0 0 0 '1 ,~ 
4 3 2 -4 
.2 ... 0 4 . .:.. 
0 1 -4 0 
0 0 2 ,:2. 
.0 0 3 0 
0 4 0 D 
1 3 1 n 
0 0 0 0 
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.. 0 1 1 ..::. 
0 0 0 0 
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3 0 2 0 
0 .2 0 D 
3 3 1 1 
0 2 0 3 
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Sensation Prox 
of Rfx 
something Heartburn, Ewnts 
Coughing sticking in chest pain, 
a"fberyou Breal1ing your in d i'gestion 
,e~or d iffi (1J It ies th mat Dr a or 
after Dr Trou blesome lump in stomach 
lying choking or.an noying your acid 
down episod'e5 cou'llh throat coming up RSI 
0 0 2 1 0 e. 8 
1 .0 4 0 3 21 22 
1 0 2 2: 4 ·17 10 
0 0 1 0 1 "7 17 , 
0 0 0 .. 0 e 8 .it.. 
0 0 0 0 1 4 4 
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') 
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4 0 3 19 17 
'1 0 0 1 3 10 2.1 
n 0 0 0 D 0 34 
-4 4 3 4 4 32 ')7 ... , 
1 0 3 0 2 10 42 
0 1 1 1 1 4 19 
D ... 3 3 4 17 37 . .:.. 
0 0 0 -0 !S, 10 11 
1 0 2 0 2. 7 10 
D 0 0 [) D 12 B 
D 0 0 2 D 7 51 
A d' 10 R .ooen IX . esults of Gastric Juice Analysis . 
!"" 
GJ Bile Acid Pepsin Trypsin Sample Diagnosis Medication Age Sex pH (uM) ug/ml (ug/ml) 'Hcro 
- Normal SP Nil 20 f 2.3 300 3039 nla . 
I PUI peptic ulcer pentagastrin 0 0 n.'a I 
r U2 pej)tic ulcer pentagastrin I P 0 65...l- ola ! 
PU3 peptic ulcer pentagastrin 0 916 nla 
LTx1 LT PPJ 41 f 7.8 30 0 nia 
LTX2 LT PPl 24 f nla 1000 n/a nla 
LTx3 LT PPJ 29 f 4.8 30 0 nla 
LTx4 LT PPJ 25 f 2.2 0 548 n/a 
oesophageal 
CRI adenocarcinoma Nil 61 m 1.9 100 380 nla 
CR2 Gastritis PPl 67 f 7.5 8000 61.9 n/a 
CR3 Barrett's/Gastric ulcer PPJ 62 f 3.9 0 640 nla 
CR4 Barrett's PPJ 88 m 8.4 0 0 n/a 
CR5 Nad Nil 81 m 2.2 100 1684 n/a 
oesophagitis, gastritis, 
CR6 duodenitis Nil 37 m 1.8 250 358 n/a 
CR7 oesoghagitis, gastritis, Nil 73 m 2.9 30 0 n/a 
CR8 gasttric ulcer PPJ 71 m 4.7 nla n/a n/a 
ulcer, oesophagitis, gastro-
CR9 jejunostomy PPJ 82 f 6.7 10 0 n/a 
CR10 gastric erosion PPJ 51 f 1.7 100 123 n/a 
CR11 Normal Nil 48 f 4.7 8000 1778 n/a 
CR12 Barrett's PPJ 84 m 6.9 0 210 n/a 
CR13 Oesophagitis Nil 46 f 0.8 0 95.2 n/a 
Barrett's, duodenitis peptic 
CR14 ulcer Nil 75 f l.9 1200 68.2 n/a 
CR15 Oesophagitis Nil 57 m l.5 200 893 n/a 
CR16 metastatic carcinoma PPJ 70 m 6.6 100 0 nla 
CR17 Normal Nil 45 m 2.8 0 0 nla 
LTx5 LT PPJ 35 f 2.9 150 233.2 n/a 
CR18 Normal Nil 38 f 3.5 20 829 n/a 
CR19 gastricJPolyp Nil 50 f 1.6 100 1010 nla 
oesophagitis Grade 4, 
CR20 gastritis, duodenitis Nil 53 m l.7 100 606 n/a 
CR21 gastric ulcer PPJ 53 f 2.6 50 27.5 n/a 
CR22 Oesophagitis Nil 75 f 1.6 200 67...l- n/a I 
CR23 Oesophagitis Nil 64 m 7.5 100 19.8 n/a i 
- I CR24 Duodenitis Nil 59 f 7.9 70 0 nla 
CR25 healed _gastric ulcer PPJ 47 f 4.1 60 1957 n/a J ~ 
CR26 gastric ulcer Nil 67 f l.6 30 873 n/a 
I I 
oesophagitis, duodenal 
CR27 ulcer Nil 29 f l.8 100 515 n/a c-
CR28 
---
mild antral gastritis Nil 49 f l.6 30 981 n/a 
CR29 oesophagitis grade 2 Nil 68 f 1.4 50 ·f''''' .)- n'a 
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CR30 oesophageal nodule Nil 69 f 7.6 220 0 na ~ CR31 oesophagitis Grade A Nil 34 f l.5 50 1478 nJa 1 I 
CR32 Normal Nil 31 f 2.1 360 479 n/a 
.... Normal Nil LTx6 37 f 1.4 40 572 n/a I I-
oesophagitis grade A, HH, 
iLTx7 bile in oesophagus PPI 60 f 7.5 2200 0 n/a I 
I-
oesophagitis Grade A, HH nil ,CR33 42 f l.5 50 791 nJa 
~ 
duodenitis, nodule nil 48 f CR34 l.6 80 1247 nJa 
CR35 oesophagitis, gastritis nil 81 f 1.8 0 100 n/a I , 
oesophagitis Grade B, 
CR36 gastritis nil 63 f l.8 50 249 nJa 
CR37 oesophagitis Grade A, PPI 75 f 2.4 20 798 n/a N 
Oesophagitis and 
CR38 pyloroplasty PPI 56 m 6.6 400 0 n/a Y 
CR39 Barrett's oesophagus, HH PPI 65 f 4.8 40 127 nJa Y 
CR40 HH PPI 59 f 2 20 90 5 N 
Duodenitis, HH, 
CR41 oesophagitis nil 45 f 1.4 50 840 10 N 
CR42 Gastritis, HH PPI 42 f 5.5 600 3153 15 Y 
CR43 Oesophagitis, HH PPI 58 f 4.1 500 533 4 N 
CR44 normal nil 80 m 4.7 10 0 8 Y 
CR45 gastric ulcer PPI 50 m 8.4 0 57 5 Y 
CR46 gastritis, HH nil 78 f l.6 80 761 4 Y 
CR47 Barrett's oesophagus PPI 73 m 5.1 60 460 4 Y 
CR48 Barrett's oesophagus PPI 62 m 6.8 nJa 0 nJa N 
CR49 gastritis PPI 78 m 6 n/a 0 n/a Y 
CR50 normal nil 55 f 5.2 2050 3772 100 Y 
CR51 duodenal ulcer nil 68 f 6 30 1181 20 Y 
CR52 gastritis nil 65 f 1.7 80 1319 5 N 
LTx8 HH PPI 30 f l.6 530 1346 5 Y 
LTx9 normal PPI 30 f 4 nJa 3892 12 N 
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